View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2011	Feb. 10, 2012	Jun. 30, 2011
Document and Entity Information [Abstract]
Entity Registrant Name	AMGEN INC
Entity Central Index Key	0000318154
Document Type	10-K
Document Period End Date	Dec. 31, 2011
Amendment Flag	false
Document Fiscal Year Focus	2011
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Public Float			$ 53,861,879,805
Entity Common Stock, Shares Outstanding		791,432,134

Document and Entity Information (Parenthetical)	Jun. 30, 2011 shares
Document and Entity Information [Abstract]
Shares of common stock held by directors and executive officers	966,638

Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Revenues:
Product sales	$ 15,295	$ 14,660	$ 14,351
Other revenues	287	393	291
Total revenues	15,582	15,053	14,642
Operating expenses:
Cost of sales (excludes amortization of certain acquired intangible assets presented separately)	2,427	2,220	2,091
Research and development	3,167	2,894	2,864
Selling, general and administrative	4,486	3,983	3,820
Amortization of certain acquired intangible assets	294	294	294
Other	896	117	67
Total operating expenses	11,270	9,508	9,136
Operating income	4,312	5,545	5,506
Interest expense, net	610	604	578
Interest and other income, net	448	376	276
Income before income taxes	4,150	5,317	5,204
Provision for income taxes	467	690	599
Net income	$ 3,683	$ 4,627	$ 4,605
Earnings per share:
Basic	$ 4.07	$ 4.82	$ 4.53
Diluted	$ 4.04	$ 4.79	$ 4.51
Shares used in the calculation of earnings per share:
Basic	905	960	1,016
Diluted	912	965	1,021

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2011	Dec. 31, 2010
Current assets:
Cash and cash equivalents	$ 6,946	$ 3,287
Marketable securities	13,695	14,135
Trade receivables, net	2,896	2,335
Inventories	2,484	2,022
Other current assets	1,572	1,350
Total current assets	27,593	23,129
Property, plant and equipment, net	5,420	5,522
Intangible assets, net	2,584	2,230
Goodwill	11,750	11,334
Other assets	1,524	1,271
Total assets	48,871	43,486
Current liabilities:
Accounts payable	642	716
Accrued liabilities	5,028	3,366
Current portion of long-term debt	84	2,488
Total current liabilities	5,754	6,570
Long-term debt	21,344	10,874
Other noncurrent liabilities	2,744	2,098
Contingencies and commitments
Stockholders' equity:
Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding - 795.6 shares in 2011 and 932.1 shares in 2010	27,777	27,299
Accumulated deficit	(8,919)	(3,508)
Accumulated other comprehensive income	171	153
Total stockholders' equity	19,029	23,944
Total liabilities and stockholders' equity	$ 48,871	$ 43,486

Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Millions	Dec. 31, 2011	Dec. 31, 2010
Consolidated Balance Sheets [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	2,750.0	2,750.0
Common stock, shares outstanding	795.6	932.1

Consolidated Statements of Stockholders' Equity - USD ($) shares in Millions, $ in Millions	Total	Number of shares of common stock	Common stock and additional paid-in capital	Accumulated deficit	Accumulated other comprehensive income
Beginning balance at Dec. 31, 2008	$ 20,885		$ 26,441	$ (5,673)	$ 117
Beginning balance, shares at Dec. 31, 2008		1,047.5
Comprehensive income:
Net income	4,605			4,605
Other comprehensive income (loss), net of tax	(72)				(72)
Comprehensive income	4,533
Issuance of common stock in connection with the Company's equity award programs	190		190
Issuance of common stock in connection with the Company's equity award programs, shares		6.3
Stock-based compensation	324		324
Tax impact related to employee stock options	(11)		(11)
Repurchase of common stock	$ (3,254)			(3,254)
Repurchases of common stock, shares	(59.2)	(59.2)
Ending balance at Dec. 31, 2009	$ 22,667		26,944	(4,322)	45
Ending balance, shares at Dec. 31, 2009		994.6
Comprehensive income:
Net income	4,627			4,627
Other comprehensive income (loss), net of tax	108				108
Comprehensive income	4,735
Issuance of common stock in connection with the Company's equity award programs	69		69
Issuance of common stock in connection with the Company's equity award programs, shares		4.0
Stock-based compensation	357		357
Tax impact related to employee stock options	(71)		(71)
Repurchases of common stock	$ (3,800)			(3,800)
Repurchases of common stock, shares	(66.5)	(66.5)
Other	$ (13)			(13)
Ending balance at Dec. 31, 2010	$ 23,944		27,299	(3,508)	153
Ending balance, shares at Dec. 31, 2010	932.1	932.1
Comprehensive income:
Net income	$ 3,683			3,683
Other comprehensive income (loss), net of tax	18				18
Comprehensive income	3,701
Dividends	(787)			(787)
Issuance of common stock in connection with the Company's equity award programs	230		230
Issuance of common stock in connection with the Company's equity award programs, shares		7.8
Stock-based compensation	337		337
Tax impact related to employee stock options	(89)		(89)
Repurchases of common stock	$ (8,307)			(8,307)
Repurchases of common stock, shares	(144.3)	(144.3)
Ending balance at Dec. 31, 2011	$ 19,029		$ 27,777	$ (8,919)	$ 171
Ending balance, shares at Dec. 31, 2011	795.6	795.6

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Cash flows from operating activities:
Net income	$ 3,683	$ 4,627	$ 4,605
Depreciation and amortization	1,060	1,017	1,049
Stock-based compensation expense	341	353	284
Deferred income taxes	(399)	(167)	47
Property, plant and equipment impairments	6	118	21
Dividend received from equity investee	0	0	110
Other items, net	63	140	111
Changes in operating assets and liabilities, net of acquisitions:
Trade receivables, net	(557)	(210)	(36)
Inventories	(383)	153	(134)
Other assets	(133)	36	(3)
Accounts payable	(95)	142	71
Accrued income taxes	(20)	(656)	(142)
Legal reserve	780	0	0
Other liabilities	773	234	353
Net cash provided by operating activities	5,119	5,787	6,336
Cash flows from investing activities:
Purchases of property, plant and equipment	(567)	(580)	(530)
Cash paid for acquisitions, net of cash acquired	(701)	0	0
Purchases of marketable securities	(21,183)	(14,602)	(12,418)
Proceeds from sales of marketable securities	20,871	10,485	8,252
Proceeds from maturities of marketable securities	749	642	1,443
Other	45	(97)	51
Net cash used in investing activities	(786)	(4,152)	(3,202)
Cash flows from financing activities:
Repurchases of common stock	(8,315)	(3,786)	(3,208)
Repayment of debt	(2,500)	0	(1,000)
Repayments of commercial paper	(762)	0	0
Dividends paid	(500)	0	0
Net proceeds from issuance of debt	10,387	2,471	1,980
Net proceeds from issuance of commercial paper	762	0	0
Other	254	83	204
Net cash used in financing activities	(674)	(1,232)	(2,024)
Increase in cash and cash equivalents	3,659	403	1,110
Cash and cash equivalents at beginning of period	3,287	2,884	1,774
Cash and cash equivalents at end of period	$ 6,946	$ 3,287	$ 2,884

Summary of significant accounting policies

12 Months Ended

Dec. 31, 2011

Summary of significant accounting policies [Abstract]

Summary of significant accounting policies

1. Summary of significant accounting policies

Business

Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. We concentrate on innovating novel medicines based on advances in cellular and molecular biology, and we operate in one business segment: human therapeutics.

Principles of consolidation

The consolidated financial statements include the accounts of Amgen as well as its wholly owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation.

Use of estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from those estimates.

Product sales

Product sales consist primarily of sales of Neulasta^® (pegfilgrastim), NEUPOGEN^® (Filgrastim), Enbrel^® (etanercept), Aranesp^® (darbepoetin alfa) and EPOGEN^® (epoetin alfa). Sales of our products are recognized when shipped and title and risk of loss have passed. Product sales are recorded net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively “sales deductions”) and returns. Taxes collected from customers and remitted to government authorities related to the sales of the Company’s products, primarily in Europe, are excluded from revenues.

We have the exclusive right to sell epoetin alfa for dialysis, certain diagnostics and all non-human, non-research uses in the United States. We sell epoetin alfa under the brand name EPOGEN^®. We granted to Ortho Pharmaceutical Corporation (which has assigned its rights under the product license agreement to Janssen Biotech, Inc., formerly known as Centocor Ortho Biotech Products, L.P.), a subsidiary of Johnson & Johnson (J&J), a license relating to epoetin alfa for sales in the United States for all human uses except dialysis and diagnostics. This license agreement, which is perpetual, may be terminated for various reasons, including upon mutual agreement of the parties, or default. The parties are required to compensate each other for epoetin alfa sales that either party makes into the other party’s exclusive market, sometimes referred to as “spillover.” Accordingly, we do not recognize product sales we make into the exclusive market of J&J and do recognize the product sales made by J&J into our exclusive market. Sales in our exclusive market are derived from our sales to our customers, as adjusted for spillover. We are employing an arbitrated audit methodology to measure each party’s spillover based on estimates of and subsequent adjustments thereto of third-party data on shipments to and usage by end users.

Other revenues

Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded in accordance with contract terms when third-party results are reliably measurable and collectability is reasonably assured. Royalty estimates are made in advance of amounts collected using historical and forecasted trends. Corporate partner revenues are comprised of amounts earned from Kirin-Amgen, Inc. (K-A) for certain research and development (R&D) activities, which are earned as the R&D activities are performed. Corporate partner revenues also include license fees and milestone payments earned from K-A and from third parties. See Multiple-deliverable revenue arrangements, discussed below, Note 6, Collaborative arrangements, and Note 7, Related party transactions.

Muliple-deliverable revenue arrangements

Effective January 1, 2011, we adopted a new accounting standard that amends the guidance on the accounting for arrangements involving the delivery of more than one element. Pursuant to the new standard, each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting. For Amgen this determination is generally based on whether the deliverable has “stand-alone value” to the customer. The arrangement’s consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. In general, the consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. The Company adopted this new accounting standard on a prospective basis for all multiple-deliverable revenue arrangements (MDRAs) entered into on or after January 1, 2011, and for any MDRAs that were entered into prior to January 1, 2011, but materially modified on or after that date.

For MDRAs entered into prior to January 1, 2011, (pre-2011 arrangements) and not materially modified thereafter, we continue to apply our prior accounting policy with respect to such arrangements. Under this policy, in general, revenue from non-refundable, up-front fees related to intellectual property rights/licenses, where we have continuing involvement and where standalone value could not be determined under the previous guidance, is recognized ratably over the estimated period of ongoing involvement. In general, the consideration with respect to the other deliverables is recognized when the goods or services are delivered.

Under all of our MDRAs, consideration associated with at-risk substantive performance milestones is recognized as revenue upon the achievement of the related milestone, as defined in the respective contracts.

The primary impact of adopting the new accounting standard is expected to be the earlier recognition of revenue associated with delivering rights to the underlying intellectual property. The adoption of this accounting standard did not have a material impact on our consolidated results of operations for the year ended December 31, 2011, or on our financial position as of December 31, 2011. Our consolidated results of operations for the year ended December 31, 2010, or our financial position as of December 31, 2010, also would not have been materially impacted if the accounting standard had been adopted on January 1, 2010. The impact of adopting this new accounting standard is dependent on the terms and conditions of any future arrangements that we may enter into that include multiple-deliverables and pre-2011 arrangements that are materially modified. Depending on the terms of any such arrangements, the adoption of this accounting standard may have a material impact on our consolidated results of operations or financial position.

Research and development costs

R&D costs are expensed as incurred and include primarily salaries, benefits and other staff-related costs; facilities and overhead costs; clinical trial and related clinical manufacturing costs; contract services and other outside costs; information systems’ costs and amortization of acquired technology used in R&D with alternative future uses. R&D expenses also include costs and cost recoveries associated with K-A and third-party R&D arrangements, including upfront fees and milestones paid to third parties in connection with technologies which had not reached technological feasibility and did not have an alternative future use. Net payment or reimbursement of R&D costs is recognized when the obligations are incurred or as we become entitled to the cost recovery. See Note 6, Collaborative arrangements, and Note 7, Related party transactions.

Selling, general and administrative costs

Selling, general and administrative (SG&A) expenses are comprised primarily of salaries, benefits and other staff-related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; and other general and administrative costs. Advertising costs are expensed as incurred. SG&A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaboration arrangements. Net payment or reimbursement of SG&A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 6, Collaborative arrangements.

Beginning January 1, 2011, SG&A expenses also include the amortization of the annual fee mandated by the Patient Protection and Affordable Care Act and the companion Health Care and Education Reconciliation Act (the U.S. healthcare reform federal excise fee). The liability for the annual U.S. healthcare reform federal excise fee is estimated and recorded in full upon the first qualifying sale of our covered products with a corresponding deferred cost established that is amortized on a straight-line basis over the calendar year that it is payable.

Stock-based compensation

We have stock-based compensation plans under which various types of equity-based awards are granted, including stock options, restricted stock units (RSU) and performance units. The estimated fair values of stock option and RSU awards which are subject only to service conditions with graded vesting are generally recognized as compensation expense on a straight-line basis over the service period. The estimated fair values of performance unit awards are generally recognized as compensation expense on a straight-line basis from the grant date to the end of the performance period. See Note 3, Stock-based compensation.

Income taxes

We provide for income taxes based on pretax income, applicable tax rates and tax planning opportunities available in the various jurisdictions in which we operate.

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. The amount of unrecognized tax benefits (UTBs) is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to UTBs in income tax expense. See Note 4, Income taxes.

Business combinations

Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process research and development (IPR&D) projects and liabilities assumed, are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies are resolved. The resulting changes in fair values are recorded in earnings. See Note 2, Business combinations, and Note 16, Fair value measurement.

Cash equivalents

We consider cash equivalents to be only those investments which are highly liquid, readily convertible to cash and which mature within three months from the date of purchase.

Available-for-sale investments

We consider our investment portfolio available-for-sale and, accordingly, these investments are recorded at fair value with unrealized gains and losses generally recorded in other comprehensive income. See Note 9, Available-for-sale investments, and Note 16, Fair value measurement.

Inventories

Inventories are stated at the lower of cost or market. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner that approximates the first-in, first-out method. Cost also includes the Puerto Rico excise tax enacted in 2011 related to our manufacturing operations in Puerto Rico. See Note 10, Inventories.

Derivatives

We recognize all of our derivative instruments as either assets or liabilities at fair value in the Consolidated Balance Sheets. The accounting for changes in the fair value of a derivative instrument depends on whether it has been formally designated and qualifies as part of a hedging relationship under the applicable accounting standards and, further, on the type of hedging relationship. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter, whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings. See Note 16, Fair value measurement, and Note 17, Derivative instruments.

Property, plant and equipment, net

Property, plant and equipment is recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. We review our property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Depreciation is provided over the assets’ useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 11, Property, plant and equipment.

Intangible assets and goodwill

Finite-lived intangible assets are recorded at cost, net of accumulated amortization and, if applicable, impairment charges. Amortization of finite-lived intangible assets is provided over their estimated useful lives on a straight-line basis. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See Note 12, Intangible assets.

The estimated fair values of IPR&D projects acquired in a business combination which have not reached technological feasibility are capitalized and accounted for as indefinite-lived intangible assets subject to impairment testing until completion or abandonment of the project. Capitalized IPR&D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written-off immediately.

Goodwill relates principally to our 2002 acquisition of Immunex Corporation (Immunex). We perform an impairment test of goodwill annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

Convertible debt

The debt and equity components of convertible debt instruments that may be partially or wholly cash settled (cash settleable convertible notes), including our 0.125% 2011 Convertible Notes and 0.375% 2013 Convertible Notes, are bifurcated and accounted for separately. The debt component of cash settleable convertible notes, which excludes the associated equity conversion option, is recorded at fair value as of the issuance date. The difference between the amount allocated to the debt component and the proceeds received upon issuance of the debt is allocated to the equity component and recorded in Common stock and additional paid-in capital in the Consolidated Balance Sheets. The reduced or discounted carrying value of cash settleable convertible notes resulting from bifurcation is subsequently accreted back to its principal amount through the recognition of non-cash interest expense. This results in recognizing interest expense on the borrowing at an effective rate approximating what would have been incurred had nonconvertible debt with otherwise similar terms been issued. See Note 14, Financing arrangements.

Recent accounting pronouncements

In June 2011, a new accounting standard was issued that changed the disclosure requirements for the presentation of other comprehensive income (OCI) in the financial statements, including the elimination of the option to present OCI in the statement of stockholders’ equity. OCI and its components will be required to be presented for both interim and annual periods either in a single financial statement, the statement of comprehensive income, or in two separate but consecutive financial statements, consisting of a statement of income followed by a separate statement presenting OCI. This standard is required to be applied retrospectively beginning January 1, 2012, except for certain provisions for which adoption was delayed.

Business Combinations

12 Months Ended

Dec. 31, 2011

Business Combinations [Abstract]

Business combinations

2. Business combinations

BioVex Group, Inc.

On March 4, 2011, we acquired all of the outstanding stock of BioVex Group, Inc. (BioVex), a privately held biotechnology company developing treatments for cancer and for the prevention of infectious disease, including talimogene laherparepvec (formerly referred to as OncoVEX^GM-CSF), a novel oncolytic vaccine in phase 3 clinical development for the treatment of malignant melanoma. This transaction, which was accounted for as a business combination, provides us with an opportunity to expand our efforts to bring novel therapeutics to market. Upon its acquisition, BioVex became a wholly owned subsidiary of Amgen, and its operations have been included in our consolidated financial statements commencing on the acquisition date.

The aggregate acquisition date consideration to acquire BioVex consisted of (in millions):


Cash paid to former shareholders of BioVex	$	407
Fair value of contingent consideration obligations		190

Total consideration	$	597

In connection with this acquisition, we are obligated to make additional payments to the former shareholders of BioVex of up to $575 million contingent upon the achievement of various regulatory and sales milestones with regard to talimogene laherparepvec, including the filing of a Biologics License Application with the U.S. Food and Drug Administration (FDA); the first commercial sale in each of the United States and the European Union (EU) following receipt of marketing approval, which includes use of the product in specified patient populations; and upon achieving specified levels of sales. The estimated fair values of the contingent consideration obligations aggregated $190 million as of the acquisition date and were determined using a combination of valuation techniques. The contingent consideration obligations to make regulatory milestone payments were valued based on assumptions regarding the probability of achieving the milestones and making the related payments, with such amounts discounted to present value based on our credit risk. The contingent consideration obligations to make sales milestone payments were valued based on assumptions regarding the probability of achieving specified product sales thresholds to determine the required payments, with such amounts discounted to present value based on our credit risk.

We allocated the total consideration to the acquisition date fair values of assets acquired and liabilities assumed as follows (in millions):


Intangible assets — IPR&D	$	675
Goodwill		170
Deferred tax liabilities		(246	)
Other assets (liabilities) acquired, net		(2	)

Total consideration	$	597

Intangible assets are composed of the estimated fair value of acquired IPR&D related to talimogene laherparepvec. The estimated fair value was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The estimated net cash flows were discounted to present value using a discount rate of 11%, which is based on the estimated weighted-average cost of capital for companies with characteristics similar to those of BioVex. This is comparable to the estimated internal rate of return on BioVex operations and represents the rate that market participants would use to value the intangible assets. The projected cash flows from talimogene laherparepvec were based on certain key assumptions, including estimates of future revenue and expenses and taking into account the stage of development of talimogene laherparepvec at the acquisition date, the time and resources needed to complete development and the probabilities of obtaining marketing approval from the FDA and other regulatory agencies. IPR&D intangible assets acquired in a business combination are considered to be indefinite-lived until the completion or abandonment of the associated R&D efforts.

The estimated incremental R&D costs to be incurred to obtain necessary regulatory approvals for talimogene laherparepvec are not material. The major risks and uncertainties associated with the timely and successful completion of development and commercialization of this product candidate include our ability to confirm its safety and efficacy based on data from clinical trials, our ability to obtain necessary regulatory approvals and our ability to successfully complete these tasks within budgeted costs. We are not able to market a human therapeutic without obtaining regulatory approvals, and such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&D may vary from its estimated fair value at the date of acquisition.

The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $170 million was recorded as goodwill, which is not deductible for tax purposes. Goodwill is attributable primarily to the deferred tax consequences of acquired IPR&D recorded for financial statement purposes.

Other acquisitions

During the year ended December 31, 2011, we also acquired the businesses described below, which were accounted for as business combinations, and accordingly, their operations have been included in our consolidated financial statements commencing on their respective acquisition dates.

On April 7, 2011, we acquired all of the outstanding stock of Laboratório Químico Farmacêutico Bérgamo Ltda (Bergamo), a privately held Brazilian pharmaceutical company. Upon its acquisition, Bergamo became a wholly owned subsidiary of Amgen.

On May 16, 2011, we acquired a manufacturing facility in Dun Laoghaire, Ireland, from Pfizer Inc. (Pfizer) (Dun Laoghaire). Under the terms of the agreement, most staff at the facility became Amgen employees, and we agreed to manufacture certain products for Pfizer at the facility for an interim period.

On June 15, 2011, we reacquired rights to distribute certain of our products in the Brazilian pharmaceutical market from our local distributor in Brazil and its parent company, Hypermarcas, and in connection therewith acquired all business operations relating to these products in Brazil.

The aggregate acquisition date consideration for these businesses was approximately $453 million, composed primarily of cash paid to the former owners of the businesses. The aggregate acquisition date consideration was allocated to (i) goodwill of $265 million, of which $130 million related to Bergamo was tax deductible: (ii) property, plant and equipment of $99 million; (iii) amortizable intangible assets composed primarily of licenses to distribute products and customer contracts of $58 million; and (iv) other assets, net of $31 million. The purchase price allocation for the Bergamo transaction is preliminary and will be finalized upon collection of information regarding certain tax-related items. Goodwill resulting from these acquisitions is attributable primarily to the benefits of immediate, direct access to the Brazilian market for expediting our international expansion efforts and geographic diversification to assist in risk mitigation efforts related to our manufacturing operations.

Pro forma supplemental consolidated results of operations for the years ended December 31, 2011 and 2010, that assumes the acquisitions of BioVex, Bergamo, Dun Laoghaire and Hypermarcas all occurred on January 1, 2010, are not provided because the impact would not be material to our consolidated results of operations either individually or in the aggregate.

In addition to the increase in goodwill for the acquisitions of the businesses discussed above, goodwill decreased by $19 million for the year ended December 31, 2011, due to changes in foreign currency exchange rates.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 88-16
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51, 52
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Appendix F
-Paragraph F4
-Subparagraph e

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 67-73
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e6927-128479

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1490-128463

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e7008-128479

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e6996-128479

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1524-128463

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1392-128463

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e7000-128479

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1497-128463

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1486-128463

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1383-128463

+ Details

Stock-based compensation

12 Months Ended

Dec. 31, 2011

Stock-based compensation [Abstract]

Stock-based compensation

3. Stock-based compensation

Our 2009 Equity Incentive Plan (the 2009 Plan) provides for the grant of equity-based awards, including stock options, RSUs and performance units, to employees and consultants of Amgen, its subsidiaries and non-employee members of our Board of Directors. The 2009 Plan, which was approved by our stockholders on May 6, 2009, replaced our prior equity plans (the Prior Plans) and no further awards may be made under these Prior Plans. The 2009 Plan authorizes the issuance of 100 million shares of our common stock. Under the terms of the 2009 Plan, the pool of available shares that may be used for all types of awards, including those issued under our Prior Plans after December 31, 2008, and before May 6, 2009 (the stub period), is reduced by one share for each stock option granted and by 1.9 shares for other types of awards granted, including RSUs and performance units. If any shares subject to an award granted under our Prior Plans during the stub period or any awards granted under the 2009 Plan expire, or are forfeited, terminated or cancelled without the issuance of shares, the shares subject to such awards are added back to the pool of available shares under the 2009 Plan on the same basis that they were removed. As of December 31, 2011, the 2009 Plan provides for future grants and/or issuances of up to approximately 58 million shares of our common stock. Stock-based awards under our employee compensation plans are made with newly issued shares reserved for this purpose.

The following table reflects the components of stock-based compensation expense recognized in our Consolidated Statements of Income for the years ended December 31, 2011, 2010 and 2009 (in millions):


	2011			2010			2009
Stock options	$	85		$	124		$	115
Restricted stock units		188			182			134
Performance units		68			47			35

Total stock-based compensation expense, pre-tax		341			353			284
Tax benefit from stock-based compensation expense		(124	)		(120	)		(97	)

Total stock-based compensation expense, net of tax	$	217		$	233		$	187

Employee stock options and restricted stock units

Eligible employees generally receive a grant of stock options and/or RSUs annually with the size and type of award generally determined by the employee’s salary grade and performance level. In addition, certain management and professional level employees typically receive RSU grants upon commencement of employment. Our stock option and RSU grants provide for accelerated or continued vesting in certain circumstances as defined in the plans and related grant agreements, including upon death, disability, a change in control, termination in connection with a change in control and retirement of employees who meet certain service and/or age requirements. Stock options and RSUs granted prior to April 25, 2011, generally vest in equal amounts on each of the first four anniversaries of the grant date. Stock options and RSUs granted on and after April 25, 2011, generally vest in approximately equal amounts on the second, third and fourth anniversaries of the grant date.

Stock options

The exercise price for stock options is set at the closing price of our common stock on the date of grant and the related number of shares granted is fixed at that point in time. Awards granted to employees on and after April 26, 2010, expire 10 years from the date of grant; options granted to employees prior to that date expire seven years from the date of grant.

We use an option valuation model to estimate the grant date fair value of our employee stock options. The weighted-average assumptions used in the option valuation model and the resulting weighted-average estimated grant date fair values of our employee stock options were as follows for the years ended December 31, 2011, 2010 and 2009:


	2011		2010		2009
Closing price of our common stock on grant date	$	54.66	$	58.32	$	50.65
Expected volatility		23.5%		28.0%		39.6%
Expected life (in years)		5.9		6.6		4.6
Risk-free interest rate		2.5%		3.2%		2.1%
Expected dividend yield		2.0%		0%		0%
Fair value of stock options granted	$	11.39	$	20.97	$	18.35

The expected volatility reflects the consideration of the implied volatility in publicly traded instruments associated with Amgen’s common stock during the period the options were granted. We believe implied volatility in these instruments is more indicative of expected future volatility than the historical volatility in the price of our common stock. We use historical data to estimate the expected life of the options. The risk-free interest rates for periods within the expected life of the option are based on the U.S. Treasury yield curve in effect during the period the options were granted. The expected dividend yield for options granted on and after April 25, 2011, was based on expectations regarding our policy of paying dividends announced in April 2011.

The following summarizes select information regarding our stock options during the year ended December 31, 2011:


	Options (in millions)			Weighted- average exercise price		Weighted- average remaining contractual life (years)		Aggregate intrinsic value (in millions)
Balance unexercised at December 31, 2010		46.8		$	58.66
Granted		2.3		$	54.66
Exercised		(5.0	)	$	50.22
Expired/forfeited		(9.9	)	$	60.43

Balance unexercised at December 31, 2011		34.2		$	59.11		3.8	$	245

Vested or expected to vest at December 31, 2011		33.8		$	59.15		3.7	$	242

Exercisable at December 31, 2011		23.6		$	61.49		2.3	$	135

The total intrinsic value of options exercised during the three years ended December 31, 2011, 2010 and 2009, was $47 million, $15 million and $57 million, respectively.

Restricted stock units

The fair value of an RSU granted prior to April 25, 2011, is equal to the closing price of our common stock on the grant date. The fair values of RSUs granted on and after April 25, 2011, are based on the closing price of our common stock on the grant date reduced by the weighted average expected dividend yield of 1.9% over the weighted-average vesting period, discounted at a weighted-average risk-free interest rate of 1.0%. The weighted-average grant date fair values of RSUs granted in 2011, 2010 and 2009 were $51.83, $58.19 and $51.24, respectively. The following summarizes select information regarding our RSUs during the year ended December 31, 2011:


	Units (in millions)			Weighted-average grant date fair value
Balance nonvested at December 31, 2010		9.3		$	52.67
Granted		4.0		$	51.83
Vested		(3.4	)	$	52.06
Forfeited		(0.9	)	$	52.77

Balance nonvested at December 31, 2011		9.0		$	52.64

The total fair values of shares associated with RSUs that vested during the year ended December 31, 2011, 2010 and 2009, were $176 million, $184 million and $139 million, respectively.

As of December 31, 2011, there was approximately $407 million of unrecognized compensation costs related to nonvested stock option and RSU awards, which is expected to be recognized over a weighted-average period of 1.7 years.

Performance units

Certain management-level employees also receive annual grants of performance units, which give the recipient the right to receive common stock that is contingent upon achievement of specified pre-established performance goals over the performance period, which is generally three years. The performance goals for the units granted in 2011, 2010 and 2009, which are accounted for as equity awards, are based upon Amgen’s annual stockholder return compared with a comparator group of companies, which are considered market conditions and are reflected in the grant date fair value of the units, and for units granted in 2010 and 2009, Amgen’s standalone financial performance, which are considered performance conditions. The expense recognized for the awards granted in 2011 is based on the grant date fair value of a unit multiplied by the number of units granted, net of estimated forfeitures. The expense recognized for the awards granted in 2010 and 2009 was based on the grant date fair value of a unit multiplied by the number of units expected to be earned with respect to the performance conditions, net of estimated forfeitures. Depending on the outcome of these performance goals, a recipient may ultimately earn a number of units greater or less than the number of units granted. Shares of our common stock are issued on a one-for-one basis for each performance unit earned. In general, participants vest in their performance unit awards at the end of the performance period. The performance award program provides for accelerated or continued vesting in certain circumstances as defined in the plan, including upon death, disability, a change in control and retirement of employees who meet certain service and/or age requirements.

We used payout simulation models to estimate the grant date fair value of performance units granted in 2011, 2010 and 2009. The weighted average assumptions used in these models and the resulting weighted average grant date fair values of our performance units were as follows for the years ended December 31, 2011, 2010 and 2009:


	2011		2010		2009
Closing price of our common stock on grant date	$	51.67	$	56.90	$	47.63
Volatility		32.8%		34.7%		34.3%
Risk-free interest rate		1.2%		1.3%		1.2%
Expected dividend yield		0.1%		0%		0%
Fair value of unit	$	49.50	$	62.06	$	48.22

The payout simulation models also assumed correlations of returns of the stock prices of our common stock and the common stocks of the comparator groups of companies and stock price volatilities of the comparator groups of companies.

As of December 31, 2011 and 2010, a total of 4.1 million and 2.7 million performance units were outstanding with weighted-average grant date fair values of $51.92 and $49.49 per unit, respectively. During the year ended December 31, 2011, 2.5 million performance units with a weighted average grant date fair value of $49.50 were granted, 0.4 million performance units with a grant date fair value of $48.22 vested and 0.2 million performance units with a weighted-average grant date fair value of $52.70 were forfeited.

The total fair values of performance units that vested during 2011, 2010 and 2009 were $25 million, $34 million and $29 million, respectively, based upon the number of performance units earned multiplied by the closing stock price of our common stock on the last day of the performance period. Performance unit awards granted for performance periods that ended prior to 2009 were accounted for as liability awards and were paid in the year after the performance period ended. Performance unit liability awards paid in 2009 aggregated $30 million.

As of December 31, 2011, there was approximately $90 million of unrecognized compensation cost related to the 2011 and 2010 performance unit grants that is expected to be recognized over a weighted-average period of approximately 1.1 years.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

+ Details

Income taxes

12 Months Ended

Dec. 31, 2011

Income taxes [Abstract]

Income taxes

4. Income taxes

The provision for income taxes includes the following for the years ended December 31, 2011, 2010 and 2009 (in millions):


	2011			2010			2009
Current provision:
Federal	$	618		$	636		$	325
State		58			52			85
Foreign		148			153			155

Total current provision		824			841			565

Deferred (benefit) provision:
Federal		(340	)		(196	)		92
State		(16	)		43			(59	)
Foreign		(1	)		2			1

Total deferred (benefit) provision		(357	)		(151	)		34

Total provision	$	467		$	690		$	599

Deferred income taxes reflect the temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, tax credit carryforwards and the tax effects of net operating loss carryforwards.

Significant components of our deferred tax assets and liabilities are as follows as of December 31, 2011 and 2010 (in millions):


	2011			2010
Deferred income tax assets:
Intercompany inventory related items	$	387		$	306
Expense accruals		751			626
Acquired net operating loss and credit carryforwards		192			147
Expenses capitalized for tax		167			188
Stock-based compensation		241			269
Deferred revenue		133			117
Other		72			72

Total deferred income tax assets		1,943			1,725
Valuation allowance		(126	)		(80	)

Net deferred income tax assets		1,817			1,645


Deferred income tax liabilities:
Acquired intangibles		(832	)		(739	)
Fixed assets		(219	)		(181	)
Unremitted foreign earnings		(61	)		(118	)
Other		(110	)		(142	)

Total deferred income tax liabilities		(1,222	)		(1,180	)

Total deferred income taxes, net	$	595		$	465

The valuation allowance for deferred tax assets increased by $46 million in 2011, due primarily to valuation allowances established as part of the BioVex and Dun Laoghaire acquisitions and the Company’s expectation that some state R&D credits will not be utilized, offset partially by the release of valuation allowance related to the expiration of state investment credits. The valuation allowance for deferred tax assets decreased by $12 million in 2010, due primarily to the utilization and expiration of certain acquired net operating loss carryforwards. Valuation allowances are provided when we believe our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax planning strategies.

At December 31, 2011, we had $44 million of tax credit carryforwards available to reduce future federal income taxes for which a full valuation allowance has been provided. In addition, we had $176 million of tax credit carryforwards available to reduce future state income taxes and have provided a valuation allowance for $67 million of those state tax credit carryforwards. The majority of the state tax credit carryforwards have no expiry; the remainder expires between 2012 and 2025.

The reconciliation of the total gross amounts of UTBs (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to UTBs) for the years ended December 31, 2011, 2010 and 2009, is as follows (in millions):


	2011			2010			2009
Balance at beginning of year	$	920		$	1,140		$	1,113
Additions based on tax positions related to the current year		283			305			302
Reductions for tax positions of prior years		(7	)		(110	)		(215	)
Settlements		(221	)		(415	)		(60	)

Balance at end of year	$	975		$	920		$	1,140

Substantially all of the UTBs as of December 31, 2011, if recognized, would affect our effective tax rate.

During the year ended December 31, 2011, we settled our examination with the Internal Revenue Service (IRS) related to certain transfer pricing tax positions for the years ended December 31, 2007, 2008 and 2009. As a result of these developments, we remeasured our UTBs accordingly.

During the year ended December 31, 2010, we settled our examination with the IRS related to certain transfer pricing tax positions for the years ended December 31, 2007 and 2008. In addition, we also settled issues under appeal with the IRS for the years ended December 31, 2005 and 2006, primarily related to the impact of transfer pricing adjustments on the repatriation of funds. During the year ended December 31, 2010, the IRS also agreed to Competent Authority relief for certain transfer pricing tax positions for the years ended December 31, 2002, through December 31, 2006. As a result of these developments, we remeasured our UTBs accordingly.

During the year ended December 31, 2009, we settled the examination of our U.S. income tax returns with the IRS for certain matters, primarily related to transfer pricing tax positions, for the years ended December 31, 2005 and 2006. Also during the year ended December 31, 2009, we settled the examination of our California state income tax returns for certain matters for the years ended December 31, 2004 and 2005. As a result of these developments, we remeasured our UTBs accordingly.

As of December 31, 2011, we believe it is reasonably possible that our gross liabilities for UTBs may decrease by approximately $270 million within the succeeding twelve months due to the resolution of federal and state audits.

Interest and penalties related to UTBs are included in our provision for income taxes. During 2011, 2010 and 2009, we accrued approximately $23 million, $41 million and $57 million, respectively, of interest and penalties through the income tax provision in the Consolidated Statements of Income. At December 31, 2011 and 2010, accrued interest and penalties associated with UTBs totaled approximately $105 million and $90 million, respectively.

The reconciliation between the federal statutory tax rate applied to income before income taxes and our effective tax rate for the years ended December 31, 2011, 2010 and 2009, is as follows:


	2011		2010		2009
Federal statutory tax rate		35.0 %		35.0 %		35.0 %
Foreign earnings, including earnings invested indefinitely		(19.4)%		(19.1)%		(19.6)%
State taxes		0.7 %		1.6 %		1.1 %
Credits, Puerto Rico Excise Tax		(6.5)%		0.0 %		0.0 %
Credits, primarily research and experimentation		(1.5)%		(0.9)%		(0.8)%
Legal settlements		2.2 %		0.0 %		0.0 %
Audit settlements		0.0 %		(3.1)%		(4.2)%
Other, net		0.8 %		(0.5)%		0.0 %

Effective tax rate		11.3 %		13.0 %		11.5 %

We do not provide for U.S. income taxes on undistributed earnings of our foreign operations that are intended to be invested indefinitely outside of the United States. Substantially all of the benefit from foreign earnings on our effective tax rate results from foreign income associated with the Company’s operation conducted in Puerto Rico that is subject to a tax incentive grant that expires in 2020. At December 31, 2011, the cumulative amount of these earnings was approximately $19.5 billion. If these earnings were repatriated to the United States, we would be required to accrue and pay approximately $6.9 billion of additional income taxes based on the current tax rates in effect.

Our total foreign income before income taxes was approximately $2.6 billion, $3.1 billion and $3.1 billion for the years ended December 31, 2011, 2010 and 2009, respectively.

Commencing January 1, 2011, Puerto Rico imposes a temporary excise tax on the acquisition of goods and services from a related manufacturer in Puerto Rico. The excise tax is imposed over a six year period beginning in 2011 with the excise tax rate declining in each year (4% in 2011, 3.75% in 2012, 2.75% in 2013, 2.5% in 2014, 2.25% in 2015, and 1% in 2016). We account for the excise tax as a manufacturing cost that is capitalized in inventory and expensed in cost of sales when the related products are sold. For U.S. income tax purposes, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes in the year in which the excise tax is incurred.

One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely audited by the tax authorities in those jurisdictions. Significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions, the use of tax credits and allocations of income among various tax jurisdictions because of differing interpretations of tax laws and regulations. We are no longer subject to U.S. federal income tax examinations for tax years ending on or before December 31, 2006, or to California state income tax examinations for tax years ending on or before December 31, 2003.

Income taxes paid during the years ended December 31, 2011, 2010 and 2009, totaled $595 million, $1,344 million and $497 million, respectively.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 136, 172
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43, 44, 45, 46, 47, 48, 49
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Earnings per share

12 Months Ended

Dec. 31, 2011

Earnings per share [Abstract]

Earnings per share

5. Earnings per share

The computation of basic earnings per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which principally include: shares that may be issued under our stock option, RSU and performance unit awards, determined using the treasury stock method; our outstanding convertible notes, as discussed below; and our outstanding warrants (collectively “dilutive securities”). The convertible note hedges purchased in connection with the issuance of our convertible notes are excluded from the calculation of diluted EPS because their impact is always anti-dilutive. For further information regarding our convertible notes and warrants, see Note 14, Financing arrangements.

Upon conversion of our convertible notes, the principal amount would be settled in cash, and the excess of the conversion value, as defined, over the principal amount may be settled in cash and/or shares of our common stock. Therefore, only the shares of our common stock potentially issuable with respect to the excess of the notes’ conversion value over their principal amount, if any, are considered as dilutive potential common shares for purposes of calculating diluted EPS. For the years ended December 31, 2011, 2010 and 2009, the conversion values for our convertible notes were less than the related principal amounts and, accordingly, no shares were assumed to be issued for purposes of computing diluted EPS.

The computation for basic and diluted EPS was as follows (in millions, except per share data):


	2011		2010		2009
Income (Numerator):
Net income for basic and diluted EPS	$	3,683	$	4,627	$	4,605

Shares (Denominator):
Weighted-average shares for basic EPS		905		960		1,016
Effect of dilutive securities		7		5		5

Weighted-average shares for diluted EPS		912		965		1,021

Basic EPS	$	4.07	$	4.82	$	4.53
Diluted EPS	$	4.04	$	4.79	$	4.51

For the years ended December 31, 2011, 2010 and 2009, there were employee stock-based awards, calculated on a weighted-average basis, to purchase 33 million, 43 million and 42 million shares of our common stock, respectively, that are not included in the computation of diluted EPS because their impact would have been anti-dilutive. In addition, shares of our common stock that may be issued upon exercise of our warrants are not included in the computation of diluted EPS for any of the periods presented above because their impact would have been anti-dilutive.

Collaborative arrangements

12 Months Ended

Dec. 31, 2011

Collaborative arrangements [Abstract]

Collaborative arrangements

6. Collaborative arrangements

A collaborative arrangement is a contractual arrangement that involves a joint operating activity. These arrangements involve two or more parties who are both: (i) active participants in the activity; and (ii) exposed to significant risks and rewards dependent on the commercial success of the activity.

From time to time, we enter into collaborative arrangements for the R&D, manufacture and/or commercialization of products and product candidates. These collaborations generally provide for non-refundable upfront license fees, regulatory and commercial performance milestone payments, cost sharing, royalty payments and/or profit sharing. Our collaboration agreements are performed on a “best efforts” basis with no guarantee of either technological or commercial success and each is unique in nature. Our significant arrangements are discussed below.

Pfizer Inc.

We are in a collaboration with Pfizer to co-promote ENBREL in the United States and Canada. The rights to market ENBREL outside of the United States and Canada are reserved to Pfizer. Under the agreement, a management committee comprised of equal representation from Amgen and Pfizer is responsible for overseeing the marketing and sales of ENBREL, including strategic planning, the approval of an annual marketing plan, product pricing and the establishment of a brand team. Amgen and Pfizer share in the agreed-upon selling and marketing expenses approved by the joint management committee. We currently pay Pfizer a percentage of annual gross profits on our ENBREL sales in the United States and Canada attributable to all approved indications on a scale that increases as gross profits increase; however, we maintain a majority share of ENBREL profits. After expiration of the agreement in the fourth quarter of 2013, we will be required to pay Pfizer a declining percentage of annual net ENBREL sales in the United States and Canada for three years, ranging from 12% to 10%. The amounts of such payments are anticipated to be significantly less than what would be owed based on the terms of the current ENBREL profit share.

We have determined that we are the principal participant in the collaboration with Pfizer to market ENBREL in the United States and Canada. Accordingly, we record our product sales of ENBREL to third parties net of estimated returns, rebates and other deductions. For the years ended December 31, 2011, 2010 and 2009, ENBREL sales aggregated $3.7 billion, $3.5 billion and $3.5 billion, respectively.

During the years ended December 31, 2011, 2010 and 2009, the ENBREL profit share expense was $1,288 million, $1,184 million and $1,163 million, respectively, and is included in Selling, general and administrative expense in the Consolidated Statements of Income. In addition, cost recoveries from Pfizer for their share of the selling and marketing expense were $84 million, $87 million and $75 million for the years ended December 31, 2011, 2010 and 2009, respectively, and are included in Selling, general and administrative expense in the Consolidated Statements of Income.

Glaxo Group Limited

We are in a collaboration with Glaxo Group Limited (Glaxo), a wholly owned subsidiary of GlaxoSmithKline plc, for the commercialization of denosumab for osteoporosis indications in Europe, Australia, New Zealand and Mexico (the Primary Territories). We have retained the rights to commercialize denosumab for all indications in the United States and Canada and for oncology indications in the Primary Territories. Under a related agreement, Glaxo will commercialize denosumab for all indications in countries, excluding Japan, where we did not have a commercial presence at the commencement of the agreement, including China, Brazil, India, Taiwan and South Korea (the Expansion Territories). In the Expansion Territories, Glaxo is responsible for all development and commercialization costs and will purchase denosumab from us to meet demand. In the future, we have the option of expanding our role in the commercialization of denosumab in the Primary Territories and certain of the Expansion Territories.

In the Primary Territories, we share equally in the commercialization profits and losses related to the collaboration after accounting for expenses, including an amount payable to us in recognition of our discovery and development of denosumab. Glaxo is also responsible for bearing a portion of the cost of certain specified development activities in the Primary Territories.

The collaboration agreement with Glaxo for the Primary Territories will expire in 2022 and the related agreement for the Expansion Territories will expire in 2024, unless either agreement is terminated earlier in accordance with its terms.

As the principal participant in the Primary Territories, Amgen records related product sales to third parties net of estimated returns, rebates and other deductions. During the years ended December 31, 2011 and 2010, product sales in the Primary Territories for osteoporosis indications were $62 million and $5 million, respectively. In the Expansion Territories, we record product sales to Glaxo. During the years ended December 31, 2011 and 2010, product sales of denosumab to Glaxo for the Expansion Territories were not material.

During the years ended December 31, 2011, 2010 and 2009, the net recoveries from Glaxo were $30 million, $46 million and $29 million, respectively, and are included in Selling, general and administrative expense in the Consolidated Statements of Income. In addition, during 2010, we received payments aggregating $75 million for the achievement of certain commercial milestones, which were recognized upon the achievement of the related milestone events as Other revenue in our Consolidated Statement of Income. Under these agreements, we also received an initial payment of $45 million during the year ended December 31, 2009, which was deferred and is being recognized as Other revenue in our Consolidated Statements of Income, over our estimated period of continuing involvement of approximately 13 years.

Takeda Pharmaceutical Company Limited

We are in a collaboration with Takeda Pharmaceutical Company Limited (Takeda), which provides Takeda the exclusive rights to develop and commercialize for the Japanese market up to 12 molecules from our portfolio across a range of therapeutic areas, including oncology and inflammation (collectively the “Japanese market products”) and for the worldwide development and commercialization of our product candidate, motesanib, in the oncology area. The Japanese market products include: (i) Vectibix ^®, which received regulatory approval in Japan, in 2010, for unresectable, advanced or recurrent colorectal cancer with wild-type KRAS, (ii) AMG 386, which is in a phase 3 trial for recurrent ovarian cancer, and (iii) ganitumab (AMG 479), which is in a phase 3 trial for first-line metastatic pancreatic cancer. Through collaboration committees, the parties jointly coordinate and oversee Takeda’s development and commercialization of the Japanese market products in Japan. The parties share responsibility for the development of motesanib outside Japan and Takeda is responsible for development in Japan. Additionally, Amgen shall be responsible for commercialization of motesanib in North America and Takeda shall be responsible for commercialization outside of North America. Each party has the right to participate in the commercialization of motesanib in the other party’s territory. In addition, under the collaboration Amgen will manufacture and supply Takeda motesanib and the Japanese market products for both clinical and commercial purposes. In 2011, we announced that the motesanib pivotal phase 3 trial (MONET1) did not meet its primary objective of demonstrating an improvement in overall survival.

For the Japanese market products Takeda is obligated to pay Amgen up to an additional $60 million of future worldwide development costs for these products in 2012 and a reduced amount of such costs, thereafter. Takeda will be solely responsible for all development and commercialization costs of these products in Japan and will pay Amgen royalties on future sales in Japan. Amgen has the right to participate in the promotion of these products in Japan. With respect to motesanib, Takeda is obligated to pay 60% of future worldwide development costs (excluding Japan, for which Takeda shall bear all such costs), and the parties will share equally all other costs and profits resulting from the commercialization of motesanib outside Japan. If approved for sale, Amgen will receive royalties on future sales of motesanib in Japan.

The collaboration agreements will continue in effect unless terminated earlier in accordance with their terms.

In connection with the collaboration, Amgen received upfront payments of $300 million in 2008 which were deferred and are being recognized as Other revenue in our Consolidated Statements of Income, over our estimated period of continuing involvement of approximately 20 years. Additionally, during 2010, we received payments aggregating $55 million for the achievement of certain regulatory milestones which were recognized as Other revenue in our Consolidated Statement of Income upon the achievement of the related milestone events. We may also receive numerous individually immaterial milestones aggregating $472 million upon the achievement of various substantive success-based development and regulatory approval milestones. The receipt of these amounts, however, is contingent upon the occurrence of various future events which have a high degree of uncertainty of occurring.

During the years ended December 31, 2011, 2010 and 2009, cost recoveries from Takeda were $83 million, $91 million and $112 million, respectively, and are included in Research and development expense in the Consolidated Statements of Income. In addition, for the years December 31, 2011 and 2010, we recognized royalties on sales of Vectibix^® in Japan of $20 million and $7 million, respectively.

Daiichi Sankyo Company, Limited

We are in a collaboration with Daiichi Sankyo Company, Limited (Daiichi Sankyo), which provides Daiichi Sankyo the exclusive rights to develop and commercialize denosumab in Japan for osteoporosis, oncology and certain other indications. As part of the agreement, Amgen received exclusive worldwide rights to certain Daiichi Sankyo intellectual property to the extent applicable to denosumab. Through collaboration committees, the parties jointly coordinate and oversee Daiichi Sankyo’s development and commercialization of denosumab in Japan.

Under the terms of the agreement, Daiichi Sankyo assumed all related development and commercialization costs in Japan and agreed to reimburse Amgen for certain worldwide development costs related to denosumab. As of December 31, 2009, Daiichi Sankyo had substantially satisfied its obligations to reimburse Amgen for these costs. If approved for sale, Amgen will receive royalties on future sales of denosumab recorded by Daiichi Sankyo in Japan.

Pursuant to the terms of the agreement, we paid Daiichi Sankyo milestone payments aggregating $60 million, in 2010, as a result of various regulatory approvals of denosumab. The milestone payments were capitalized within Intangible assets, net in the Consolidated Balance Sheets and are being amortized over 11 years and the amortization expense is included in Cost of sales (excludes amortization of certain acquired intangible assets) in the Consolidated Statements of Income.

The collaboration agreement will expire in 2027 unless terminated earlier in accordance with its terms.

During the years ended December 31, 2011, 2010 and 2009, cost recoveries from Daiichi Sankyo were $4 million, $3 million and $64 million, respectively. The cost recoveries are included in Research and development expense in the Consolidated Statements of Income.

Other

We have various other collaborations, in addition to those discussed above, that are not individually significant to our business at this time. Pursuant to the terms of those agreements, we may be required to pay or we may receive additional amounts upon the achievement of various development, regulatory and commercial milestones which in the aggregate could be significant. We may also incur or have reimbursed to us significant R&D costs if the related product candidate were to advance to late stage clinical trials. In addition, if any products related to these collaborations are approved for sale, we may be required to pay or we may receive significant royalties on future sales. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty of occurring.

Related party transactions

12 Months Ended

Dec. 31, 2011

Related party transaction

7. Related party transactions

We own a 50% interest in K-A, a corporation formed in 1984 with Kirin Holdings Company, Limited (Kirin) for the development and commercialization of certain products based on advanced biotechnology. All of our rights to manufacture and market certain products including pegfilgrastim, granulocyte colony-stimulating factor, darbepoetin alfa, recombinant human erythropoietin and romiplostim are pursuant to exclusive licenses from K-A, which we currently market under the brand names Neulasta^®, NEUPOGEN^®, Aranesp ^®, EPOGEN^®, and Nplate^®, respectively.

We account for our interest in K-A using the equity method and include our share of K-A’s profits or losses in Selling, general and administrative expense in the Consolidated Statements of Income. For the years ended December 31, 2011, 2010 and 2009, our share of K-A’s profits was $47 million, $71 million and $72 million, respectively. During 2009, we received $110 million in dividends from K-A. At both December 31, 2011 and 2010, the carrying value of our equity method investment in K-A, net of dividends received, was approximately $0.4 billion and is included in noncurrent Other assets in the Consolidated Balance Sheets.

K-A’s revenues consist of royalty income related to its licensed technology rights. K-A receives royalty income from us, as well as from Kirin, J&J and F. Hoffmann-La Roche Ltd. (Roche) under separate product license contracts for certain geographic areas outside of the United States. During the years ended December 31, 2011, 2010 and 2009, K-A earned royalties from us of $298 million, $322 million and $327 million, respectively. These amounts are included in Cost of sales (excludes amortization of certain acquired intangible assets) in the Consolidated Statements of Income.

K-A’s expenses consist primarily of costs related to R&D activities conducted on its behalf by Amgen and Kirin. K-A pays Amgen and Kirin for such services at negotiated rates. During the years ended December 31, 2011, 2010 and 2009, we earned revenues from K-A of $130 million, $96 million and $102 million, respectively, for certain R&D activities performed on K-A’s behalf. These amounts are recognized as Other revenues in the Consolidated Statements of Income. We may also receive numerous individually immaterial milestones aggregating $125 million upon the achievement of various substantive success-based development and regulatory approval milestones contingent upon the occurrence of various future events, most of which have a high degree of uncertainty of occurring. During the years ended December 31, 2011, 2010 and 2009, we recorded cost recoveries from K-A of $85 million, $88 million and $96 million, respectively, related to certain third-party costs. These amounts are included in Research and development expense in the Consolidated Statements of Income.

As of December 31, 2011 and 2010, we owed K-A $75 million and $62 million, respectively, which are included in Accrued liabilities in the Consolidated Balance Sheets.

- Definition

The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 4
-Section 08
-Paragraph k

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 3A
-Section 04
-Paragraph b

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 57
-Paragraph 1-4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

+ Details

Cost savings initiatives and restructuring

12 Months Ended

Dec. 31, 2011

Cost savings initiatives and restructuring [Abstract]

Cost savings initiatives and restructuring

8. Cost savings initiatives and restructuring

Manufacturing operations optimization

As part of our continuing efforts to optimize our network of manufacturing facilities and improve cost efficiencies, on January 18, 2011, we entered into an agreement whereby Boehringer Ingelheim (BI) agreed to acquire our rights in and substantially all assets at our manufacturing facility located in Fremont, California. The transaction was approved by Amgen’s Board of Directors in December 2010 and closed in March 2011. In connection with the closing of this transaction, BI has assumed our obligations under certain of the facility’s operating lease contracts and has entered into an agreement to manufacture certain quantities of our marketed product Vectibix^® for us at this facility through December 31, 2012 (the supply period).

We considered the transaction with BI to be a potential indicator of impairment, and accordingly, we performed an impairment analysis of the carrying values of the related fixed assets as of December 31, 2010. Based on this analysis, we determined that no future economic benefit would be received from a manufacturing line at the facility that had not yet been completed. As a result, we wrote off its entire carrying value, which aggregated $118 million during the year ended December 31, 2010. This amount is included in Other operating expenses in the Consolidated Statement of Income. The carrying values of the remaining fixed assets, aggregating approximately $133 million at December 31, 2010, were determined to be fully recoverable.

Due to the lack of sufficient initial investment by BI in the acquisition of this facility and our ongoing involvement with these operations, the transaction did not meet the accounting requirements to be treated as a sale involving real estate. As a result, the related assets continue to be carried on our Consolidated Balance Sheets.

As a result of this transaction, we reduced the estimated useful lives of the remaining fixed assets to coincide with the supply period. During the year ended December 31, 2011, we recorded incremental depreciation of approximately $42 million in excess of what otherwise would have been recorded. In addition, due to the assignment to BI of the obligations under certain of the facility’s operating leases, we recorded charges of approximately $23 million during the year ended December 31, 2011, with respect to the lease period beyond the end of the supply period. These amounts are recorded in Cost of sales (excludes amortization of certain acquired intangible assets presented separately) in the Consolidated Statement of Income.

Other cost savings initiatives

As part of our continuing efforts to improve cost efficiencies in our operations, we recorded certain charges, primarily severance-related, aggregating approximately $109 million during the year ended December 31, 2011, which are included in Other operating expenses in the Consolidated Statement of Income.

Restructuring

On August 15, 2007, we announced a plan to restructure our worldwide operations in order to improve our cost structure. This restructuring plan was primarily the result of regulatory and reimbursement developments that began in 2007 involving erythropoiesis-stimulating agents (ESAs), including our marketed ESAs, Aranesp^® and EPOGEN^®, and the resulting impact on our operations. As of December 31, 2009, we completed all of the actions included in our restructuring plan and subsequently identified initiatives. During the year ended December 31, 2009, we recorded charges associated with these actions aggregating $70 million, comprised primarily of staff separation costs of $25 million, included principally in Other operating expenses in the Consolidated Statement of Income, and integration-related costs of $32 million, which were included principally in Selling, general and administrative expenses in the Consolidated Statement of Income.

- Definition

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

+ References + Details

Available-for-sale investments

12 Months Ended

Dec. 31, 2011

Available-for-sale investments [Abstract]

Available-for-sale investments

9. Available-for-sale investments

The amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security were as follows (in millions):


Type of security as of December 31, 2011	Amortized cost		Gross unrealized gains		Gross unrealized losses			Estimated fair value
U.S. Treasury securities	$	3,878	$	68	$	—		$	3,946
Other government-related debt securities:
Obligations of U.S. government agencies and FDIC-guaranteed bank debt		1,548		23		—			1,571
Foreign and other		441		9		—			450
Corporate debt securities:
Financial		2,493		30		(15	)		2,508
Industrial		3,077		79		(10	)		3,146
Other		280		9		-			289
Mortgage- and asset-backed securities		1,789		6		(10	)		1,785
Money market mutual funds		6,266		—		—			6,266

Total debt security investments		19,772		224		(35	)		19,961
Equity securities		42		—		—			42

Total available-for-sale investments	$	19,814	$	224	$	(35	)	$	20,003


Type of security as of December 31, 2010	Amortized cost		Gross unrealized gains		Gross unrealized losses			Estimated fair value
U.S. Treasury securities	$	5,044	$	50	$	(14	)	$	5,080
Other government-related debt securities:
Obligations of U.S. government agencies and FDIC-guaranteed bank debt		2,158		51		(1	)		2,208
Foreign and other		837		16		(1	)		852
Corporate debt securities:
Financial		2,252		53		(9	)		2,296
Industrial		2,441		71		(5	)		2,507
Other		307		10		(1	)		316
Mortgage- and asset-backed securities		841		5		(5	)		841
Money market mutual funds		3,030		—		—			3,030
Other short-term interest-bearing securities		147		—		—			147

Total debt security investments		17,057		256		(36	)		17,277
Equity securities		50		—		(2	)		48

Total available-for-sale investments	$	17,107	$	256	$	(38	)	$	17,325

The fair values of available-for-sale investments by classification in the Consolidated Balance Sheets were as follows as of December 31, 2011 and 2010 (in millions):


Classification in the Consolidated Balance Sheets	2011		2010
Cash and cash equivalents	$	6,266	$	3,142
Marketable securities		13,695		14,135
Other assets — noncurrent		42		48

Total available-for-sale investments	$	20,003	$	17,325

Cash and cash equivalents in the table above excludes cash of $680 million and $145 million as of December 31, 2011 and 2010, respectively.

The fair values of available-for-sale debt security investments by contractual maturity were as follows as of December 31, 2011 and 2010 (in millions):


Contractual maturity	2011		2010
Maturing in one year or less	$	6,811	$	4,118
Maturing after one year through three years		6,346		6,736
Maturing after three years through five years		5,710		5,812
Maturing after five years		1,094		611

Total debt securities	$	19,961	$	17,277

For the years ended December 31, 2011, 2010 and 2009, realized gains totaled $191 million, $115 million and $104 million, respectively, and realized losses totaled $37 million, $25 million and $62 million, respectively. The cost of securities sold is based on the specific identification method.

The primary objective of our investment portfolio is to enhance overall returns in an efficient manner while maintaining safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits debt security investments to certain types of debt and money market instruments issued by institutions with primarily investment grade credit ratings and places restrictions on maturities and concentration by asset class and issuer.

We review our available-for-sale investments for other-than-temporary declines in fair value below our cost basis each quarter and whenever events or changes in circumstances indicate that the cost basis of an asset may not be recoverable. This evaluation is based on a number of factors including, the length of time and the extent to which the fair value has been below our cost basis and adverse conditions related specifically to the security, including any changes to the credit rating of the security. As of December 31, 2011 and 2010, we believe the cost bases for our available-for-sale investments were recoverable in all material respects.

- Definition

Tabular disclosure of investments in certain debt and equity securities (and certain other trading assets) which include all debt and equity securities (other than those equity securities accounted for under the equity or cost methods of accounting) with readily determinable fair values. Other trading assets include assets that are carried on the balance sheet at fair value and held for trading purposes. A debt security represents a creditor relationship with an enterprise that is in the form of a security. Debt securities include, among other items, US Treasury securities, US government securities, municipal securities, corporate bonds, convertible debt, commercial paper, and all securitized debt instruments. An equity security represents an ownership interest in an enterprise or the right to acquire or dispose of an ownership interest in an enterprise at fixed or determinable prices. Equity securities include, among other things, common stock, certain preferred stock, warrant rights, call options, and put options, but do not include convertible debt. An entity may opt to provide the reader with additional narrative text to better understand the nature of investments in debt and equity securities (and other trading assets).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 3, 19, 20, 21, 22, 137
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6379141&loc=d3e15032-111544

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27161-111563

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27357-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27290-111563

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27405-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27232-111563

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Debt Security
-URI http://asc.fasb.org/extlink&oid=6509901
-Topic 320

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Equity Security
-URI http://asc.fasb.org/extlink&oid=6511694
-Topic 320

+ Details

Inventories

12 Months Ended

Dec. 31, 2011

Inventories [Abstract]

Inventories

10. Inventories

Inventories consisted of the following as of December 31, 2011 and 2010 (in millions):


	2011		2010
Raw materials	$	158	$	128
Work in process		1,802		1,382
Finished goods		524		512

Total inventories	$	2,484	$	2,022

Property, plant and equipment

12 Months Ended

Dec. 31, 2011

Property, plant and equipment [Abstract]

Property, plant and equipment

11. Property, plant and equipment

Property, plant and equipment consisted of the following as of December 31, 2011 and 2010 (dollar amounts in millions):


	Useful life (in years)		2011		2010
Land		—	$	366	$	361
Buildings and improvements		10-40		3,463		3,392
Manufacturing equipment		8-12		1,897		1,802
Laboratory equipment		8-12		1,016		955
Other		3-15		3,745		3,547
Construction in progress		—		744		631

Property, plant and equipment, gross				11,231		10,688
Less accumulated depreciation and amortization				(5,811)		(5,166)

Property, plant and equipment, net			$	5,420	$	5,522

During the years ended December 31, 2011, 2010 and 2009, we recognized depreciation and amortization charges associated with our property, plant and equipment of $679 million, $594 million and $624 million, respectively.

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References + Details

Intangible assets

12 Months Ended

Dec. 31, 2011

Intangible assets [Abstract]

Intangible assets

12. Intangible assets

Finite-lived and indefinite-lived identifiable intangible assets consisted of the following as of December 31, 2011 and 2010 (in millions):


	2011						2010
	Gross carrying amount		Accumulated amortization		Intangible assets, net		Gross carrying amount		Accumulated amortization		Intangible assets, net
Finite-lived intangible assets:
Acquired product technology rights:
Developed product technology	$	2,872	$	(1,811)	$	1,061	$	2,872	$	(1,619)	$	1,253
Core technology		1,348		(850)		498		1,348		(760)		588
Trade name		190		(120)		70		190		(107)		83
Acquired R&D technology rights		350		(350)		—		350		(329)		21
Other acquired intangible assets		686		(406)		280		627		(342)		285

Total finite-lived intangible assets		5,446		(3,537)		1,909		5,387		(3,157)		2,230
Indefinite-lived intangible assets — IPR&D		675		—		675		—		—		—

Total identifiable intangible assets	$	6,121	$	(3,537)	$	2,584	$	5,387	$	(3,157)	$	2,230

Amortization of finite-lived intangible assets is provided over their estimated useful lives ranging from 5 to 15 years on a straight-line basis.

Acquired product technology rights relate to the identifiable intangible assets acquired in connection with the 2002 Immunex acquisition and the related amortization expense is included in Amortization of certain acquired intangible assets in the Consolidated Statements of Income. Acquired R&D technology rights consist of technology used in R&D with alternative future uses and the related amortization expense is included in Research and development expense in the Consolidated Statements of Income. The amortization expense related to other acquired intangible assets is included principally in Cost of sales (excludes amortization of certain acquired intangible assets) and Selling, general and administrative expense in the Consolidated Statements of Income. During the years ended December 31, 2011, 2010 and 2009, we recognized amortization charges associated with our finite-lived intangible assets of $380 million, $423 million and $425 million, respectively. The total estimated amortization for each of the next five years for our intangible assets is $354 million, $359 million, $340 million, $327 million and $317 million in 2012, 2013, 2014, 2015 and 2016, respectively.

IPR&D relates to identifiable intangible assets acquired in connection with the acquisition of BioVex. (See Note 2, Business combinations — BioVex Group, Inc.)

Accrued liabilities

12 Months Ended

Dec. 31, 2011

Accrued liabilities [Abstract]

Accrued Liabilities

13. Accrued liabilities

Accrued liabilities consisted of the following as of December 31, 2011 and 2010 (in millions):


	2011		2010
Sales deductions	$	1,326	$	1,144
Employee compensation and benefits		916		764
Sales returns reserve		339		339
Legal reserve		780		—
Other		1,667		1,119

Total accrued liabilities	$	5,028	$	3,366

See Note 18, Contingencies and commitments, for further discussion of the legal reserve.

Financing arrangements

12 Months Ended

Dec. 31, 2011

Financing arrangements [Abstract]

Financing arrangements

14. Financing arrangements

The carrying values and the fixed contractual coupon rates of our long-term borrowings were as follows as of December 31, 2011 and 2010 (in millions):


	2011		2010
0.125% convertible notes due 2011 (0.125% 2011 Convertible Notes)	$	—	$	2,488
0.375% convertible notes due 2013 (0.375% 2013 Convertible Notes)		2,346		2,213
1.875% notes due 2014 (1.875% 2014 Notes)		1,000		—
4.85% notes due 2014 (4.85% 2014 Notes)		1,000		1,000
2.30% notes due 2016 (2.30% 2016 Notes)		748		—
2.50% notes due 2016 (2.50% 2016 Notes)		999		—
5.85% notes due 2017 (5.85% 2017 Notes)		1,099		1,099
6.15% notes due 2018 (6.15% 2018 Notes)		499		499
4.375% euro denominated notes due 2018 (4.375% 2018 euro Notes)		714		—
5.70% notes due 2019 (5.70% 2019 Notes)		998		998
4.50% notes due 2020 (4.50% 2020 Notes)		300		300
3.45% notes due 2020 (3.45% 2020 Notes)		897		897
4.10% notes due 2021 (4.10% 2021 Notes)		998		—
3.875% notes due 2021 (3.875% 2021 Notes)		1,745		—
5.50% pound sterling denominated notes due 2026 (5.50% 2026 pound sterling Notes)		739		—
6.375% notes due 2037 (6.375% 2037 Notes)		899		899
6.90% notes due 2038 (6.90% 2038 Notes)		499		499
6.40% notes due 2039 (6.40% 2039 Notes)		996		996
5.75% notes due 2040 (5.75% 2040 Notes)		697		696
4.95% notes due 2041 (4.95% 2041 Notes)		595		595
5.15% notes due 2041 (5.15% 2041 Notes)		2,232		—
5.65% notes due 2042 (5.65% 2042 Notes)		1,244		—
Other notes, including our zero-coupon convertible notes		184		183

Total debt		21,428		13,362
Less current portion		(84)		(2,488)

Total noncurrent debt	$	21,344	$	10,874

Debt repayments

In February 2011, our 0.125% 2011 Convertible Notes became due, and we repaid the $2.5 billion aggregate principal amount. As these convertible notes were cash settleable, their debt and equity components were bifurcated and accounted for separately. The discounted carrying value of the debt component resulting from the bifurcation was accreted back to the principal amount over the period the notes were outstanding. The total aggregate amount repaid, including the amount related to the debt discount of $643 million resulting from the bifurcation, is included in Cash flows from financing activities in the Consolidated Statement of Cash Flows. No debt was due or repaid in 2010, and we repaid $1.0 billion aggregate principal amount of notes with a fixed interest rate of 4.00% in 2009.

Debt issuances

We issued debt securities in various offerings during the three years ended December 31, 2011, including:

•

In 2011, we issued $10.5 billion aggregate principal amount of notes, comprised of the 1.875% 2014 Notes, the 2.30% 2016 Notes, the 2.50% 2016 Notes, the 4.375% 2018 euro Notes (€550 million aggregate principal amount), the 4.10% 2021 Notes, the 3.875% 2021 Notes, the 5.50% 2026 pound sterling Notes (£475 million aggregate principal amount), the 5.15% 2041 Notes and the 5.65% 2042 Notes.

•

In 2010, we issued $2.5 billion aggregate principal amount of notes, comprised of the 4.50% 2020 Notes, the 3.45% 2020 Notes, the 5.75% 2040 Notes and the 4.95% 2041 Notes.

•

In 2009, we issued $2.0 billion aggregate principal amount of notes, comprised of the 5.70% 2019 Notes and the 6.40% 2039 Notes.

Debt issuance costs incurred in connection with these debt offerings in 2011, 2010 and 2009 totaled $55 million, $17 million and $13 million, respectively. These debt issuance costs are being amortized over the respective lives of the notes, and the related charge is included in Interest expense, net, in the Consolidated Statements of Income.

All of our debt issuances other than our 0.375% 2013 Convertible Notes and Other notes may be redeemed at any time at our option, in whole or in part, at the principal amount of the notes being redeemed plus accrued interest and a make-whole amount, as defined. In addition, except with respect to our 0.375% 2013 Convertible Notes, the 4.85% 2014 Notes and Other notes, in the event of a change in control triggering event, as defined, we may be required to purchase for cash all or a portion of these debt issuances at a price equal to 101% of the principal amount of the notes plus accrued interest.

Convertible Notes

In 2006, we issued $5.0 billion principal amount of convertible notes at par. While outstanding, the notes are convertible into shares of our common stock upon the occurrence of specified events. In February 2011, $2.5 billion principal amount of the convertible notes (the 0.125% 2011 Convertible Notes) became due and were repaid in full. While outstanding, the conversion rate on the 0.125% 2011 Convertible Notes was 12.5247 shares per $1,000 principal amount of notes, which represented a conversion price of approximately $79.84 per share. The conversion rate on the $2.5 billion principal amount of convertible notes, which mature in February 2013 (the 0.375% 2013 Convertible Notes), was 12.7473 shares per $1,000 principal amount of notes at December 31, 2011, which represents a conversion price of approximately $78.45 per share. This conversion rate is adjusted as we make specified types of distributions, including paying cash dividends on our common stock, or enter into certain other transactions with respect to our common stock. The 0.375% 2013 Convertible Notes may only be converted: (i) during any calendar quarter if the closing price of our common stock exceeds 130% of the then conversion price per share during a defined period at the end of the previous quarter, (ii) if we make specified distributions to holders of our common stock or specified corporate transactions occur or (iii) within one month prior to the maturity date. Upon conversion, a holder would receive the conversion value equal to the conversion rate multiplied by the volume weighted-average price of our common stock during a specified period following the conversion date. The conversion value will be paid in: (i) cash equal to the lesser of the principal amount of the note or the conversion value, as defined, and (ii) cash, shares of our common stock, or a combination of cash and shares of our common stock, at our option, to the extent the conversion value exceeds the principal amount of the note (the excess conversion value). In addition, upon a change in control, as defined, the holders may require us to purchase for cash all or a portion of their notes for the principal amount of the notes plus accrued interest. As of December 31, 2011, the 0.375% 2013 Convertible Notes were not convertible. While outstanding, the 0.125% 2011 Convertible Notes had terms similar to the 0.375% 2013 Convertible Notes.

Concurrent with the issuance of the 0.375% 2013 Convertible Notes, we purchased a convertible note hedge. The convertible note hedge allows us to receive shares of our common stock and/or cash from the counterparty to the transaction equal to the amounts of common stock and/or cash related to the excess conversion value that we would issue and/or pay to the holders of the 0.375% 2013 Convertible Notes upon conversion. This convertible note hedge will terminate at the earlier of the maturity of the 0.375% 2013 Convertible Notes or the first day none of these notes remain outstanding due to conversion or otherwise. We also purchased a convertible note hedge with similar terms in connection with the issuance of the 0.125% 2011 Convertible Notes, which terminated unexercised when these notes were repaid.

Also concurrent with the issuance of the 0.375% 2013 Convertible Notes, we sold warrants to acquire 31.5 million shares of our common stock in May 2013 (the settlement date) at an exercise price of $107.90 per share. If the average price of our common stock during a defined period ending on or about the settlement date exceeds the exercise price of the warrants, the warrants will be net settled, at our option, in cash or shares of our common stock. In connection with the issuance of the 0.125% 2011 Convertible Notes, we sold warrants to purchase 31.3 million shares of our stock on similar terms, which expired unexercised in May 2011.

Because the convertible note hedges and warrants can be settled at our option in cash or shares of our common stock, and these contracts meet all of the applicable criteria for equity classification under the applicable accounting standards, the cost of the convertible note hedges and net proceeds from the sale of the warrants are classified in Stockholders’ equity in the Consolidated Balance Sheets. In addition, because both of these contracts are classified in Stockholders’ equity and are indexed to our common stock, they are not accounted for as derivatives.

As required for cash settleable convertible notes, the debt and equity components of the 0.375% 2013 Convertible Notes were bifurcated and accounted for separately. The resulting discounted carrying value of the debt is being accreted back to the principal amount through the scheduled maturity date, resulting in the recognition of non-cash interest expense. After giving effect to this bifurcation, the effective interest rate on this borrowing is 6.35%. For the years ended December 31, 2011, 2010 and 2009, total interest expense for the 0.375% 2013 Convertibles Notes was $143 million, $134 million, and $127 million, respectively, including non-cash interest expense of $133 million, $125 million, and $118 million, respectively. While outstanding, the 0.125% 2011 Convertible Notes were accounted for in the same manner, resulting in an effective interest rate of 6.24%. For the years ended December 31, 2011, 2010 and 2009, total interest expense for the 0.125% 2011 Convertible Notes was $13 million, $149 million, and $140 million, respectively, including non-cash interest expense of $12 million, $146 million, and $136 million, respectively.

The principal balance, unamortized discount and net carrying amount of the liability and equity components of our 0.375% 2013 Convertible Notes were as follows as of December 31, 2011 and 2010 (in millions):


	Liability component						Equity component
0.375% 2013 Convertible Notes	Principal balance		Unamortized discount		Net carrying amount		Net carrying amount
December 31, 2011	$	2,500	$	154	$	2,346	$	829
December 31, 2010	$	2,500	$	287	$	2,213	$	829

Other

Other notes include zero-coupon convertible notes due in 2032 with a carrying value of $84 million and $83 million at December 31, 2011 and 2010, respectively, and notes due in 2097 with a carrying value of $100 million.

Interest rate swaps

To achieve a desired mix of fixed and floating interest rate debt, we enter into interest rate swap contracts that effectively convert a fixed rate interest coupon for certain of our debt issuances to a floating London Interbank Offered Rate (LIBOR)-based coupon over the life of the respective note. These interest rate swap contracts qualify and are designated as fair value hedges. The effective interest rates on these notes after giving effect to the related interest rate swap contracts and the notional amounts of these interest rate swap contracts were as follows as of December 31, 2011 and 2010 (dollar amounts in millions):


		Notional amount
	Effective interest rate	2011		2010
4.85% 2014 Notes	LIBOR + 0.3%	$	1,000	$	1,000
5.85% 2017 Notes	LIBOR + 2.5%		1,100		1,100
6.15% 2018 Notes	LIBOR + 1.8%		500		500
5.70% 2019 Notes	LIBOR + 2.6%		1,000		1,000

		$	3,600	$	3,600

Cross currency swaps

In order to hedge our exposure to foreign currency exchange rate risk associated with our pound sterling denominated long-term notes issued in 2011, we entered into cross currency swap contracts. These cross currency swap contracts qualify and are designated as cash flow hedges. Under the terms of these contracts, we receive interest payments in pounds sterling at a fixed rate of 5.5% on £475 million and pay interest in U.S. dollars at a fixed rate of 5.8% on $748 million, the aggregate notional amounts paid to/received from the counterparties upon exchange of currencies at the inception of these contracts. We will pay U.S. dollars to and receive pounds sterling from the counterparties at the maturity of the contracts for the same notional amounts. The terms of these contracts correspond to the related hedged notes, effectively converting the interest payments and principal repayment on these notes from pounds sterling to U.S. dollars.

Shelf registration statements and other facilities

As of December 31, 2011, we have a commercial paper program that allows us to issue up to $2.5 billion of unsecured commercial paper to fund our working capital needs. At December 31, 2011 and 2010, we had no amounts outstanding under our commercial paper program.

In December 2011, we entered into a $2.5 billion syndicated, unsecured, revolving credit agreement which is available for general corporate purposes or as a liquidity backstop to our commercial paper program. The commitments under the revolving credit agreement may be increased by up to $500 million with the agreement of the banks. Each bank which is a party to the agreement has an initial commitment term of five years. This term may be extended for up to two additional one-year periods with the agreement of the banks. Annual commitment fees for this agreement are 0.1% based on our current credit rating. We would be charged interest at LIBOR plus 0.9% for any amounts borrowed under this facility. As of December 31, 2011, no amounts were outstanding under this facility. In connection with the new revolving credit agreement we terminated our prior $2.3 billion revolving credit agreement that was scheduled to expire in November 2012.

In March 2011, we filed a shelf registration statement with the U.S. Securities and Exchange Commission to replace an existing shelf registration statement that was scheduled to expire in April 2011. This shelf registration statement allows us to issue unspecified amounts of debt securities; common stock; preferred stock; warrants to purchase debt securities, common stock, preferred stock or depository shares; rights to purchase common stock or preferred stock; securities purchase contracts; securities purchase units; and depository shares. Under this shelf registration statement, all of the securities available for issuance may be offered from time to time with terms to be determined at the time of issuance. This shelf registration statement expires in March 2014.

In 1997, we established a $400 million medium-term note program under which medium-term debt securities may be offered from time to time with terms to be determined at the time of issuance. As of December 31, 2011 and 2010, no securities were outstanding under this medium-term note program.

Certain of our financing arrangements contain non-financial covenants. In addition, our revolving credit agreement includes a financial covenant with respect to the level of our borrowings in relation to our equity, as defined. We were in compliance with all applicable covenants under these arrangements as of December 31, 2011.

Contractual maturities of long-term debt obligations

The aggregate contractual maturities of all long-term debt obligations due subsequent to December 31, 2011, are as follows (in millions):


Maturity date	Amount
2012⁽¹⁾	$	84
2013⁽²⁾		2,500
2014		2,000
2015		—
2016		1,750
Thereafter		15,312

Total	$	21,646

⁽¹⁾	This amount represents the accreted value of our zero-coupon convertible notes due in 2032 which will be redeemed on March 1, 2012.

⁽²⁾	This amount represents the principal amount for our 0.375% 2013 Convertible Notes after full accretion of the debt discount.

Interest costs

Interest costs are expensed as incurred, except to the extent such interest is related to construction in progress, in which case interest is capitalized. Interest expense, net, for the years ended December 31, 2011, 2010 and 2009, was $610 million, $604 million and $578 million, respectively. Interest costs capitalized for the years ended December 31, 2011, 2010 and 2009, were $22 million, $33 million and $32 million, respectively. Interest paid, net of interest rate swaps, during the years ended December 31, 2011, 2010 and 2009, totaled $446 million, $323 million and $293 million, respectively.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References + Details

Stockholders' equity

12 Months Ended

Dec. 31, 2011

Stockholders' equity [Abstract]

Stockholders' equity

15. Stockholders’ equity

Stock repurchase program

Activity under our stock repurchase program was as follows for the years ended December 31, 2011, 2010 and 2009 (in millions):


	2011					2010				2009
	Shares		Dollars			Shares		Dollars		Shares		Dollars
First quarter		—	$	—			29.1	$	1,684		37.5	$	1,997
Second quarter		12.9		732			10.3		616		—		—
Third quarter		45.4		2,421			6.6		364		—		—
Fourth quarter		86.0		5,154	⁽¹⁾		20.5		1,136		21.7		1,211

Total stock repurchases		144.3	$	8,307			66.5	$	3,800		59.2	$	3,208

⁽¹⁾	Includes the repurchase of 83.3 million shares of our common stock at an average price paid per share of $60.08 including related expenses, for an aggregate cost of $5.0 billion, under a modified Dutch auction tender offer.

In April 2011, the Board of Directors authorized us to repurchase up to an additional $5.0 billion of our common stock under our stock repurchase program, and in October 2011, the Board of Directors further increased the total authorization for stock repurchases by $6.1 billion to $10.0 billion. As of December 31, 2011, $5.0 billion remained available under the program.

In July and October 2011, the Board of Directors declared quarterly cash dividends of $0.28 per share of common stock, which were paid in September and December 2011, respectively. Additionally, on December 15, 2011, the Board of Directors declared a quarterly cash dividend of $0.36 per share of common stock, which will be paid on March 7, 2012, to all stockholders of record as of the close of business on February 15, 2012.

Accumulated other comprehensive income

The components of Accumulated Other Comprehensive Income (AOCI) are as follows for the years ended December 31, 2011, 2010 and 2009 (in millions):


	Foreign currency translation			Cash flow hedges			Available-for-sale securities			Other			AOCI
Balance as of December 31, 2008	$	25		$	50		$	49		$	(7	)	$	117
Foreign currency translation adjustments		25			—			—			—			25
Unrealized (losses) gains		—			(213	)		116			(12	)		(109	)
Reclassification adjustments to income		—			8			(42	)		—			(34	)
Other		—			—			—			5			5
Income taxes		(10	)		73			(28	)		6			41

Balance as of December 31, 2009		40			(82	)		95			(8	)		45
Foreign currency translation adjustments		(29	)		—			—			—			(29	)
Unrealized gains		—			186			155			1			342
Reclassification adjustments to income		—			(46	)		(90	)		—			(136	)
Income taxes		11			(55	)		(25	)		—			(69	)

Balance as of December 31, 2010		22			3			135			(7	)		153
Foreign currency translation adjustments		(6	)		—			—			—			(6	)
Unrealized (losses) gains		—			(51	)		125			2			76
Reclassification adjustments to income		—			112			(154	)		—			(42	)
Other		—			—			—			(8	)		(8	)
Income taxes		5			(21	)		14			—			(2	)

Balance as of December 31, 2011	$	21		$	43		$	120		$	(13	)	$	171

Income tax expense or benefit for unrealized gains and losses and the related reclassification adjustments to income for cash flow hedges was a $20 million benefit and $41 million expense in 2011, a $71 million expense and $16 million benefit in 2010 and a $76 million benefit and $3 million expense in 2009, respectively. Income tax expense/benefit for unrealized gains and losses and the related reclassification adjustments to income for available-for-sale securities was a $45 million expense and $59 million benefit for 2011, a $60 million expense and $35 million benefit in 2010 and a $44 million expense and $16 million benefit in 2009, respectively.

Other

In addition to common stock, our authorized capital includes 5 million shares of preferred stock, $0.0001 par value. As of December 31, 2011 and 2010, no shares of preferred stock were issued or outstanding.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 4
-Section 08
-Paragraph d

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 1
-Section B
-Paragraph 7, 11A
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

+ Details

Fair value measurement

12 Months Ended

Dec. 31, 2011

Fair value measurement [Abstract]

Fair value measurement

16. Fair value measurement

To determine the fair value of our financial assets and liabilities we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows:


Level 1	—	Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access

Level 2	—	Valuations for which all significant inputs are observable, either directly or indirectly, other than level 1 inputs

Level 3	—	Valuations based on inputs that are unobservable and significant to the overall fair value measurement

The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.

The fair value of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis was as follows (in millions):


Fair value measurement as of December 31, 2011, using:	Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)		Total
Assets:
Available-for-sale investments:
U.S. Treasury securities	$	3,946	$	—	$	—	$	3,946
Other government-related debt securities:
Obligations of U.S. government agencies and FDIC-guaranteed bank debt		—		1,571		—		1,571
Foreign and other		—		450		—		450
Corporate debt securities:
Financial		—		2,508		—		2,508
Industrial		—		3,146		—		3,146
Other		—		289		—		289
Mortgage- and asset-backed securities		—		1,785		—		1,785
Money market mutual funds		6,266		—		—		6,266
Equity securities		42		—		—		42
Derivatives:
Foreign currency contracts		—		172		—		172
Interest rate swap contracts		—		377		—		377

Total assets	$	10,254	$	10,298	$	—	$	20,552

Liabilities:
Derivatives:
Foreign currency contracts	$	—	$	48	$	—	$	48
Cross currency swap contracts		—		26		—		26
Contingent consideration obligations in connection with a business combination		—		—		190		190

Total liabilities	$	—	$	74	$	190	$	264


Fair value measurement as of December 31, 2010, using:	Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)		Total
Assets:
Available-for-sale investments:
U.S. Treasury securities	$	5,080	$	—	$	—	$	5,080
Other government-related debt securities:
Obligations of U.S. government agencies and FDIC-guaranteed bank debt		—		2,208		—		2,208
Foreign and other		—		852		—		852
Corporate debt securities:
Financial		—		2,296		—		2,296
Industrial		—		2,507		—		2,507
Other		—		316		—		316
Mortgage- and asset-backed securities		—		841		—		841
Money market mutual funds		3,030		—		—		3,030
Other short-term interest-bearing securities		—		147		—		147
Equity securities		48		—		—		48
Derivatives:
Foreign currency contracts		—		154		—		154
Interest rate swap contracts		—		195		—		195

Total assets	$	8,158	$	9,516	$	—	$	17,674

Liabilities:
Derivatives:
Foreign currency contracts	$	—	$	103	$	—	$	103

Total liabilities	$	—	$	103	$	—	$	103

The fair values of our U.S. Treasury securities, money market mutual funds and equity securities are based on quoted market prices in active markets with no valuation adjustment.

Substantially all of our other government related and corporate debt securities are investment grade with maturity dates of five years or less from the balance sheet date. Our other government related debt securities portfolio is composed of securities with weighted-average credit ratings of AA+ by Standard & Poor’s (S&P) and AAA or equivalent by Moody’s Investors Service, Inc. (Moody’s) or Fitch, Inc. (Fitch); and our corporate debt securities portfolio has a weighted-average credit rating of A- by S&P and A or equivalent by Moody’s or Fitch. We estimate the fair values of these securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs.

Our mortgage and asset backed securities portfolio is composed entirely of senior tranches, with credit ratings of AAA or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs.

We value our other short-term interest bearing securities at amortized cost, which approximates fair value given their near-term maturity dates.

Substantially all of our foreign currency forward and option derivatives contracts have maturities of three years or less and all are with counterparties that have a minimum credit rating of A- or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency rates, LIBOR, swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts also include implied volatility measures. These inputs, where applicable, are at commonly quoted intervals. As of December 31, 2011 and 2010, we had open foreign currency forward contracts with notional amounts of $3.5 billion and $3.2 billion, respectively, and open foreign currency option contracts with notional amounts of $292 million and $398 million, respectively, that were primarily euro-based and were designated as cash flow hedges. In addition, as of December 31, 2011 and 2010, we had $389 million and $670 million, respectively, of open foreign currency forward contracts to reduce exposure to fluctuations in value of certain assets and liabilities denominated in foreign currencies that were primarily euro-based and that were not designated as hedges. (See Note 17, Derivative instruments.)

Our interest rate and cross currency swap contracts are with counterparties that have a minimum credit rating of A- or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency rates, LIBOR, swap rates, obligor credit default swap rates and cross currency basis swap spreads. We had interest rate swap contracts with an aggregate notional amount of $3.6 billion as of December 31, 2011 and 2010, that were designated as fair value hedges. We had cross currency swap contracts on all of our 5.50% 2026 pound sterling Notes as of December 31, 2011, that were designated as cash flow hedges. (See Note 17, Derivative instruments.)

Contingent consideration obligations in connection with a business combination result from our acquisition of BioVex in March 2011. The fair value measurements of these obligations are based on significant unobservable inputs, and accordingly, such amounts are considered Level 3 measurements. There were no changes in assumptions that had a material impact on the estimated fair values of these obligations during the period from the acquisition date to December 31, 2011, and accordingly, there was no significant impact on net income for this period. For a description of the valuation methodology and related assumptions used for estimating the fair values of these obligations, see Note 2, Business combinations.

There have been no transfers of assets or liabilities between the fair value measurement levels, and there were no material remeasurements to fair value during the years ended December 31, 2011 and 2010, of assets and liabilities that are not measured at fair value on a recurring basis, except as discussed in Note 8, Cost savings initiatives and restructuring, regarding an impairment of fixed assets that we recognized in 2010.

Summary of the fair value of other financial instruments

Cash equivalents

The estimated fair values of cash equivalents approximate their carrying values due to the short-term nature of these financial instruments.

Borrowings

We estimate the fair values of our convertible notes by using an income-based industry standard valuation model for which all significant inputs are observable either directly or indirectly, including benchmark yields adjusted for our credit risk (Level 2). The fair value of our convertible notes represent only the liability components of these instruments, as their equity components are included in Common stock and additional paid-in capital in the Consolidated Balance Sheets. We estimate the fair values of our other long-term notes by taking into consideration indicative prices obtained from a third-party financial institution that utilizes industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable either directly or indirectly. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; credit spreads; benchmark yields; and other observable inputs (Level 2). As of December 31, 2011 and 2010, the aggregate fair values of our long-term debt were $23.0 billion and $14.5 billion, respectively, and the carrying values were $21.4 billion and $13.4 billion, respectively.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19207-110258

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13537-108611

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13433-108611

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13504-108611

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19296-110258

+ Details

Derivative instruments

12 Months Ended

Dec. 31, 2011

Derivative instruments [Abstract]

Derivative instruments

17. Derivative instruments

The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to these exposures, we utilize certain derivative instruments, including foreign currency forward, foreign currency option, cross currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative trading purposes.

Cash flow hedges

We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates, associated primarily with our euro-denominated international product sales. Increases or decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are offset partially by the corresponding increases and decreases in our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations on our international product sales, we enter into foreign currency forward and option contracts to hedge a portion of our projected international product sales primarily over a three-year time horizon, with, at any given point in time, a higher percentage of nearer-term projected product sales being hedged than in successive periods. As of December 31, 2011, 2010 and 2009, we had open foreign currency forward contracts with notional amounts of $3.5 billion, $3.2 billion and $3.4 billion and open foreign currency option contracts with notional amounts of $292 million, $398 million and $376 million, respectively. These foreign currency forward and option contracts, primarily euro-based, have been designated as cash flow hedges, and accordingly, the effective portion of the unrealized gains and losses on these contracts are reported in AOCI and reclassified to earnings in the same periods during which the hedged transactions affect earnings.

In order to hedge our exposure to foreign currency exchange rate risk associated with our pound sterling denominated long-term notes issued in 2011, we entered into cross currency swap contracts. Under the terms of these contracts, we receive interest payments in pounds sterling at a fixed rate of 5.5% on £475 million and pay interest in U.S. dollars at a fixed rate of 5.8% on $748 million, the aggregate notional amounts paid to/received from the counterparties upon exchange of currencies at the inception of these contracts. We will pay U.S. dollars to and receive pounds sterling from the counterparties at the maturity of the contracts for the same notional amounts. The terms of these contracts correspond to the related hedged notes, effectively converting the interest payments and principal repayment on these notes from pounds sterling to U.S. dollars. These cross currency swap contracts have been designated as cash flow hedges, and accordingly, the effective portion of the unrealized gains and losses on these contracts are reported in AOCI and reclassified to earnings in the same periods during which the hedged debt affects earnings.

In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on such contracts, which are designated as cash flow hedges, are reported in AOCI and amortized into earnings over the lives of the associated debt issuances.

The effective portion of the unrealized gain/(loss) recognized in OCI for our derivative instruments designated as cash flow hedges was as follows (in millions):


	Years ended December 31,
Derivatives in cash flow hedging relationships	2011			2010			2009
Foreign currency contracts	$	(25	)	$	191		$	(202	)
Cross currency swap contracts		(26	)		—			—
Forward interest rate contracts		—			(5	)		(11	)

Total	$	(51	)	$	186		$	(213	)

The location in the Consolidated Statements of Income and the effective portion of the gain/(loss) reclassified from AOCI into earnings for our derivative instruments designated as cash flow hedges was as follows (in millions):


		Years ended December 31,
Derivatives in cash flow hedging relationships	Statements of Income location	2011			2010			2009
Foreign currency contracts	Product sales	$	(108	)	$	47		$	(7	)
Cross currency swap contracts	Interest and other income, net		(3	)		—			—
Forward interest rate contracts	Interest expense, net		(1	)		(1	)		(1	)

Total		$	(112	)	$	46		$	(8	)

No portions of our cash flow hedge contracts are excluded from the assessment of hedge effectiveness, and the ineffective portions of these hedging instruments were approximately $1 million of gain for the year ended December 31, 2011, and approximately $1 million of loss for both the years ended December 31, 2010 and 2009. As of December 31, 2011, the amounts expected to be reclassified from AOCI into earnings over the next 12 months are approximately $75 million of net gains on foreign currency and cross currency swap contracts and approximately $1 million of losses on forward interest rate contracts.

Fair value hedges

To achieve a desired mix of fixed and floating interest rates on our long-term debt, we have entered into interest rate swap contracts, which qualify and have been designated as fair value hedges. The terms of these interest rate swap contracts correspond to the related hedged debt instruments and effectively convert a fixed interest rate coupon to a floating LIBOR-based coupon over the lives of the respective notes. The rates on these swaps range from LIBOR plus 0.3% to LIBOR plus 2.6%. As of December 31, 2011, 2010 and 2009, we had interest rate swap contracts with aggregate notional amounts of $3.6 billion, $3.6 billion and $1.5 billion, respectively. The interest rate swap contracts as of December 31, 2011 and 2010, were for our 4.85% 2014 Notes, 5.85% 2017 Notes, 6.15% 2018 Notes and 5.70% 2019 Notes, and, as of December 31, 2009, for our 4.85% 2014 Notes and 6.15% 2018 Notes. For derivative instruments that are designated and qualify as fair value hedges, the unrealized gain or loss on the derivative resulting from the change in fair value during the period as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk is recognized in current earnings. For the years ended December 31, 2011 and 2010, we included unrealized losses on the hedged debt of $182 million and $105 million, respectively, in the same line item, Interest expense, net, in the Consolidated Statements of Income, as the offsetting unrealized gains of $182 million and $105 million, respectively, on the related interest rate swap contracts. For the year ended December 31, 2009, we included the unrealized gain on the hedged debt of $116 million in the same line item, Interest expense, net, in the Consolidated Statement of Income, as the offsetting unrealized loss of $116 million on the related interest rate swap contracts.

Derivatives not designated as hedges

We enter into foreign currency forward contracts that are not designated as hedging transactions to reduce our exposure to foreign currency fluctuations of certain assets and liabilities denominated in foreign currencies. These exposures are hedged on a month-to-month basis. As of December 31, 2011, 2010 and 2009, the total notional amounts of these foreign currency forward contracts, primarily euro-based, were $389 million, $670 million and $414 million, respectively.

The location in the Consolidated Statements of Income and the amount of gain/(loss) recognized in earnings for the derivative instruments not designated as hedging instruments was as follows (in millions):


		Years ended December 31,
Derivatives not designated as hedging instruments	Statements of Income location	2011			2010		2009
Foreign currency contracts	Interest and other income, net	$	(1	)	$	32	$	(24	)

The fair values of both derivatives designated as hedging instruments and derivatives not designated as hedging instruments included in the Consolidated Balance Sheets were as follows (in millions):


	Derivative assets			Derivative liabilities
December 31, 2011	Balance Sheet location	Fair value		Balance Sheet location	Fair value
Derivatives designated as hedging instruments:
Interest rate swap contracts	Other current assets/ Other noncurrent assets	$	377	Accrued liabilities/ Other noncurrent liabilities	$	—
Cross currency swap contracts	Other current assets/ Other noncurrent assets		—	Accrued liabilities/ Other noncurrent liabilities		26
Foreign currency contracts	Other current assets/ Other noncurrent assets		172	Accrued liabilities/ Other noncurrent liabilities		48

Total derivatives designated as hedging instruments			549			74

Derivatives not designated as hedging instruments:
Foreign currency contracts	Other current assets		—	Accrued liabilities		—

Total derivatives not designated as hedging instruments			—			—

Total derivatives		$	549		$	74


	Derivative assets			Derivative liabilities
December 31, 2010	Balance Sheet location	Fair value		Balance Sheet location	Fair value

Derivatives designated as hedging instruments:
Interest rate swap contracts	Other current assets/ Other noncurrent assets	$	195	Accrued liabilities/ Other noncurrent liabilities	$	—
Foreign currency contracts	Other current assets/ Other noncurrent assets		154	Accrued liabilities/ Other noncurrent liabilities		103

Total derivatives designated as hedging instruments			349			103

Derivatives not designated as hedging instruments:
Foreign currency contracts	Other current assets		—	Accrued liabilities		—

Total derivatives not designated as hedging instruments			—			—

Total derivatives		$	349		$	103

Our derivative contracts that were in liability positions as of December 31, 2011, contain certain credit risk related contingent provisions that would be triggered if (i) we were to undergo a change in control and (ii) our or the surviving entity’s creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right, but not the obligation, to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts.

The cash flow effects of our derivatives contracts for the three years ended December 31, 2011, are included within Net cash provided by operating activities in the Consolidated Statements of Cash Flows.

- Definition

The entire disclosure for the entity's entire derivative instruments and hedging activities. Describes an entity's risk management strategies, derivatives in hedging activities and non-hedging derivative instruments, the assets, obligations, liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 45
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6887037&loc=d3e80784-113994

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5579245-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624163-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624171-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41638-113959

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5580258-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5579240-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41641-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41620-113959

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624181-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624177-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6887037&loc=d3e80748-113994

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624258-113959

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5708775-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41635-113959

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5708773-113959

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

+ Details

Contingencies and commitments

12 Months Ended

Dec. 31, 2011

Contingencies and commitments [Abstract]

Contingencies and commitments

18. Contingencies and commitments

Contingencies

In the ordinary course of business, we are involved in various legal proceedings and other matters, including those discussed in this Note, that are complex in nature and have outcomes that are difficult to predict.

We record accruals for loss contingencies to the extent that we conclude that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously. As more fully described below, in the three months ended September 30, 2011, excluding fees paid to our external counsel, the Company recorded a $780 million legal settlement charge associated with the proposed settlement of the allegations arising out of the previously disclosed federal civil and criminal investigations pending in the U.S. Attorney’s Offices for the Eastern District of New York and the Western District of Washington. The charge is included in Other operating expenses in the Consolidated Statements of Income.

Our legal proceedings range from cases brought by a single plaintiff to a class action with thousands of putative class members. These legal proceedings, as well as other matters, involve various aspects of our business and a variety of claims (including but not limited to patent infringement, marketing, pricing and trade practices and securities law), some of which present novel factual allegations and/or unique legal theories. Except for the proposed settlement of the litigation referenced above, in each of the matters described in this filing, plaintiffs seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process (which in complex proceedings of the sort faced by us often extend for several years). As a result, some pending matters have not yet progressed sufficiently through discovery and/or development of important factual information and legal issues to enable us to estimate a range of possible loss, if any. While it is not possible to accurately predict or determine the eventual outcomes of these items, an adverse determination in one or more of these items currently pending, including further adverse determinations associated with the pending investigations described above, could have a material adverse effect on our consolidated results of operations, financial position or cash flows.

Certain of our legal proceedings and other matters are discussed below:

Roche U.S. International Trade Commission Complaint

On April 11, 2006, Amgen filed a complaint with the U.S. International Trade Commission (ITC) in Washington D.C. requesting that the ITC institute an investigation of the importation of pegylated erythropoietin (alternatively referred to as peg-EPO or MIRCERA^®) into the United States as Amgen believes that importation of peg-EPO is unlawful because peg-EPO, and the method of its manufacture, are covered by Amgen’s EPO patents. Amgen asked the ITC to issue a permanent exclusion order that would prohibit importation of peg-EPO into the United States. The ITC instituted an investigation naming Roche Holding Ltd., F. Hoffmann-La Roche Ltd., Roche Diagnostics GmbH, and Hoffmann-La Roche Inc. (collectively, Roche) as respondents in the investigation. On July 7, 2006, the Administrative Law Judge (ALJ) at the ITC issued a summary determination that Roche’s importation and use of peg-EPO in the United States had been subject to a clinical trial exemption to patent infringement under 35 U.S.C. 271(e)(1). On August 31, 2006, the ITC adopted the ALJ’s summary determination terminating the investigation.

On October 11, 2006, Amgen filed a petition for review of the ITC’s decision with the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit Court). On March 19, 2008, the Federal Circuit Court reversed the ITC’s dismissal of the investigation on jurisdictional grounds. In response to Roche’s request for rehearing, on April 30, 2009, the Federal Circuit Court vacated the ITC’s dismissal of the ITC investigation for non-infringement. The Federal Circuit Court remanded the case back to the ITC for further proceedings to determine if patent infringement had occurred and to provide a remedy, if appropriate.

Amgen had previously filed a separate lawsuit in November 2006 in the U.S. District Court for the District of Massachusetts (the Massachusetts District Court) against F. Hoffmann-La Roche Ltd., Roche Diagnostics GmbH and Hoffmann-La Roche Inc. (collectively, Roche Defendants) seeking a declaration by the Massachusetts District Court that the importation, use, sale or offer to sell peg-EPO infringes Amgen’s EPO patents, specifically U.S. Patent Nos. 5,547,933; 5,621,080; 5,955,422; 5,756,349; 5,618,698 and 5,441,868. After a jury trial and an appeal, on December 22, 2009, the Massachusetts District Court entered final judgment and a permanent injunction against the Roche Defendants prohibiting the Roche Defendants from infringing the five Amgen patents-in-suit. The judgment was accompanied by the Roche Defendants’ admission that the patents involved in the lawsuit are valid, enforceable and infringed by the Roche Defendant’s peg-EPO product, and by Amgen allowing Roche to begin selling peg-EPO in the United States in mid-2014 under terms of a limited license agreement. The settlement terms did not include any financial payments between the parties. Thereafter, in the ITC matter Amgen filed a motion for summary determination of violation with a request for entry of a limited exclusion order. The Roche respondents notified the ITC that they were not opposing Amgen’s motion. On March 11, 2011, the ITC issued an order to show cause why the investigation should not be terminated without a determination of violation or by way of consent order in view of the resolution of the Massachusetts District Court proceedings. In response, on April 21, 2011, the parties filed a joint response requesting termination of the investigation on the basis of a proposed Consent Order and Stipulation. On October 17, 2011, the ITC terminated the investigation without entry of a consent order on the basis of the December 2009 settlement between the parties and resolution of the parallel litigation in the Massachusetts District Court.

Average Wholesale Price (AWP) Litigation

Amgen and its wholly owned subsidiary Immunex Inc. are named as defendants, either separately or together, in numerous civil actions broadly alleging that they, together with many other pharmaceutical manufacturers, reported prices for certain products in a manner that allegedly inflated reimbursement under Medicare and/or Medicaid programs and commercial insurance plans, including co-payments paid to providers who prescribe and administer the products. The complaints generally assert varying claims under the Medicare and Medicaid statutes, as well as state law claims for deceptive trade practices, common law fraud and various related state law claims. The complaints seek an undetermined amount of damages, as well as other relief, including declaratory and injunctive relief.

The AWP litigation was commenced against Amgen and Immunex on December 19, 2001 with the filing of Citizens for Consumer Justice, et al. v. Abbott Laboratories, Inc., et al. Additional cases have been filed since that time. Most of these actions, as discussed below, have been consolidated, or are in the process of being consolidated, in a federal Multi-District Litigation proceeding (the MDL Proceeding), captioned In Re: Pharmaceutical Industry Average Wholesale Price Litigation MDL No. 1456 and pending in the Massachusetts District Court.

The following cases have been consolidated into the MDL Proceeding, and include cases brought by consumer classes and certain state and local governmental entities:

Citizens for Consumer Justice, et al., v. Abbott Laboratories, Inc., et al.; Teamsters Health & Welfare Fund of Philadelphia, et al., v. Abbott Laboratories, Inc., et al.; Action Alliance of Senior Citizens of Greater Philadelphia v. Immunex Corporation; Constance Thompson, et al., v. Abbott Laboratories, Inc., et al.; Ronald Turner, et al., v. Abbott Laboratories, Inc., et al.; Congress of California Seniors v. Abbott Laboratories, Inc., et al.

In the MDL Proceeding, the Massachusetts District Court has set various deadlines relating to motions to dismiss the complaints, discovery, class certification, summary judgment and other pre-trial issues. For the private class action cases, the Massachusetts District Court has divided the defendant companies into a Track I group and a Track II group. Both Amgen and Immunex are in the Track II group. On March 2, 2006, plaintiffs filed a fourth amended master consolidated complaint, which did not include their motion for class certification as to the Track II group. On September 12, 2006, a hearing before the Massachusetts District Court was held on plaintiffs’ motion for class certification as to the Track II group defendants, which include Amgen and Immunex. On March 7, 2008, the Track II defendants reached a tentative class settlement of the MDL Proceeding, which was subsequently amended on April 3, 2008. The tentative Track II settlement relates to claims against numerous defendants, including Abbott Laboratories, Inc., Amgen Inc., Aventis Pharmaceuticals Inc., Hoechst Marion Roussel, Inc., Baxter Healthcare Corporation, Baxter International Inc., Bayer Corporation, Dey, Inc., Fujisawa Healthcare, Inc., Fujisawa USA, Inc., Immunex Corporation, Pharmacia Corporation, Pharmacia & Upjohn LLC (f/k/a Pharmacia & Upjohn, Inc.), Sicor, Inc., Gensia, Inc., Gensia Sicor Pharmaceuticals, Inc., Watson Pharmaceuticals, Inc. and ZLB Behring, L.L.C. Following repeated hearings on the sufficiency of the notice given by the plaintiffs, the Massachusetts District Court approved the Track II settlement on December 8, 2011, and dismissed with prejudice the fourth amended master consolidated complaint effective January 31, 2012.

The following AWP litigation case is not part of the MDL Proceeding:

State of Louisiana v. Abbott Laboratories, Inc., et al. The State of Louisiana filed a complaint against Amgen and several other pharmaceutical manufacturers, on November 3, 2010, in the Parish of East Baton Rouge, 19th Judicial District (the Louisiana Court). Amgen was served the complaint on November 9, 2010. The complaint alleges that the manufacturers misrepresented product pricing information reported to the state by falsely inflating those prices. On May 12, 2011, Amgen and the other defendants filed joint exceptions seeking to dismiss the complaint. On October 27, 2011 the Louisiana Court denied the defendants’ joint exceptions.

Federal Securities Litigation — In re Amgen Inc. Securities Litigation

The six federal class action stockholder complaints filed against Amgen Inc., Kevin W. Sharer, Richard D. Nanula, Dennis M. Fenton, Roger M. Perlmutter, Brian M. McNamee, George J. Morrow, Edward V. Fritzky, Gilbert S. Omenn and Franklin P. Johnson, Jr., (the Federal Defendants) in the U.S. District Court for the Central District of California (the California Central District Court) on April 17, 2007 (Kairalla v. Amgen Inc., et al.), May 1, 2007 (Mendall v. Amgen Inc., et al., & Jaffe v. Amgen Inc., et al.), May 11, 2007 (Eldon v. Amgen Inc., et al.), May 21, 2007 (Rosenfield v. Amgen Inc., et al.) and June 18, 2007 (Public Employees’ Retirement Association of Colorado v. Amgen Inc., et al.) were consolidated by the California Central District Court into one action captioned In re Amgen Inc. Securities Litigation. The consolidated complaint was filed with the California Central District Court on October 2, 2007. The consolidated complaint alleges that Amgen and these officers and directors made false statements that resulted in: (i) deceiving the investing public regarding Amgen’s prospects and business; (ii) artificially inflating the prices of Amgen’s publicly traded securities and (iii) causing plaintiff and other members of the class to purchase Amgen publicly traded securities at inflated prices. The complaint also makes off-label marketing allegations that, throughout the class period, the Federal Defendants improperly marketed Aranesp^® and EPOGEN^® for off-label uses while aware that there were alleged safety signals with these products. The plaintiffs seek class certification, compensatory damages, legal fees and other relief deemed proper. The Federal Defendants filed a motion to dismiss on November 8, 2007. On February 4, 2008, the California Central District Court granted in part, and denied in part, the Federal Defendants’ motion to dismiss the consolidated amended complaint. Specifically, the California Central District Court granted the Federal Defendants’ motion to dismiss as to individual defendants Fritzky, Omenn, Johnson, Fenton and McNamee, but denied the Federal Defendants’ motion to dismiss as to individual defendants Sharer, Nanula, Perlmutter and Morrow.

A class certification hearing before the California Central District Court, was held on July 17, 2009 and on August 12, 2009, the California Central District Court granted plaintiffs’ motion for class certification. On August 28, 2009, Amgen filed a petition for permission to appeal with the U.S. Court of Appeals for the Ninth Circuit (the Ninth Circuit Court) under Rule 23(f), regarding the Order on Class Certification and the Ninth Circuit Court granted Amgen’s permission to appeal on December 11, 2009. On February 2, 2010, the California Central District Court granted Amgen’s motion to stay the underlying action pending the outcome of the Ninth Circuit Court 23(f) appeal. On October 14, 2011, the appeal under Rule 23(f) was argued before the Ninth Circuit Court and on December 28, 2011, the Ninth Circuit Court denied the appeal. On January 3, 2012, Amgen filed a motion to stay the mandate and the Ninth Circuit Court granted the motion and stayed the mandate on January 12, 2012. The staying of the mandate effectively stays the underlying action in the California Central District Court for ninety days pending the filing of a writ of certiorari with the U.S. Supreme Court. Amgen has until March 27, 2012 to file a petition for certiorari with the U.S. Supreme Court.

State Derivative Litigation

Larson v. Sharer, et al.

The three state stockholder derivative complaints filed against Amgen Inc., Kevin W. Sharer, George J. Morrow, Dennis M. Fenton, Brian M. McNamee, Roger M. Perlmutter, David Baltimore, Gilbert S. Omenn, Judith C. Pelham, Frederick W. Gluck, Jerry D. Choate, J. Paul Reason, Frank J. Biondi, Jr., Leonard D. Schaeffer, Frank C. Herringer, Richard D. Nanula, Willard H. Dere, Edward V. Fritzky, Franklin P. Johnson, Jr. and Donald B. Rice as defendants (the State Defendants) on May 1, 2007 (Larson v. Sharer, et al., & Anderson v. Sharer, et al.), and August 13, 2007 (Weil v. Sharer, et al.) in the Superior Court of the State of California, Ventura County (the Superior Court) were consolidated by the Superior Court under one action captioned Larson v. Sharer, et al. The consolidated complaint was filed on July 5, 2007. The complaint alleges that the State Defendants breached their fiduciary duties, wasted corporate assets, were unjustly enriched and violated the California Corporations Code. Plaintiffs allege that the State Defendants failed to disclose and/or misrepresented results of Aranesp^® clinical studies, marketed both Aranesp ^® and EPOGEN^® for off-label uses and that these actions or inactions caused stockholders to suffer damages. The complaints also allege insider trading by the State Defendants. The plaintiffs seek treble damages based on various causes of action, reformed corporate governance, equitable and/or injunctive relief, restitution, disgorgement of profits, benefits and other compensation, and legal costs.

An amended consolidated complaint was filed on March 13, 2008, adding Anthony Gringeri as a State Defendant and removing the causes of action for insider selling and misappropriation of information, violation of California Corporations Code Section 25402 and violation of California Corporations Code Section 25403. On July 14, 2008, the Superior Court dismissed without prejudice the consolidated state derivative class action. The judge also ordered a stay of any re-filing of an amended complaint until the federal court has determined whether any securities fraud occurred.

Birch v. Sharer, et al.

On January 23, 2009, a stockholder derivative lawsuit titled Birch v. Sharer, et al. was filed in the Superior Court of the State of California, Los Angeles County (the Los Angeles Superior Court) naming Amgen Inc., Kevin W. Sharer, David Baltimore, Frank J. Biondi, Jr., Jerry D. Choate, Vance D. Coffman, Frederick W. Gluck, Frank C. Herringer, Gilbert S. Omenn, Judith C. Pelham, J. Paul Reason, Leonard D. Schaeffer and Tom Zindrick as defendants. The complaint alleges derivative claims for breach of fiduciary duty based on a purported failure to implement adequate internal controls and to oversee the Company’s operations, which plaintiff claims resulted in numerous lawsuits and investigations over a number of years. Plaintiff seeks damages on behalf of Amgen, including costs and expenses, allegedly incurred, among other things, in connection with wrongful termination lawsuits and potential violations of the Health Insurance Portability and Accountability Act. On February 25, 2009, the case was reassigned to a judge in the Complex Department of the Los Angeles Superior Court. Amgen and the individual defendants filed motions to dismiss on June 23, 2009.

Oral argument on Amgen and the individual defendants’ motions to dismiss were heard on September 25, 2009 before the Los Angeles Superior Court and the court granted the motions to dismiss but allowed the plaintiff an opportunity to amend her complaint by October 21, 2009. Plaintiff filed a request for dismissal without prejudice with the court on October 23, 2009. On October 29, 2009, Amgen received from plaintiff a stockholder demand on the Board of Directors to take action to remedy breaches of fiduciary duties by the directors and certain executive officers of the Company. Ms. Birch alleged that the directors and certain executive officers violated their core fiduciary principles, causing Amgen to suffer damages. She demanded that the Board of Directors take action against each of the officers and directors to recover damages and to correct deficiencies in the Company’s internal controls that allowed the misconduct to occur. The Board of Directors completed its investigation and determined in its business judgment that it was not in the best interests of the Company to pursue the claims made in the demand against any of the individuals mentioned in the demand. Therefore, the Board voted to reject the demand and communicated this to Ms. Birch on May 19, 2010.

On February 8, 2010, plaintiff filed another stockholder demand lawsuit in the Los Angeles Superior Court against the same defendants in the original lawsuit but also added Board of Director members François de Carbonnel and Rebecca Henderson. The allegations in the new complaint are nearly identical to those in the previously filed complaint. The case filed on February 8, 2010 by plaintiff Birch was assigned to the Complex Division of the Los Angeles Superior Court. On June 30, 2010, Amgen filed its demurrer to plaintiff’s complaint with the Complex Division of the Los Angeles Superior Court. On September 29, 2010, the Complex Division of the Los Angeles Superior Court denied Amgen’s and the individual defendants’ demurrers finding that the plaintiff had adequately pled wrongful refusal. Amgen and the individual defendants filed answers on October 29, 2010. On December 9, 2010, the Complex Division of the Los Angeles Superior Court stayed the underlying action and Amgen and the individual defendants filed a motion for judgment on the pleadings/motion for summary judgment. The motion for the judgment on the pleadings was heard on January 31, 2011 and the Complex Division of the Los Angeles Superior Court dismissed the entire lawsuit with prejudice against both Amgen and the individual defendants without leave to amend. On February 24, 2011, plaintiff filed a notice of appeal with the California State Appellate Court. The briefing schedule for the appeal was issued by the California State Appellate Court and plaintiff’s opening brief was filed September 7, 2011. The opposition brief from Amgen and the individual defendants was filed on November 21, 2011. No date has been set for oral argument.

Federal Derivative Litigation

On May 7, 2007, the stockholder derivative lawsuit of Durgin v. Sharer, et al., was filed in the California Central District Court and named Amgen Inc., Kevin W. Sharer, George J. Morrow, Dennis M. Fenton, Brian M. McNamee, Roger M. Perlmutter, David Baltimore, Gilbert S. Omenn, Judith C. Pelham, Frederick W. Gluck, Jerry D. Choate, J. Paul Reason, Frank J. Biondi, Jr., Leonard D. Schaeffer, Frank C. Herringer, Richard D. Nanula, Edward V. Fritzky and Franklin P. Johnson, Jr. as defendants. The complaint alleges the same claims and requests the same relief as in the three state stockholder derivative complaints now consolidated as Larson v. Sharer, et al. The case has been stayed for all purposes until thirty days after a final ruling on the motion to dismiss by the California Central District Court in the In re Amgen Inc. Securities Litigation action.

On September 21, 2007, the stockholder derivative lawsuit of Rosenblum v. Sharer, et al., was filed in the California Central District Court. This lawsuit was brought by the stockholder who previously made a demand on the Amgen Board on May 14, 2007. The complaint alleges that the defendants breached their fiduciary duties, wasted corporate assets and were unjustly enriched. Plaintiffs allege that the defendants failed to disclose and/or misrepresented results of Aranesp ^® clinical studies, marketed both Aranesp^® and EPOGEN^® for off-label uses and that these actions or inactions as well as the Amgen market strategy caused damage to the Company resulting in several inquiries, investigations and lawsuits that are costly to defend. The complaint also alleges insider trading by the defendants. The plaintiffs seek treble damages based on various causes of action, reformed corporate governance, equitable and/or injunctive relief, restitution, disgorgement of profits, benefits and other compensation, and legal costs. The case was stayed for all purposes until thirty days after a final ruling on the motion to dismiss by the California Central District Court in the In re Amgen Inc. Securities Litigation action.

Thereafter, on May 1, 2008, plaintiff in Rosenblum v. Sharer, et al., filed an amended complaint which removed Dennis Fenton as a defendant and also eliminated the claims for insider selling by defendants. On July 28, 2008, the California Central District Court heard Amgen and the defendants’ motion to dismiss and motion to stay. On July 30, 2008, the California Central District Court granted Amgen and the defendants’ motion to dismiss without prejudice and also granted a stay of the case pending resolution of the In re Amgen Inc. Securities Litigation action.

ERISA Litigation

On August 20, 2007, the ERISA class action lawsuit of Harris v. Amgen Inc., et al., was filed in the California Central District Court and named Amgen Inc., Kevin W. Sharer, Frank J. Biondi, Jr., Jerry Choate, Frank C. Herringer, Gilbert S. Omenn, David Baltimore, Judith C. Pelham, Frederick W. Gluck, Leonard D. Schaeffer, Jacqueline Allred, Raul Cermeno, Jackie Crouse, Lori Johnston, Michael Kelly and Charles Bell as defendants. Plaintiffs claim that Amgen and the individual defendants breached their fiduciary duties by failing to inform current and former employees who participated in the Amgen Retirement and Savings Plan and the Retirement and Savings Plan for Amgen Manufacturing Limited of the alleged off-label promotion of both Aranesp^® and EPOGEN ^® while a number of studies allegedly demonstrated safety concerns in patients using ESAs. On February 4, 2008, the California Central District Court dismissed the complaint with prejudice as to plaintiff Harris, who had filed claims against Amgen Inc. The claims alleged by the second plaintiff, Ramos, were also dismissed but the court granted the plaintiff leave to amend his complaint. On February 1, 2008, the plaintiffs appealed the decision by the California Central District Court to dismiss the claims of both plaintiffs Harris and Ramos to the Ninth Circuit Court, which remains pending before the Ninth Circuit Court. On May 19, 2008, plaintiff Ramos in the Harris v. Amgen Inc., et al., action filed another lawsuit captioned Ramos v. Amgen Inc., et al., in the California Central District Court. The lawsuit is another ERISA class action. The Ramos v. Amgen Inc., et al., matter names the same defendants in the Harris v. Amgen Inc., et al., matter plus four new defendants: Amgen Manufacturing Limited, Richard Nanula, Dennis Fenton and the Fiduciary Committee. Pursuant to the parties’ stipulation, the Ramos matter has been stayed pending the outcome of the Harris matter appeal. Oral argument before the Ninth Circuit Court on the plaintiffs’ appeal of the California Central District Court’s dismissal of the plaintiffs’ claims occurred on May 8, 2009. On July 14, 2009, the Ninth Circuit Court reversed the California Central District Court’s decision and remanded the case back to the district court. In the meantime, a third ERISA class action was filed by Don Hanks on June 2, 2009 in the California Central District Court alleging the same ERISA violations as in the Harris and Ramos lawsuits.

On October 13, 2009, the California Central District Court granted plaintiffs Harris’ and Ramos’ motion to be appointed interim co-lead counsel. Plaintiffs filed an amended complaint on November 11, 2009 and added two additional plaintiffs, Jorge Torres and Albert Cappa. Amgen filed a motion to dismiss the amended/consolidated complaint, and on March 2, 2010, the California Central District Court dismissed the entire lawsuit without prejudice. Plaintiffs filed an amended complaint on March 23, 2010. Amgen then filed another motion to dismiss on April 20, 2010. On June 16, 2010, the California Central District Court entered an order dismissing the entire lawsuit with prejudice. On June 24, 2010, the plaintiffs filed a notice of appeal with the Ninth Circuit Court. Petitioner’s opening brief was served on December 20, 2010 and Amgen’s answering brief was filed on February 2, 2011. Oral argument occurred on February 17, 2012.

Government Investigations and Qui Tam Actions

On May 10, 2007, Amgen received a subpoena from the Attorney General of the State of New York seeking documents related to Amgen’s promotional activities, sales and marketing activities, medical education, clinical studies, pricing and contracting, license and distribution agreements and corporate communications. Amgen fully cooperated in responding to the subpoena.

Beginning in late 2007, Amgen received a number of subpoenas from the U.S. Attorney’s Offices for the Eastern District of New York and the Western District of Washington, pursuant to the Health Insurance Portability and Accountability Act (18 U.S.C. 3486), for broad production of documents relating to its products and clinical trials. Amgen fully cooperated with the government’s document requests. Over the next several years, numerous current and former Amgen employees received civil and grand jury subpoenas to provide testimony on a wide variety of subjects. We refer herein to these investigations being conducted by the U.S. Attorney’s Offices for the Eastern District of New York and the Western District of Washington as the Federal Investigations.

On January 14, 2008, Amgen received a subpoena from the New Jersey Attorney General’s Office for production of documents relating to one of its products. Amgen completed its response per the terms of the subpoena.

A U.S. government filing in the Massachusetts District Court concerning the partially unsealed complaint filed pursuant to the Qui Tam provisions of the Federal Civil False Claims Act and on behalf of 17 named states and the District of Columbia under their respective State False Claims Acts (the Massachusetts Qui Tam Action) became public on or about May 7, 2009. The filing stated that the relator in the Massachusetts Qui Tam Action is a former Amgen employee. Further, the filing represented that, in addition to the Massachusetts Qui Tam Action, there were nine other actions under the False Claim Act pending under seal against Amgen, including eight pending in the U.S. District Court for the Eastern District of New York and one pending in the U.S. District Court for the Western District of Washington (together, the Qui Tam Actions). In the filing made public on May 7, 2009, the U.S. government represented that these ten Qui Tam Actions alleged that Amgen engaged in a wide variety of illegal marketing practices with respect to various Amgen products and that these were joint civil and criminal investigations being conducted by a wide variety and large number of federal and state agencies.

On September 1, 2009, the U.S. government filed a notice of non-intervention and 14 states and the District of Columbia filed notices of intervention in the Massachusetts Qui Tam Action. On October 30, 2009, 14 states and the District of Columbia filed an amended complaint in the Massachusetts District Court entitled The United States of America, States of California, Delaware, Florida, Georgia, Hawaii, Illinois, Indiana, Louisiana, Michigan, Nevada, New Hampshire, New Mexico, New York, Tennessee and Texas and the Commonwealths of Massachusetts and Virginia and the District of Columbia, ex rel Kassie Westmoreland v. Amgen Inc., Integrated Nephrology Network, AmerisourceBergen Specialty Group, ASD Healthcare and AmerisourceBergen Corporation. The relator, Kassie Westmoreland, also filed a second amended complaint with the Massachusetts District Court on the same day. The complaints alleged violations of the federal Anti-Kickback Statute and violations of state false claims act statutes with regard to Amgen’s marketing of overfill in vials of Aranesp^® and with regard to Amgen’s relationship with the Integrated Nephrology Network (INN), a group purchasing organization. The relator’s seconded amended complaint also alleged that Amgen retaliated against and wrongfully terminated Ms. Westmoreland.

On January 20, 2010, the states of Florida and Texas voluntarily dismissed their complaints against Amgen. On February 12, 2010, February 16, 2010 and February 18, 2010, respectively, the states of New Hampshire, Louisiana and Nevada voluntarily dismissed their complaints against Amgen. On February 23, 2010, the state of Delaware voluntarily dismissed its complaint against Amgen. Also, on February 23, 2010, the Massachusetts District Court granted Amgen’s motion to stay and sever the relator’s employment claims.

On April 23, 2010, the Massachusetts District Court dismissed all of the claims of the relator, on behalf of the federal government and the states of New Mexico and Georgia, and all of the claims of the remaining states, for failure to state valid legal grounds upon which relief could be granted. On May 26, 2010, the Massachusetts District Court granted leave for the relator to file a fourth amended complaint. On May 24, 2010, the states of New York, Massachusetts, Michigan, California, Illinois, and Indiana (the States) filed notices of intent to appeal the Massachusetts District Court’s judgment to the U.S. Court of Appeals for the First Circuit (the First Circuit Court).

On September 20, 2010, the Massachusetts District Court entered a written ruling denying Amgen’s motions to dismiss the relator’s fourth amended complaint. On April 11, 2011, the Massachusetts District Court heard summary judgment arguments on the fourth amended complaint from Amgen, INN and the relator. On July 22, 2011, the First Circuit Court issued a written decision reversing the Massachusetts District Court’s dismissal of the claims of the states of California, Illinois, Indiana, Massachusetts, New Mexico, and New York and affirming the dismissal of the claims of Georgia.

In March 2011, the U.S. Attorney’s Office of the Western District of Washington informed Amgen that the subject matter of its investigation would be transferred to the U.S. Attorney’s Office of the Eastern District of New York.

On October 24, 2011, Amgen announced it had reached an agreement in principle to settle allegations relating to its sales and marketing practices arising out of the Federal Investigations. In connection with the agreement in principle, Amgen recorded a $780 million charge in the three months ended September 30, 2011. This amount represents Amgen’s currently estimable loss with respect to these matters. If the ongoing discussions are successfully concluded, Amgen expects that the proposed settlement will resolve the Federal Investigations, the related state Medicaid claims and the claims in U.S. ex rel. Westmoreland v. Amgen, et al. and the other nine Qui Tam Actions in a manner that will not result in exclusion from U.S. federally-funded health care programs. In connection with the settlement discussions, the Massachusetts District Court vacated the previously scheduled trial date and administratively closed that case. The relators in the Qui Tam Actions have the opportunity to join in the proposed settlement or, if they object, to have the settlement evaluated in a federal court fairness hearing to determine whether it is fair, adequate and reasonable under all the circumstances. The proposed settlement remains subject to continuing discussions regarding the components of the agreement and the completion and execution of all required documentation, and until the proposed settlement becomes final, there can be no guarantee that these matters will be resolved by the agreement in principle.

In addition, on September 19, 2011, Amgen filed a petition for certiorari with the U.S. Supreme Court in the U.S. ex rel. Westmoreland v. Amgen, et al. matter. The petition sought leave to appeal the First Circuit Court’s reinstatement of the claims of the states of California, Illinois, Indiana, Massachusetts, New Mexico and New York, which had been dismissed by the Massachusetts District Court. However, as described above, Amgen expects that these state claims will be resolved if the ongoing settlement discussions are successfully concluded. Accordingly, on December 12, 2011, Amgen withdrew its petition for certiorari and the U.S. Supreme Court subsequently dismissed the petition on December 29, 2011.

As part of the settlement discussions described above, Amgen was made aware that it is a defendant in several other civil qui tam actions. These other qui tam actions are in addition to the Qui Tam Actions described above. One of these other qui tam actions, U.S. ex rel. May v. Amgen, et al. was filed by Samuel May on June 6, 2010, in the U.S. District Court for the Northern District of California, and was unsealed in connection with it being dismissed by the Court on January 5, 2012 for failure to prosecute the matter. The remaining other qui tam actions remain under seal in the U.S. federal courts in which they were filed. Included with these other actions (including the May action) are allegations that Amgen’s promotional, contracting, sales and marketing activities relating to Enbrel^® and Aranesp^® caused the submission of various false claims under the Federal Civil False Claims Act and various State False Claims Acts. Certain of the allegations in these remaining other actions are not encompassed in the proposed settlement described above, and Amgen intends to cooperate fully with the government in its investigation of these new allegations. Amgen continues to explore with the government whether these remaining matters will be resolved in connection with the proposed settlement discussed above.

U.S. ex rel. Streck v. Allergan, et al.

A complaint filed in the U.S. District Court for the Eastern District of Pennsylvania against Amgen and numerous other pharmaceutical manufacturers, pursuant to the Qui Tam provisions of the Federal Civil False Claims Act and on behalf of 24 named states and the District of Columbia under their respective State False Claims Acts, was unsealed and became public on or about June 6, 2011. The plaintiff, Ronald Streck, alleges that from 2004 to the present, defendants failed to report accurate pricing data to Medicare and Medicaid, including data used to calculate average sales price and average manufacturer’s price, thereby causing the federal and state governments to reimburse defendants at inflated rates and causing the manufacturers to underpay Medicaid rebates. This matter, in which the federal government has declined to intervene, is not affected by the proposed settlement described above. On September 7, 2011, plaintiff filed a fourth amended complaint and on December 9, 2011, defendants filed a joint motion to dismiss the plaintiff’s complaint.

Commitments

We lease certain facilities and equipment related primarily to administrative, R&D, sales and marketing activities under non-cancelable operating leases that expire through 2032. The following table summarizes the minimum future rental commitments under non-cancelable operating leases as of December 31, 2011 (in millions):


2012	$	116
2013		104
2014		85
2015		76
2016		65
Thereafter		328

Total minimum operating lease commitments	$	774

Included in the table above are future rental commitments for abandoned leases in the amount of $254 million. Rental expense on operating leases for the years ended December 31, 2011, 2010 and 2009, was $131 million, $115 million and $114 million, respectively.

In addition, we have minimum contractual purchase commitments with third-party manufacturers through 2014 that total $157 million as of December 31, 2011. Amounts purchased under these contractual purchase commitments for the years ended December 31, 2011, 2010 and 2009, were $87 million, $68 million and $207 million, respectively.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

+ Details

Segment information

12 Months Ended

Dec. 31, 2011

Segment information [Abstract]

Segment information

19. Segment information

We operate in one business segment — human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Enterprise-wide disclosures about product sales, revenues and long-lived assets by geographic area, and revenues from major customers are presented below.

Revenues

Revenues were as follows for the years ended December 31, 2011, 2010 and 2009 (in millions):


	2011		2010		2009
Product sales:
Neulasta^® — U.S.	$	3,006	$	2,654	$	2,527
NEUPOGEN^® — U.S.		959		932		901
Neulasta^® — International		946		904		828
NEUPOGEN^® — International		301		354		387
ENBREL — U.S.		3,458		3,304		3,283
ENBREL — Canada		243		230		210
Aranesp^® — U.S.		986		1,103		1,251
Aranesp^® — International		1,317		1,383		1,401
EPOGEN^® — U.S.		2,040		2,524		2,569
Sensipar^® — U.S.		518		459		429
Sensipar^® (Mimpara^®) — International		290		255		222
Vectibix^® — U.S.		122		115		97
Vectibix^® — International		200		173		136
Nplate^® — U.S.		163		129		78
Nplate^® — International		134		100		32
Prolia^® — U.S.		130		26		—
Prolia^® — International		73		7		—
XGEVA^® — U.S.		343		8		—
XGEVA^® — International		8		—		—
Other — International		58		—		—

Total product sales		15,295		14,660		14,351
Other revenues		287		393		291

Total revenues	$	15,582	$	15,053	$	14,642

Geographic information

Outside the United States, we sell products principally in Europe and Canada. The geographic classification of product sales was based upon the location of the customer. The geographic classification of all other revenues was based upon the domicile of the entity from which the revenues were earned.

Certain geographical information with respect to revenues and long-lived assets (consisting of property, plant and equipment) was as follows (in millions):


	Years ended December 31,
	2011		2010		2009
Revenues:
United States	$	11,985	$	11,636	$	11,421
International countries		3,597		3,417		3,221

Total revenues	$	15,582	$	15,053	$	14,642


	December 31,
	2011		2010
Long-lived assets:
United States	$	3,144	$	3,248
Puerto Rico		1,993		2,079
International countries		283		195

Total long-lived assets	$	5,420	$	5,522

Major customers

In the United States, we sell primarily to pharmaceutical wholesale distributors. We utilize those wholesale distributors as the principal means of distributing our products to healthcare providers. In Europe, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors depending on the distribution practice in each country. We monitor the financial condition of our larger customers, and we limit our credit exposure by setting credit limits and, for certain customers, by requiring letters of credit.

We had product sales to three customers each accounting for more than 10% of total revenues for the years ended December 31, 2011, 2010 and 2009. For 2011, on a combined basis, these customers accounted for 72% and 90% of worldwide gross revenues and U.S. gross product sales, respectively, as noted in the following table. Certain information with respect to these customers for the years ended December 31, 2011, 2010 and 2009, was as follows (dollar amounts in millions):


	2011		2010		2009
AmerisourceBergen Corporation:
Gross product sales	$	7,574	$	7,678	$	7,179
% of total gross revenues		36%		38%		37%
% of U.S. gross product sales		45%		47%		46%
McKesson Corporation:
Gross product sales	$	4,591	$	3,913	$	3,694
% of total gross revenues		22%		19%		19%
% of U.S. gross product sales		27%		24%		24%
Cardinal Health, Inc:
Gross product sales	$	3,021	$	2,813	$	2,841
% of total gross revenues		14%		14%		15%
% of U.S. gross product sales		18%		17%		18%

At December 31, 2011 and 2010, amounts due from these three customers each exceeded 10% of gross trade receivables, and accounted for 60% and 54%, respectively, of net trade receivables on a combined basis. At December 31, 2011 and 2010, 39% and 44%, respectively, of trade receivables, net were due from customers located outside the United States, primarily in Europe. Our total allowance for doubtful accounts as of December 31, 2011 and 2010, was not material.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

+ Details

Subsequent Event

12 Months Ended

Dec. 31, 2011

Subsequent event [Abstract]

Subsequent events

20. Subsequent event

On January 26, 2012, we announced that we had entered into an agreement to acquire Micromet, Inc. (Micromet), a publicly held biotechnology company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. The acquisition includes blinatumomab, a Bispecific T cell Engager (BiTE) antibody in phase 2 clinical development for acute lymphoblastic leukemia and BiTE antibody technology, which is proprietary to Micromet, which provides an innovative platform for future clinical research. Blinatumomab is also in clinical development for the treatment of non-Hodgkin’s lymphoma and could have applications in other hematologic malignancies. In connection with this acquisition, which will be accounted for as a business combination, we have commenced a tender offer to acquire all of the outstanding shares of Micromet’s common stock at a price of $11 per share in cash, which values Micromet at approximately $1.16 billion. Upon its acquisition, Micromet will become a wholly owned subsidiary of Amgen. This acquisition will provide us with an opportunity to further expand our oncology pipeline. Micromet will be included in our consolidated financial statements commencing on the acquisition date. The acquisition, which is subject to customary closing conditions, is expected to close during the three months ended March 31, 2012.

Quarterly financial data (unaudited)

12 Months Ended

Dec. 31, 2011

Quarterly financial data (unaudited) [Abstract]

Quarterly financial data (unaudited)

21. Quarterly financial data (unaudited)


	2011 Quarters ended
(In millions, except per share data)	December 31		September 30⁽¹⁾		June 30		March 31

Product sales	$	3,907	$	3,877	$	3,893	$	3,618
Gross profit from product sales		3,251		3,272		3,291		3,054
Net income		934		454		1,170		1,125
Earnings per share:
Basic	$	1.09	$	0.50	$	1.26	$	1.21
Diluted	$	1.08	$	0.50	$	1.25	$	1.20

	2010 Quarters ended
(In millions, except per share data)	December 31⁽²⁾		September 30⁽³⁾		June 30		March 31

Product sales	$	3,760	$	3,759	$	3,613	$	3,528
Gross profit from product sales		3,188		3,172		3,060		3,020
Net income		1,022		1,236		1,202		1,167
Earnings per share:
Basic	$	1.09	$	1.29	$	1.25	$	1.19
Diluted	$	1.08	$	1.28	$	1.25	$	1.18

⁽¹⁾	We recorded a $780 million legal settlement charge ($705 million, net of tax) in connection with an agreement in principle to settle allegations relating to our sales and marketing practices.

⁽²⁾

We recorded $113 million of income tax benefit as the result of resolving certain transfer pricing issues with tax authorities for prior periods and a $118 million ($74 million, net of tax) asset impairment charge associated with a strategic decision to optimize our network of manufacturing facilities and improve cost efficiencies.

⁽³⁾	We recorded $38 million of income tax benefit as the result of resolving certain transfer pricing issues with tax authorities for prior periods.

See Note 4, Income taxes, and Note 18, Contingencies and commitments, for further discussion of the items described above.

- Definition

The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.

+ References + Details

Valuation Accounts

12 Months Ended

Dec. 31, 2011

Valuation Accounts [Abstract]

Valuation Accounts

SCHEDULE II

AMGEN INC.

VALUATION ACCOUNTS

Years ended December 31, 2011, 2010 and 2009

(In millions)


Allowance for doubtful accounts	Balance at beginning of period		Additions charged to costs and expenses			Other additions		Deductions		Balance at end of period

Year ended December 31, 2011	$	42	$	17		$	—	$	5	$	54
Year ended December 31, 2010	$	32	$	10		$	—	$	—	$	42
Year ended December 31, 2009	$	38	$	(6	)	$	—	$	—	$	32

Summary of significant accounting policies (Policies)	12 Months Ended
Summary of significant accounting policies (Policies)	Dec. 31, 2011
Summary of significant accounting policies [Abstract]
Business	Business Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. We concentrate on innovating novel medicines based on advances in cellular and molecular biology, and we operate in one business segment: human therapeutics.
Principles of consolidation	Principles of consolidation The consolidated financial statements include the accounts of Amgen as well as its wholly owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation.
Use of estimates	Use of estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
Product sales	Product sales Product sales consist primarily of sales of Neulasta^® (pegfilgrastim), NEUPOGEN^® (Filgrastim), Enbrel^® (etanercept), Aranesp^® (darbepoetin alfa) and EPOGEN^® (epoetin alfa). Sales of our products are recognized when shipped and title and risk of loss have passed. Product sales are recorded net of accruals for estimated rebates, wholesaler chargebacks, discounts and other deductions (collectively “sales deductions”) and returns. Taxes collected from customers and remitted to government authorities related to the sales of the Company’s products, primarily in Europe, are excluded from revenues. We have the exclusive right to sell epoetin alfa for dialysis, certain diagnostics and all non-human, non-research uses in the United States. We sell epoetin alfa under the brand name EPOGEN^®. We granted to Ortho Pharmaceutical Corporation (which has assigned its rights under the product license agreement to Janssen Biotech, Inc., formerly known as Centocor Ortho Biotech Products, L.P.), a subsidiary of Johnson & Johnson (J&J), a license relating to epoetin alfa for sales in the United States for all human uses except dialysis and diagnostics. This license agreement, which is perpetual, may be terminated for various reasons, including upon mutual agreement of the parties, or default. The parties are required to compensate each other for epoetin alfa sales that either party makes into the other party’s exclusive market, sometimes referred to as “spillover.” Accordingly, we do not recognize product sales we make into the exclusive market of J&J and do recognize the product sales made by J&J into our exclusive market. Sales in our exclusive market are derived from our sales to our customers, as adjusted for spillover. We are employing an arbitrated audit methodology to measure each party’s spillover based on estimates of and subsequent adjustments thereto of third-party data on shipments to and usage by end users.
Other revenues	Other revenues Other revenues consist primarily of royalty income and corporate partner revenues. Royalties from licensees are based on third-party sales of licensed products and are recorded in accordance with contract terms when third-party results are reliably measurable and collectability is reasonably assured. Royalty estimates are made in advance of amounts collected using historical and forecasted trends. Corporate partner revenues are comprised of amounts earned from Kirin-Amgen, Inc. (K-A) for certain research and development (R&D) activities, which are earned as the R&D activities are performed. Corporate partner revenues also include license fees and milestone payments earned from K-A and from third parties. See Multiple-deliverable revenue arrangements, discussed below, Note 6, Collaborative arrangements, and Note 7, Related party transactions.
Multiple-deliverable revenue arrangements	Muliple-deliverable revenue arrangements Effective January 1, 2011, we adopted a new accounting standard that amends the guidance on the accounting for arrangements involving the delivery of more than one element. Pursuant to the new standard, each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting. For Amgen this determination is generally based on whether the deliverable has “stand-alone value” to the customer. The arrangement’s consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. In general, the consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. The Company adopted this new accounting standard on a prospective basis for all multiple-deliverable revenue arrangements (MDRAs) entered into on or after January 1, 2011, and for any MDRAs that were entered into prior to January 1, 2011, but materially modified on or after that date. For MDRAs entered into prior to January 1, 2011, (pre-2011 arrangements) and not materially modified thereafter, we continue to apply our prior accounting policy with respect to such arrangements. Under this policy, in general, revenue from non-refundable, up-front fees related to intellectual property rights/licenses, where we have continuing involvement and where standalone value could not be determined under the previous guidance, is recognized ratably over the estimated period of ongoing involvement. In general, the consideration with respect to the other deliverables is recognized when the goods or services are delivered. Under all of our MDRAs, consideration associated with at-risk substantive performance milestones is recognized as revenue upon the achievement of the related milestone, as defined in the respective contracts. The primary impact of adopting the new accounting standard is expected to be the earlier recognition of revenue associated with delivering rights to the underlying intellectual property. The adoption of this accounting standard did not have a material impact on our consolidated results of operations for the year ended December 31, 2011, or on our financial position as of December 31, 2011. Our consolidated results of operations for the year ended December 31, 2010, or our financial position as of December 31, 2010, also would not have been materially impacted if the accounting standard had been adopted on January 1, 2010. The impact of adopting this new accounting standard is dependent on the terms and conditions of any future arrangements that we may enter into that include multiple-deliverables and pre-2011 arrangements that are materially modified. Depending on the terms of any such arrangements, the adoption of this accounting standard may have a material impact on our consolidated results of operations or financial position.
Research and development costs	Research and development costs R&D costs are expensed as incurred and include primarily salaries, benefits and other staff-related costs; facilities and overhead costs; clinical trial and related clinical manufacturing costs; contract services and other outside costs; information systems’ costs and amortization of acquired technology used in R&D with alternative future uses. R&D expenses also include costs and cost recoveries associated with K-A and third-party R&D arrangements, including upfront fees and milestones paid to third parties in connection with technologies which had not reached technological feasibility and did not have an alternative future use. Net payment or reimbursement of R&D costs is recognized when the obligations are incurred or as we become entitled to the cost recovery. See Note 6, Collaborative arrangements, and Note 7, Related party transactions.
Selling, general and administrative costs	Selling, general and administrative costs Selling, general and administrative (SG&A) expenses are comprised primarily of salaries, benefits and other staff-related costs associated with sales and marketing, finance, legal and other administrative personnel; facilities and overhead costs; outside marketing, advertising and legal expenses; and other general and administrative costs. Advertising costs are expensed as incurred. SG&A expenses also include costs and cost recoveries associated with marketing and promotion efforts under certain collaboration arrangements. Net payment or reimbursement of SG&A costs is recognized when the obligations are incurred or we become entitled to the cost recovery. See Note 6, Collaborative arrangements. Beginning January 1, 2011, SG&A expenses also include the amortization of the annual fee mandated by the Patient Protection and Affordable Care Act and the companion Health Care and Education Reconciliation Act (the U.S. healthcare reform federal excise fee). The liability for the annual U.S. healthcare reform federal excise fee is estimated and recorded in full upon the first qualifying sale of our covered products with a corresponding deferred cost established that is amortized on a straight-line basis over the calendar year that it is payable.
Stock-based compensation	Stock-based compensation We have stock-based compensation plans under which various types of equity-based awards are granted, including stock options, restricted stock units (RSU) and performance units. The estimated fair values of stock option and RSU awards which are subject only to service conditions with graded vesting are generally recognized as compensation expense on a straight-line basis over the service period. The estimated fair values of performance unit awards are generally recognized as compensation expense on a straight-line basis from the grant date to the end of the performance period. See Note 3, Stock-based compensation.
Income taxes	Income taxes We provide for income taxes based on pretax income, applicable tax rates and tax planning opportunities available in the various jurisdictions in which we operate. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. The amount of unrecognized tax benefits (UTBs) is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to UTBs in income tax expense. See Note 4, Income taxes.
Business combinations	Business combinations Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process research and development (IPR&D) projects and liabilities assumed, are recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with a business combination are recorded at their fair values on the acquisition date and remeasured at their fair values each subsequent reporting period until the related contingencies are resolved. The resulting changes in fair values are recorded in earnings. See Note 2, Business combinations, and Note 16, Fair value measurement.
Cash equivalents	Cash equivalents We consider cash equivalents to be only those investments which are highly liquid, readily convertible to cash and which mature within three months from the date of purchase.
Available-for-sale investments	Available-for-sale investments We consider our investment portfolio available-for-sale and, accordingly, these investments are recorded at fair value with unrealized gains and losses generally recorded in other comprehensive income. See Note 9, Available-for-sale investments, and Note 16, Fair value measurement.
Inventories	Inventories Inventories are stated at the lower of cost or market. Cost, which includes amounts related to materials, labor and overhead, is determined in a manner that approximates the first-in, first-out method. Cost also includes the Puerto Rico excise tax enacted in 2011 related to our manufacturing operations in Puerto Rico. See Note 10, Inventories.
Derivatives	Derivatives We recognize all of our derivative instruments as either assets or liabilities at fair value in the Consolidated Balance Sheets. The accounting for changes in the fair value of a derivative instrument depends on whether it has been formally designated and qualifies as part of a hedging relationship under the applicable accounting standards and, further, on the type of hedging relationship. For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter, whether the hedging derivatives are highly effective in offsetting changes in either the fair value or cash flows of the hedged item. Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings. See Note 16, Fair value measurement, and Note 17, Derivative instruments.
Property, plant and equipment, net	Property, plant and equipment, net Property, plant and equipment is recorded at historical cost, net of accumulated depreciation, amortization and, if applicable, impairment charges. We review our property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Depreciation is provided over the assets’ useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. See Note 11, Property, plant and equipment.
Intangible assets and goodwill	Intangible assets and goodwill Finite-lived intangible assets are recorded at cost, net of accumulated amortization and, if applicable, impairment charges. Amortization of finite-lived intangible assets is provided over their estimated useful lives on a straight-line basis. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. See Note 12, Intangible assets. The estimated fair values of IPR&D projects acquired in a business combination which have not reached technological feasibility are capitalized and accounted for as indefinite-lived intangible assets subject to impairment testing until completion or abandonment of the project. Capitalized IPR&D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written-off immediately. Goodwill relates principally to our 2002 acquisition of Immunex Corporation (Immunex). We perform an impairment test of goodwill annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.
Convertible debt	Convertible debt The debt and equity components of convertible debt instruments that may be partially or wholly cash settled (cash settleable convertible notes), including our 0.125% 2011 Convertible Notes and 0.375% 2013 Convertible Notes, are bifurcated and accounted for separately. The debt component of cash settleable convertible notes, which excludes the associated equity conversion option, is recorded at fair value as of the issuance date. The difference between the amount allocated to the debt component and the proceeds received upon issuance of the debt is allocated to the equity component and recorded in Common stock and additional paid-in capital in the Consolidated Balance Sheets. The reduced or discounted carrying value of cash settleable convertible notes resulting from bifurcation is subsequently accreted back to its principal amount through the recognition of non-cash interest expense. This results in recognizing interest expense on the borrowing at an effective rate approximating what would have been incurred had nonconvertible debt with otherwise similar terms been issued. See Note 14, Financing arrangements.
Recent accounting pronouncements	Recent accounting pronouncements In June 2011, a new accounting standard was issued that changed the disclosure requirements for the presentation of other comprehensive income (OCI) in the financial statements, including the elimination of the option to present OCI in the statement of stockholders’ equity. OCI and its components will be required to be presented for both interim and annual periods either in a single financial statement, the statement of comprehensive income, or in two separate but consecutive financial statements, consisting of a statement of income followed by a separate statement presenting OCI. This standard is required to be applied retrospectively beginning January 1, 2012, except for certain provisions for which adoption was delayed.

Business Combinations (Tables) - BioVex Group Inc [Member]

12 Months Ended

Dec. 31, 2011

Business Combinations [Line Items]

Aggregate acquisition date consideration to acquire an entity


Cash paid to former shareholders of BioVex	$	407
Fair value of contingent consideration obligations		190

Total consideration	$	597

Allocation of the total consideration to the acquisition date fair values of assets acquired and liabilities assumed


Intangible assets — IPR&D	$	675
Goodwill		170
Deferred tax liabilities		(246	)
Other assets (liabilities) acquired, net		(2	)

Total consideration	$	597

Stock-based compensation (Tables)

12 Months Ended

Dec. 31, 2011

Stock-based compensation [Abstract]

Components of stock-based compensation expense recognized in the Consolidated Statements of Income


	2011			2010			2009
Stock options	$	85		$	124		$	115
Restricted stock units		188			182			134
Performance units		68			47			35

Total stock-based compensation expense, pre-tax		341			353			284
Tax benefit from stock-based compensation expense		(124	)		(120	)		(97	)

Total stock-based compensation expense, net of tax	$	217		$	233		$	187

Weighted average assumptions used and the resulting weighted average grant date fair value of employee stock options


	2011		2010		2009
Closing price of our common stock on grant date	$	54.66	$	58.32	$	50.65
Expected volatility		23.5%		28.0%		39.6%
Expected life (in years)		5.9		6.6		4.6
Risk-free interest rate		2.5%		3.2%		2.1%
Expected dividend yield		2.0%		0%		0%
Fair value of stock options granted	$	11.39	$	20.97	$	18.35

Stock options information


	Options (in millions)			Weighted- average exercise price		Weighted- average remaining contractual life (years)		Aggregate intrinsic value (in millions)
Balance unexercised at December 31, 2010		46.8		$	58.66
Granted		2.3		$	54.66
Exercised		(5.0	)	$	50.22
Expired/forfeited		(9.9	)	$	60.43

Balance unexercised at December 31, 2011		34.2		$	59.11		3.8	$	245

Vested or expected to vest at December 31, 2011		33.8		$	59.15		3.7	$	242

Exercisable at December 31, 2011		23.6		$	61.49		2.3	$	135

Restricted stock units Information


	Units (in millions)			Weighted-average grant date fair value
Balance nonvested at December 31, 2010		9.3		$	52.67
Granted		4.0		$	51.83
Vested		(3.4	)	$	52.06
Forfeited		(0.9	)	$	52.77

Balance nonvested at December 31, 2011		9.0		$	52.64

Weighted average assumptions used and the resulting weighted average grant date fair value of performance units


	2011		2010		2009
Closing price of our common stock on grant date	$	51.67	$	56.90	$	47.63
Volatility		32.8%		34.7%		34.3%
Risk-free interest rate		1.2%		1.3%		1.2%
Expected dividend yield		0.1%		0%		0%
Fair value of unit	$	49.50	$	62.06	$	48.22

Income taxes (Tables)

12 Months Ended

Dec. 31, 2011

Income taxes [Abstract]

Provision for income taxes


	2011			2010			2009
Current provision:
Federal	$	618		$	636		$	325
State		58			52			85
Foreign		148			153			155

Total current provision		824			841			565

Deferred (benefit) provision:
Federal		(340	)		(196	)		92
State		(16	)		43			(59	)
Foreign		(1	)		2			1

Total deferred (benefit) provision		(357	)		(151	)		34

Total provision	$	467		$	690		$	599

Significant components of deferred tax assets and liabilities


	2011			2010
Deferred income tax assets:
Intercompany inventory related items	$	387		$	306
Expense accruals		751			626
Acquired net operating loss and credit carryforwards		192			147
Expenses capitalized for tax		167			188
Stock-based compensation		241			269
Deferred revenue		133			117
Other		72			72

Total deferred income tax assets		1,943			1,725
Valuation allowance		(126	)		(80	)

Net deferred income tax assets		1,817			1,645


Deferred income tax liabilities:
Acquired intangibles		(832	)		(739	)
Fixed assets		(219	)		(181	)
Unremitted foreign earnings		(61	)		(118	)
Other		(110	)		(142	)

Total deferred income tax liabilities		(1,222	)		(1,180	)

Total deferred income taxes, net	$	595		$	465

Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)


	2011			2010			2009
Balance at beginning of year	$	920		$	1,140		$	1,113
Additions based on tax positions related to the current year		283			305			302
Reductions for tax positions of prior years		(7	)		(110	)		(215	)
Settlements		(221	)		(415	)		(60	)

Balance at end of year	$	975		$	920		$	1,140

Reconciliation between the federal statutory tax rate and effective tax rate


	2011		2010		2009
Federal statutory tax rate		35.0 %		35.0 %		35.0 %
Foreign earnings, including earnings invested indefinitely		(19.4)%		(19.1)%		(19.6)%
State taxes		0.7 %		1.6 %		1.1 %
Credits, Puerto Rico Excise Tax		(6.5)%		0.0 %		0.0 %
Credits, primarily research and experimentation		(1.5)%		(0.9)%		(0.8)%
Legal settlements		2.2 %		0.0 %		0.0 %
Audit settlements		0.0 %		(3.1)%		(4.2)%
Other, net		0.8 %		(0.5)%		0.0 %

Effective tax rate		11.3 %		13.0 %		11.5 %

Earnings per share (Tables)

12 Months Ended

Dec. 31, 2011

Earnings per share [Abstract]

Computation for basic and diluted earnings per share


	2011		2010		2009
Income (Numerator):
Net income for basic and diluted EPS	$	3,683	$	4,627	$	4,605

Shares (Denominator):
Weighted-average shares for basic EPS		905		960		1,016
Effect of dilutive securities		7		5		5

Weighted-average shares for diluted EPS		912		965		1,021

Basic EPS	$	4.07	$	4.82	$	4.53
Diluted EPS	$	4.04	$	4.79	$	4.51

Available-for-sale investments (Tables)

12 Months Ended

Dec. 31, 2011

Available-for-sale investments [Abstract]

Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security


Type of security as of December 31, 2011	Amortized cost		Gross unrealized gains		Gross unrealized losses			Estimated fair value
U.S. Treasury securities	$	3,878	$	68	$	—		$	3,946
Other government-related debt securities:
Obligations of U.S. government agencies and FDIC-guaranteed bank debt		1,548		23		—			1,571
Foreign and other		441		9		—			450
Corporate debt securities:
Financial		2,493		30		(15	)		2,508
Industrial		3,077		79		(10	)		3,146
Other		280		9		-			289
Mortgage- and asset-backed securities		1,789		6		(10	)		1,785
Money market mutual funds		6,266		—		—			6,266

Total debt security investments		19,772		224		(35	)		19,961
Equity securities		42		—		—			42

Total available-for-sale investments	$	19,814	$	224	$	(35	)	$	20,003


Type of security as of December 31, 2010	Amortized cost		Gross unrealized gains		Gross unrealized losses			Estimated fair value
U.S. Treasury securities	$	5,044	$	50	$	(14	)	$	5,080
Other government-related debt securities:
Obligations of U.S. government agencies and FDIC-guaranteed bank debt		2,158		51		(1	)		2,208
Foreign and other		837		16		(1	)		852
Corporate debt securities:
Financial		2,252		53		(9	)		2,296
Industrial		2,441		71		(5	)		2,507
Other		307		10		(1	)		316
Mortgage- and asset-backed securities		841		5		(5	)		841
Money market mutual funds		3,030		—		—			3,030
Other short-term interest-bearing securities		147		—		—			147

Total debt security investments		17,057		256		(36	)		17,277
Equity securities		50		—		(2	)		48

Total available-for-sale investments	$	17,107	$	256	$	(38	)	$	17,325

Fair values of available-for-sale investments by classification in the consolidated balance sheets


Classification in the Consolidated Balance Sheets	2011		2010
Cash and cash equivalents	$	6,266	$	3,142
Marketable securities		13,695		14,135
Other assets — noncurrent		42		48

Total available-for-sale investments	$	20,003	$	17,325

Fair values of available-for-sale debt security investments by contractual maturity


Contractual maturity	2011		2010
Maturing in one year or less	$	6,811	$	4,118
Maturing after one year through three years		6,346		6,736
Maturing after three years through five years		5,710		5,812
Maturing after five years		1,094		611

Total debt securities	$	19,961	$	17,277

- Definition

Tabular disclosure of available-for-sale securities which consist of all investments in certain debt and equity securities neither classified as trading or held-to-maturity securities. A debt security represents a creditor relationship with an enterprise. Debt securities include, among other items, US Treasury securities, US government securities, municipal securities, corporate bonds, convertible debt, commercial paper, and all securitized debt instruments. An equity security represents an ownership interest in an enterprise or the right to acquire or dispose of an ownership interest in an enterprise at fixed or determinable prices. Equity securities include, among other things, common stock, certain preferred stock, warrant rights, call options, and put options, but do not include convertible debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 03-1
-Paragraph 21
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 17
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 19, 20, 21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27337-111563

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27198-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27161-111563

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27357-111563

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27290-111563

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803

+ Details

Inventories (Tables)

12 Months Ended

Dec. 31, 2011

Inventories [Abstract]

Inventories


	2011		2010
Raw materials	$	158	$	128
Work in process		1,802		1,382
Finished goods		524		512

Total inventories	$	2,484	$	2,022

Property, plant and equipment (Tables)

12 Months Ended

Dec. 31, 2011

Property, plant and equipment [Abstract]

Property plant and equipment


	Useful life (in years)		2011		2010
Land		—	$	366	$	361
Buildings and improvements		10-40		3,463		3,392
Manufacturing equipment		8-12		1,897		1,802
Laboratory equipment		8-12		1,016		955
Other		3-15		3,745		3,547
Construction in progress		—		744		631

Property, plant and equipment, gross				11,231		10,688
Less accumulated depreciation and amortization				(5,811)		(5,166)

Property, plant and equipment, net			$	5,420	$	5,522

Intangible assets (Tables)

12 Months Ended

Dec. 31, 2011

Intangible assets [Abstract]

Identifiable finite-lived and indefinite-lived intangible assets


	2011						2010
	Gross carrying amount		Accumulated amortization		Intangible assets, net		Gross carrying amount		Accumulated amortization		Intangible assets, net
Finite-lived intangible assets:
Acquired product technology rights:
Developed product technology	$	2,872	$	(1,811)	$	1,061	$	2,872	$	(1,619)	$	1,253
Core technology		1,348		(850)		498		1,348		(760)		588
Trade name		190		(120)		70		190		(107)		83
Acquired R&D technology rights		350		(350)		—		350		(329)		21
Other acquired intangible assets		686		(406)		280		627		(342)		285

Total finite-lived intangible assets		5,446		(3,537)		1,909		5,387		(3,157)		2,230
Indefinite-lived intangible assets — IPR&D		675		—		675		—		—		—

Total identifiable intangible assets	$	6,121	$	(3,537)	$	2,584	$	5,387	$	(3,157)	$	2,230

Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2011

Accrued liabilities [Abstract]

Accrued liabilities


	2011		2010
Sales deductions	$	1,326	$	1,144
Employee compensation and benefits		916		764
Sales returns reserve		339		339
Legal reserve		780		—
Other		1,667		1,119

Total accrued liabilities	$	5,028	$	3,366

Financing arrangements (Tables)

12 Months Ended

Dec. 31, 2011

Financing arrangements [Abstract]

Carrying values and the fixed contractual coupon rates of long-term borrowings


	2011		2010
0.125% convertible notes due 2011 (0.125% 2011 Convertible Notes)	$	—	$	2,488
0.375% convertible notes due 2013 (0.375% 2013 Convertible Notes)		2,346		2,213
1.875% notes due 2014 (1.875% 2014 Notes)		1,000		—
4.85% notes due 2014 (4.85% 2014 Notes)		1,000		1,000
2.30% notes due 2016 (2.30% 2016 Notes)		748		—
2.50% notes due 2016 (2.50% 2016 Notes)		999		—
5.85% notes due 2017 (5.85% 2017 Notes)		1,099		1,099
6.15% notes due 2018 (6.15% 2018 Notes)		499		499
4.375% euro denominated notes due 2018 (4.375% 2018 euro Notes)		714		—
5.70% notes due 2019 (5.70% 2019 Notes)		998		998
4.50% notes due 2020 (4.50% 2020 Notes)		300		300
3.45% notes due 2020 (3.45% 2020 Notes)		897		897
4.10% notes due 2021 (4.10% 2021 Notes)		998		—
3.875% notes due 2021 (3.875% 2021 Notes)		1,745		—
5.50% pound sterling denominated notes due 2026 (5.50% 2026 pound sterling Notes)		739		—
6.375% notes due 2037 (6.375% 2037 Notes)		899		899
6.90% notes due 2038 (6.90% 2038 Notes)		499		499
6.40% notes due 2039 (6.40% 2039 Notes)		996		996
5.75% notes due 2040 (5.75% 2040 Notes)		697		696
4.95% notes due 2041 (4.95% 2041 Notes)		595		595
5.15% notes due 2041 (5.15% 2041 Notes)		2,232		—
5.65% notes due 2042 (5.65% 2042 Notes)		1,244		—
Other notes, including our zero-coupon convertible notes		184		183

Total debt		21,428		13,362
Less current portion		(84)		(2,488)

Total noncurrent debt	$	21,344	$	10,874

Principal balance, unamortized discount and net carrying amounts of the liability and equity components of our 2013 convertible notes


	Liability component						Equity component
0.375% 2013 Convertible Notes	Principal balance		Unamortized discount		Net carrying amount		Net carrying amount
December 31, 2011	$	2,500	$	154	$	2,346	$	829
December 31, 2010	$	2,500	$	287	$	2,213	$	829

The effective interest rates on notes after giving effect to the related interest rate swap contracts and the notional amounts of interest rate swap contracts


		Notional amount
	Effective interest rate	2011		2010
4.85% 2014 Notes	LIBOR + 0.3%	$	1,000	$	1,000
5.85% 2017 Notes	LIBOR + 2.5%		1,100		1,100
6.15% 2018 Notes	LIBOR + 1.8%		500		500
5.70% 2019 Notes	LIBOR + 2.6%		1,000		1,000

		$	3,600	$	3,600

Aggregate contractual maturities of long-term debt obligations


Maturity date	Amount
2012⁽¹⁾	$	84
2013⁽²⁾		2,500
2014		2,000
2015		—
2016		1,750
Thereafter		15,312

Total	$	21,646

⁽¹⁾	This amount represents the accreted value of our zero-coupon convertible notes due in 2032 which will be redeemed on March 1, 2012.

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6584090&loc=d3e28878-108400

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

+ Details

- Definition

Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5579245-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624163-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624171-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41678-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n)(2))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41638-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5580258-113959

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5579240-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41641-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41620-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

+ Details

Stockholders' equity (Tables)

12 Months Ended

Dec. 31, 2011

Stockholders' equity [Abstract]

Summary of activity under our stock repurchase program


	2011					2010				2009
	Shares		Dollars			Shares		Dollars		Shares		Dollars
First quarter		—	$	—			29.1	$	1,684		37.5	$	1,997
Second quarter		12.9		732			10.3		616		—		—
Third quarter		45.4		2,421			6.6		364		—		—
Fourth quarter		86.0		5,154	⁽¹⁾		20.5		1,136		21.7		1,211

Total stock repurchases		144.3	$	8,307			66.5	$	3,800		59.2	$	3,208

⁽¹⁾	Includes the repurchase of 83.3 million shares of our common stock at an average price paid per share of $60.08 including related expenses, for an aggregate cost of $5.0 billion, under a modified Dutch auction tender offer.

Components of Accumulated Other Comprehensive Income


	Foreign currency translation			Cash flow hedges			Available-for-sale securities			Other			AOCI
Balance as of December 31, 2008	$	25		$	50		$	49		$	(7	)	$	117
Foreign currency translation adjustments		25			—			—			—			25
Unrealized (losses) gains		—			(213	)		116			(12	)		(109	)
Reclassification adjustments to income		—			8			(42	)		—			(34	)
Other		—			—			—			5			5
Income taxes		(10	)		73			(28	)		6			41

Balance as of December 31, 2009		40			(82	)		95			(8	)		45
Foreign currency translation adjustments		(29	)		—			—			—			(29	)
Unrealized gains		—			186			155			1			342
Reclassification adjustments to income		—			(46	)		(90	)		—			(136	)
Income taxes		11			(55	)		(25	)		—			(69	)

Balance as of December 31, 2010		22			3			135			(7	)		153
Foreign currency translation adjustments		(6	)		—			—			—			(6	)
Unrealized (losses) gains		—			(51	)		125			2			76
Reclassification adjustments to income		—			112			(154	)		—			(42	)
Other		—			—			—			(8	)		(8	)
Income taxes		5			(21	)		14			—			(2	)

Balance as of December 31, 2011	$	21		$	43		$	120		$	(13	)	$	171

Fair value measurement (Tables)

12 Months Ended

Dec. 31, 2011

Fair value measurement [Abstract]

Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis


Fair value measurement as of December 31, 2011, using:	Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)		Total
Assets:
Available-for-sale investments:
U.S. Treasury securities	$	3,946	$	—	$	—	$	3,946
Other government-related debt securities:
Obligations of U.S. government agencies and FDIC-guaranteed bank debt		—		1,571		—		1,571
Foreign and other		—		450		—		450
Corporate debt securities:
Financial		—		2,508		—		2,508
Industrial		—		3,146		—		3,146
Other		—		289		—		289
Mortgage- and asset-backed securities		—		1,785		—		1,785
Money market mutual funds		6,266		—		—		6,266
Equity securities		42		—		—		42
Derivatives:
Foreign currency contracts		—		172		—		172
Interest rate swap contracts		—		377		—		377

Total assets	$	10,254	$	10,298	$	—	$	20,552

Liabilities:
Derivatives:
Foreign currency contracts	$	—	$	48	$	—	$	48
Cross currency swap contracts		—		26		—		26
Contingent consideration obligations in connection with a business combination		—		—		190		190

Total liabilities	$	—	$	74	$	190	$	264


Fair value measurement as of December 31, 2010, using:	Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)		Total
Assets:
Available-for-sale investments:
U.S. Treasury securities	$	5,080	$	—	$	—	$	5,080
Other government-related debt securities:
Obligations of U.S. government agencies and FDIC-guaranteed bank debt		—		2,208		—		2,208
Foreign and other		—		852		—		852
Corporate debt securities:
Financial		—		2,296		—		2,296
Industrial		—		2,507		—		2,507
Other		—		316		—		316
Mortgage- and asset-backed securities		—		841		—		841
Money market mutual funds		3,030		—		—		3,030
Other short-term interest-bearing securities		—		147		—		147
Equity securities		48		—		—		48
Derivatives:
Foreign currency contracts		—		154		—		154
Interest rate swap contracts		—		195		—		195

Total assets	$	8,158	$	9,516	$	—	$	17,674

Liabilities:
Derivatives:
Foreign currency contracts	$	—	$	103	$	—	$	103

Total liabilities	$	—	$	103	$	—	$	103

Derivative instruments (Tables)

12 Months Ended

Dec. 31, 2011

Derivative instruments [Abstract]

Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges


	Years ended December 31,
Derivatives in cash flow hedging relationships	2011			2010			2009
Foreign currency contracts	$	(25	)	$	191		$	(202	)
Cross currency swap contracts		(26	)		—			—
Forward interest rate contracts		—			(5	)		(11	)

Total	$	(51	)	$	186		$	(213	)

Location in the Consolidated Statements of Income and the effective portion of gain/(loss) reclassified from Accumulated Other Comprehensive Income into earnings for our derivative instruments designated as cash flow hedges


		Years ended December 31,
Derivatives in cash flow hedging relationships	Statements of Income location	2011			2010			2009
Foreign currency contracts	Product sales	$	(108	)	$	47		$	(7	)
Cross currency swap contracts	Interest and other income, net		(3	)		—			—
Forward interest rate contracts	Interest expense, net		(1	)		(1	)		(1	)

Total		$	(112	)	$	46		$	(8	)

Location in the Consolidated Statements of Income and the amount of gain/(loss) recognized in earnings for the derivative instruments not designated as hedging instruments


		Years ended December 31,
Derivatives not designated as hedging instruments	Statements of Income location	2011			2010		2009
Foreign currency contracts	Interest and other income, net	$	(1	)	$	32	$	(24	)

Fair values of both derivatives designated as hedging instruments and derivatives not designated as hedging instruments included in the Consolidated Balance Sheets


	Derivative assets			Derivative liabilities
December 31, 2011	Balance Sheet location	Fair value		Balance Sheet location	Fair value
Derivatives designated as hedging instruments:
Interest rate swap contracts	Other current assets/ Other noncurrent assets	$	377	Accrued liabilities/ Other noncurrent liabilities	$	—
Cross currency swap contracts	Other current assets/ Other noncurrent assets		—	Accrued liabilities/ Other noncurrent liabilities		26
Foreign currency contracts	Other current assets/ Other noncurrent assets		172	Accrued liabilities/ Other noncurrent liabilities		48

Total derivatives designated as hedging instruments			549			74

Derivatives not designated as hedging instruments:
Foreign currency contracts	Other current assets		—	Accrued liabilities		—

Total derivatives not designated as hedging instruments			—			—

Total derivatives		$	549		$	74


	Derivative assets			Derivative liabilities
December 31, 2010	Balance Sheet location	Fair value		Balance Sheet location	Fair value

Derivatives designated as hedging instruments:
Interest rate swap contracts	Other current assets/ Other noncurrent assets	$	195	Accrued liabilities/ Other noncurrent liabilities	$	—
Foreign currency contracts	Other current assets/ Other noncurrent assets		154	Accrued liabilities/ Other noncurrent liabilities		103

Total derivatives designated as hedging instruments			349			103

Derivatives not designated as hedging instruments:
Foreign currency contracts	Other current assets		—	Accrued liabilities		—

Total derivatives not designated as hedging instruments			—			—

Total derivatives		$	349		$	103

Contingencies and commitments (Tables)

12 Months Ended

Dec. 31, 2011

Contingencies and commitments [Abstract]

Minimum future rental commitments under non-cancelable operating leases


2012	$	116
2013		104
2014		85
2015		76
2016		65
Thereafter		328

Total minimum operating lease commitments	$	774

Segment information (Tables)

12 Months Ended

Dec. 31, 2011

Segment information [Abstract]

Revenues


	2011		2010		2009
Product sales:
Neulasta^® — U.S.	$	3,006	$	2,654	$	2,527
NEUPOGEN^® — U.S.		959		932		901
Neulasta^® — International		946		904		828
NEUPOGEN^® — International		301		354		387
ENBREL — U.S.		3,458		3,304		3,283
ENBREL — Canada		243		230		210
Aranesp^® — U.S.		986		1,103		1,251
Aranesp^® — International		1,317		1,383		1,401
EPOGEN^® — U.S.		2,040		2,524		2,569
Sensipar^® — U.S.		518		459		429
Sensipar^® (Mimpara^®) — International		290		255		222
Vectibix^® — U.S.		122		115		97
Vectibix^® — International		200		173		136
Nplate^® — U.S.		163		129		78
Nplate^® — International		134		100		32
Prolia^® — U.S.		130		26		—
Prolia^® — International		73		7		—
XGEVA^® — U.S.		343		8		—
XGEVA^® — International		8		—		—
Other — International		58		—		—

Total product sales		15,295		14,660		14,351
Other revenues		287		393		291

Total revenues	$	15,582	$	15,053	$	14,642

Geographical information with respect to revenues and long-lived assets


	Years ended December 31,
	2011		2010		2009
Revenues:
United States	$	11,985	$	11,636	$	11,421
International countries		3,597		3,417		3,221

Total revenues	$	15,582	$	15,053	$	14,642


	December 31,
	2011		2010
Long-lived assets:
United States	$	3,144	$	3,248
Puerto Rico		1,993		2,079
International countries		283		195

Total long-lived assets	$	5,420	$	5,522

Revenues earned from major customers


	2011		2010		2009
AmerisourceBergen Corporation:
Gross product sales	$	7,574	$	7,678	$	7,179
% of total gross revenues		36%		38%		37%
% of U.S. gross product sales		45%		47%		46%
McKesson Corporation:
Gross product sales	$	4,591	$	3,913	$	3,694
% of total gross revenues		22%		19%		19%
% of U.S. gross product sales		27%		24%		24%
Cardinal Health, Inc:
Gross product sales	$	3,021	$	2,813	$	2,841
% of total gross revenues		14%		14%		15%
% of U.S. gross product sales		18%		17%		18%

Quarterly financial data (unaudited) (Tables)

12 Months Ended

Dec. 31, 2011

Quarterly financial data (unaudited) [Abstract]

Quarterly financial data (unaudited)


	2011 Quarters ended
(In millions, except per share data)	December 31		September 30⁽¹⁾		June 30		March 31

Product sales	$	3,907	$	3,877	$	3,893	$	3,618
Gross profit from product sales		3,251		3,272		3,291		3,054
Net income		934		454		1,170		1,125
Earnings per share:
Basic	$	1.09	$	0.50	$	1.26	$	1.21
Diluted	$	1.08	$	0.50	$	1.25	$	1.20

	2010 Quarters ended
(In millions, except per share data)	December 31⁽²⁾		September 30⁽³⁾		June 30		March 31

Product sales	$	3,760	$	3,759	$	3,613	$	3,528
Gross profit from product sales		3,188		3,172		3,060		3,020
Net income		1,022		1,236		1,202		1,167
Earnings per share:
Basic	$	1.09	$	1.29	$	1.25	$	1.19
Diluted	$	1.08	$	1.28	$	1.25	$	1.18

⁽¹⁾	We recorded a $780 million legal settlement charge ($705 million, net of tax) in connection with an agreement in principle to settle allegations relating to our sales and marketing practices.

⁽²⁾

⁽³⁾	We recorded $38 million of income tax benefit as the result of resolving certain transfer pricing issues with tax authorities for prior periods.

Business Combinations (Details) - BioVex Group Inc [Member] $ in Millions	Mar. 04, 2011 USD ($)
Aggregate acquisition date consideration to acquire an entity
Cash paid to former shareholders of acquired entity	$ 407
Fair value of contingent consideration obligations	190
Total consideration	$ 597

- Definition

Fair value, as of the acquisition date, of potential payments under the contingent consideration arrangement including cash and shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph f
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph g(1)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 29, 30, 41, 42, 64
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 65
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 30
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=6910544&loc=d3e4237-128469

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 25
-Paragraph 27
-URI http://asc.fasb.org/extlink&oid=6946367&loc=d3e3629-128468

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 35
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910684&loc=d3e4570-128470

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(3),(c)(1)
-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e6927-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 30
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=6910544&loc=d3e4243-128469

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6411-128476

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 25
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6946367&loc=d3e3642-128468

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 40
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910732&loc=d3e4805-128471

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

+ Details

- Definition

This element represents the acquisition-date fair value of the total consideration transferred which consists of the sum of the acquisition-date fair values of the assets transferred by the acquirer, the liabilities incurred by the acquirer to former owners of the acquiree, and the equity interests issued by the acquirer.

+ References + Details

Business Combinations (Details 1) - BioVex Group Inc [Member] $ in Millions	Mar. 04, 2011 USD ($)
Allocation of the total consideration to the acquisition date fair values of assets acquired and liabilities assumed
Intangible assets--in-process research and development	$ 675
Goodwill	170
Deferred tax liabilities	(246)
Other assets (liabilities) acquired, net	(2)
Total consideration	$ 597

- Definition

+ References + Details

Business Combinations (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2011	Mar. 04, 2011
Business Combinations (Textual) [Abstract]
Goodwill, other increases (decreases)	$ (19)
BioVex Group Inc [Member]
Business Combinations (Textual) [Abstract]
Contingent consideration obligations		$ 575
Estimated aggregate fair value of the contingent consideration obligations		$ 190
Discount rate used to estimate fair value of acquired in process research and development		11.00%
Goodwill arising from business combinations		$ 170
Aggregate acquisition date consideration for business combinations		597
Other assets (liabilities) acquired, net		$ (2)
Laboratorio Quimco Farmaceutico Bergamo Ltda [Member]
Business Combinations (Textual) [Abstract]
Tax deductible portion of goodwill arising from a business combination	130
Other acquisitions [Member]
Business Combinations (Textual) [Abstract]
Goodwill arising from business combinations	265
Aggregate acquisition date consideration for business combinations	453
Property plant equipment acquired in business combinations	99
Amortizable intangible assets acquired in business combinations	58
Other assets (liabilities) acquired, net	$ 31

Stock-based compensation (Details) - USD ($) $ in Millions	12 Months Ended
Stock-based compensation (Details) - USD ($) $ in Millions	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Components of stock-based compensation expense
Total stock-based compensation expense, pre-tax	$ 341	$ 353	$ 284
Tax benefit from stock-based compensation expense	(124)	(120)	(97)
Total stock-based compensation expense, net of tax	217	233	187
Stock Options [Member]
Components of stock-based compensation expense
Total stock-based compensation expense, pre-tax	85	124	115
Restricted Stock Units [Member]
Components of stock-based compensation expense
Total stock-based compensation expense, pre-tax	188	182	134
Performance Units [Member]
Components of stock-based compensation expense
Total stock-based compensation expense, pre-tax	$ 68	$ 47	$ 35

Stock-based compensation (Details 1) - Stock Options [Member]	12 Months Ended
	Dec. 31, 2011 yr $ / shares	Dec. 31, 2010 yr $ / shares	Dec. 31, 2009 yr $ / shares
Weighted-average assumptions and resulting weighted-average grant date fair values
Closing price of our common stock on grant date	$ 54.66	$ 58.32	$ 50.65
Expected volatility	23.50%	28.00%	39.60%
Expected life (in years) \| yr	5.9	6.6	4.6
Risk-free interest rate	2.50%	3.20%	2.10%
Expected dividend yield	2.00%	0.00%	0.00%
Fair value of stock options granted	$ 11.39	$ 20.97	$ 18.35

Stock-based compensation (Details 2) - Stock Options [Member] $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2011 USD ($) yr $ / shares shares
Stock options information
Stock options unexercised, beginning balance \| shares	46.8
Stock options, granted \| shares	2.3
Stock options, exercised \| shares	(5.0)
Stock options, expired/forfeited \| shares	(9.9)
Stock options unexercised, ending balance \| shares	34.2
Stock options vested or expected to vest \| shares	33.8
Stock options exercisable \| shares	23.6
Weighted-average exercise price, unexercised beginning balance \| $ / shares	$ 58.66
Weighted-average exercise price, granted \| $ / shares	54.66
Weighted-average exercise price, exercised \| $ / shares	50.22
Weighted-average exercise price, expired/forfeited \| $ / shares	60.43
Weighted-average exercise price, unexercised ending balance \| $ / shares	59.11
Weighted-average exercise price, vested or expected to vest \| $ / shares	59.15
Weighted-average exercise price, exercisable \| $ / shares	$ 61.49
Weighted-average remaining contractual life (years), unexercised \| yr	3.8
Weighted-average remaining contractual life (years), vested or expected to vest \| yr	3.7
Weighted-average remaining contractual life (years), exercisable \| yr	2.3
Aggregate intrinsic value, unexercised \| $	$ 245
Aggregate intrinsic value, vested or expected to vest \| $	242
Aggregate intrinsic value, exercisable \| $	$ 135

Stock-based compensation (Details 3) - Restricted Stock Units [Member] - $ / shares shares in Millions	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Restricted stock units Information
Nonvested units, beginning balance	9.3
Units granted	4.0
Units, vested	(3.4)
Units, forfeited	(0.9)
Nonvested units, ending balance	9.0	9.3
Weighted average grant date fair value of units, beginning balance	$ 52.67
Weighted average grant date fair value, granted	51.83	$ 58.19	$ 51.24
Weighted average grant date fair value, vested	52.06
Weighted average grant date fair value, forfeited	52.77
Weighted average grant date fair value of nonvested units, end of period	$ 52.64	$ 52.67

Stock-based compensation (Details 4) - Performance Units [Member] - $ / shares	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Weighted-average assumptions and resulting weighted-average grant date fair values
Closing price of our common stock on grant date	$ 51.67	$ 56.90	$ 47.63
Expected volatility	32.80%	34.70%	34.30%
Risk-free interest rate	1.20%	1.30%	1.20%
Expected dividend yield	0.10%	0.00%	0.00%
Fair value of unit	$ 49.50	$ 62.06	$ 48.22

Stock-based compensation (Details Textual) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2011 USD ($) yr $ / shares shares	Dec. 31, 2010 USD ($) $ / shares shares	Dec. 31, 2009 USD ($) $ / shares shares
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total intrinsic value of stock options exercised during the year \| $	$ 47	$ 15	$ 57
Expected dividend yield	2.00%	0.00%	0.00%
Weighted-average risk-free interest rate	2.50%	3.20%	2.10%
Performance Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
The number of shares by which the pool of available shares will be reduced for other types of awards granted	1.9	1.9	1.9
Period over which the grants of equity instruments vest	3 years	3 years	3 years
Expected dividend yield	0.10%	0.00%	0.00%
Weighted-average risk-free interest rate	1.20%	1.30%	1.20%
Weighted average grant date fair value, granted \| $ / shares	$ 49.50	$ 62.06	$ 48.22
Total fair value of units that vested during the year \| $	$ 25	$ 34	$ 29
Total unrecognized compensation cost related to nonvested awards \| $	$ 90
Weighted average number of years over which compensation cost related to nonvested awards is expected to be recognized \| yr	1.1
Units outstanding	4,100,000	2,700,000
Weighted average grant date fair value of units, outstanding \| $ / shares	$ 51.92	$ 49.49
Units granted	2,500,000
Units, vested	400,000
Weighted average grant date fair value, vested \| $ / shares	$ 48.22
Units, forfeited	200,000
Weighted average grant date fair value, forfeited \| $ / shares	$ 52.70
Performance unit liability awards paid \| $			$ 30
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
The number of shares by which the pool of available shares will be reduced for other types of awards granted	1.9	1.9	1.9
Weighted average grant date fair value, granted \| $ / shares	$ 51.83	$ 58.19	$ 51.24
Total fair value of units that vested during the year \| $	$ 176	$ 184	$ 139
Units outstanding	9,000,000	9,300,000
Units granted	4,000,000
Units, vested	3,400,000
Weighted average grant date fair value, vested \| $ / shares	$ 52.06
Units, forfeited	900,000
Weighted average grant date fair value, forfeited \| $ / shares	$ 52.77
Stock Option and Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost related to nonvested awards \| $	$ 407
Weighted average number of years over which compensation cost related to nonvested awards is expected to be recognized \| yr	1.7
Granted on and after April 25, 2011 [Member] \| Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	1.90%
Weighted-average risk-free interest rate	1.00%
Granted on and after April 26, 2010 [Member] \| Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period of stock options from date of grant	P10Y	P10Y
Granted prior to April 26, 2010 [Member] \| Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period of stock options from date of grant		P7Y	P7Y
Granted prior to April 25, 2011 [Member] \| Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period over which the grants of equity instruments vest	4 years	4 years	4 years
Granted prior to April 25, 2011 [Member] \| Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period over which the grants of equity instruments vest	4 years	4 years	4 years

Stock-based compensation (Details Textual 1) - shares	12 Months Ended
Stock-based compensation (Details Textual 1) - shares	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	May 06, 2009
Stock Based Compensation (Textual) [Abstract]
Description of vesting of restricted stock units and stock options	Stock options and restricted stock units granted on and after April 25, 2011, generally vest in approximately equal amounts on the second, third and fourth anniversaries of the grant date.
Number of shares of common stock authorized to be issued under 2009 equity incentive plan				100,000,000
Number of common shares issued for each performance unit earned	1	1	1
Amount by which the pool of available shares will be reduced for each stock option granted	1	1	1
The amount of common stock available under the plan for future grants and/or issuances	58,000,000

Income taxes (Details) - USD ($) $ in Millions	12 Months Ended
Income taxes (Details) - USD ($) $ in Millions	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Current provision
Federal	$ 618	$ 636	$ 325
State	58	52	85
Foreign	148	153	155
Total current provision	824	841	565
Deferred (benefit) provision
Federal	(340)	(196)	92
State	(16)	43	(59)
Foreign	(1)	2	1
Total deferred (benefit) provision	(357)	(151)	34
Total provision	$ 467	$ 690	$ 599

Income taxes (Details 1) - USD ($) $ in Millions	Dec. 31, 2011	Dec. 31, 2010
Deferred income tax assets
Intercompany inventory related items	$ 387	$ 306
Expense accruals	751	626
Acquired net operating loss and credit carryforwards	192	147
Expenses capitalized for tax	167	188
Stock-based compensation	241	269
Deferred revenue	133	117
Other	72	72
Total deferred income tax assets	1,943	1,725
Valuation allowance	(126)	(80)
Net deferred income tax assets	1,817	1,645
Deferred income tax liabilities
Acquired intangibles	(832)	(739)
Fixed assets	(219)	(181)
Unremitted foreign earnings	(61)	(118)
Other	(110)	(142)
Total deferred income tax liabilities	(1,222)	(1,180)
Total deferred income taxes, net	$ 595	$ 465

Income taxes (Details 2) - USD ($) $ in Millions	12 Months Ended
Income taxes (Details 2) - USD ($) $ in Millions	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Reconciliation of total gross amounts of unrecognized tax benefits (excluding interest, penalties, foreign tax credits and the federal tax benefit of state taxes related to unrecognized tax benefits)
Balance at beginning of year	$ 920	$ 1,140	$ 1,113
Additions based on tax positions related to the current year	283	305	302
Reductions for tax positions of prior years	(7)	(110)	(215)
Settlements	(221)	(415)	(60)
Balance at end of year	$ 975	$ 920	$ 1,140

Income taxes (Details 3)	12 Months Ended
Income taxes (Details 3)	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Reconciliation between the federal statutory tax rate applied to income before income taxes and effective tax rate
Federal statutory tax rate	35.00%	35.00%	35.00%
Foreign earnings, including earnings invested indefinitely	(19.40%)	(19.10%)	(19.60%)
State taxes	0.70%	1.60%	1.10%
Credits, primarily research and experimentation	(1.50%)	(0.90%)	(0.80%)
Audit settlements	0.00%	(3.10%)	(4.20%)
Other, net	0.80%	(0.50%)	0.00%
Effective tax rate	11.30%	13.00%	11.50%
Legal Settlements [Member]
Reconciliation between the federal statutory tax rate applied to income before income taxes and effective tax rate
Legal settlements	2.20%	0.00%	0.00%
Puerto Rico Excise Tax [Member]
Reconciliation between the federal statutory tax rate applied to income before income taxes and effective tax rate
Credits, Puerto Rico Excise Tax	(6.50%)	0.00%	0.00%

Income taxes (Details Textual) - USD ($) $ in Millions	12 Months Ended
Income taxes (Details Textual) - USD ($) $ in Millions	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Income taxes (Textual) [Abstract]
Increase (decrease) in valuation allowance for deferred tax assets	$ 46	$ (12)
Interest and penalties related to unrecognized tax benefits recognized in income tax provision	23	41	$ 57
Accrued interest and penalties associated with unrecognized tax benefits	105	90
Total foreign income before income taxes	2,600	3,100	3,100
Income taxes paid	595	$ 1,344	$ 497
Decrease in unrecognized tax benefits that is reasonably possible within the succeeding twelve months due to potential tax settlements	270
State taxing jurisdictions' [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforwards available to reduce income taxes	176
Tax credit carryforwards for which a full valuation allowance has been provided	67
Domestic Country [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforwards available to reduce income taxes	44
Tax credit carryforwards for which a full valuation allowance has been provided	$ 44
Puerto Rico Excise Tax [Member]
Excise Tax Rate [Line Items]
Period of excise tax imposed	6 years
Effective excise tax rate for 2011	4.00%
Effective excise tax rate for 2012	3.75%
Effective excise tax rate for 2013	2.75%
Effective excise tax rate for 2014	2.50%
Effective excise tax rate for 2015	2.25%
Effective excise tax rate for 2016	1.00%
Investments in Foreign Subsidiaries and Foreign Corporate Joint Ventures that are Essentially Permanent in Duration [Member]
Deferred Tax Liability Not Recognized [Line Items]
Undistributed earnings of our foreign operations that are intended to be invested indefinitely outside of the United States	$ 19,500
Additional income taxes required to be accrued and paid if earnings of foreign operations that are intended to be indefinitely invested outside of the United States were repatriated	$ 6,900

Earnings per share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2010	Sep. 30, 2010	Jun. 30, 2010	Mar. 31, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Income (Numerator):
Net income for basic and diluted earnings per share	$ 934	$ 454	$ 1,170	$ 1,125	$ 1,022	$ 1,236	$ 1,202	$ 1,167	$ 3,683	$ 4,627	$ 4,605
Shares (Denominator):
Weighted-average shares for basic earnings per share									905	960	1,016
Effect of dilutive securities									7	5	5
Weighted-average shares for diluted earnings per share									912	965	1,021
Basic earnings per share	$ 1.09	$ 0.50	$ 1.26	$ 1.21	$ 1.09	$ 1.29	$ 1.25	$ 1.19	$ 4.07	$ 4.82	$ 4.53
Diluted earnings per share	$ 1.08	$ 0.50	$ 1.25	$ 1.20	$ 1.08	$ 1.28	$ 1.25	$ 1.18	$ 4.04	$ 4.79	$ 4.51

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 36, 37, 38
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 5
-Section 03
-Paragraph 20

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 7
-Paragraph 18

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 21
-Article 9

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.21)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1252-109256

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=6945512&loc=d3e4984-109258

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.23)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 5
-Section 03
-Paragraph 19

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

+ Details

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References + Details

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1448-109256

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Weighted-Average Number of Common Shares Outstanding
-URI http://asc.fasb.org/extlink&oid=6528421

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Earnings per share (Details Textual) - shares shares in Millions	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Earnings per share (Textual) [Abstract]
Antidilutive securities excluded from computation of diluted earnings per share, amount	33	43	42

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 13, 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Diluted Earnings Per Share
-URI http://asc.fasb.org/extlink&oid=6510752

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Contingent Stock Agreement
-URI http://asc.fasb.org/extlink&oid=6508534

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Antidilution
-URI http://asc.fasb.org/extlink&oid=6505113

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Collaborative arrangements (Details Textual) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2010	Sep. 30, 2010	Jun. 30, 2010	Mar. 31, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Research and Development Arrangement, Contract to Perform for Others [Line Items]
ENBREL sales	$ 3,907	$ 3,877	$ 3,893	$ 3,618	$ 3,760	$ 3,759	$ 3,613	$ 3,528	$ 15,295	$ 14,660	$ 14,351
Collaborative Arrangement with Pfizer Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum percentage of annual net ENBREL sales payable to Pfizer for three years after expiration of the collaboration agreement in the fourth quarter of 2013	12.00%								12.00%
Minimum percentage of annual net ENBREL sales payable to Pfizer for three years after expiration of the collaboration agreement in the fourth quarter of 2013	10.00%								10.00%
ENBREL sales									$ 3,700	3,500	3,500
Period required to pay percentage of net sales, after expiration of agreement in years									3 years
Collaborative Arrangement with Pfizer Inc [Member] \| Selling, General and Administrative [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Profit share expenses									$ 1,288	1,184	1,163
Cost recoveries									$ 84	$ 87	$ 75

Collaborative arrangements (Details Textual 1) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2010	Sep. 30, 2010	Jun. 30, 2010	Mar. 31, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Product sales	$ 3,907	$ 3,877	$ 3,893	$ 3,618	$ 3,760	$ 3,759	$ 3,613	$ 3,528	$ 15,295	$ 14,660	$ 14,351
Collaborative Arrangement with Glaxo Group Limited [Member] \| Primary Territories [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Product sales									62	5
Collaborative Arrangement with Glaxo Group Limited [Member] \| Selling, General and Administrative [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Cost recoveries									$ 30	46	29
Collaborative Arrangement with Glaxo Group Limited [Member] \| Other revenues [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone payments received										$ 75
Milestone payments received and deferred [Member] \| Collaborative Arrangement with Glaxo Group Limited [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone payments received											$ 45
Milestone payments received and deferred [Member] \| Collaborative Arrangement with Glaxo Group Limited [Member] \| Other revenues [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Amortization period of payments received and deferred under collaborative arrangements, in years											13 years

Collaborative arrangements (Details Textual 2) $ in Millions	12 Months Ended
	Dec. 31, 2011 USD ($) Molecule	Dec. 31, 2010 USD ($)	Dec. 31, 2009 USD ($)	Dec. 31, 2008 USD ($)
Takeda Pharmaceutical Company Limited [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments that may be received upon the achievement of various substantive success-based development and regulatory approval milestones	$ 472
Takeda Pharmaceutical Company Limited [Member] \| Other revenues [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone payments received		$ 55
Takeda Pharmaceutical Company Limited [Member] \| Research and development [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Cost recoveries	83	91	$ 112
Takeda Pharmaceutical Company Limited [Member] \| Vectibix [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalties received on sales	20	$ 7
Takeda Pharmaceutical Company Limited [Member] \| Japanese market products [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Potential additional future worldwide development costs recoverable from Takeda through 2012	$ 60
Number of molecules developed and commercialized as per collaborations \| Molecule	12
Collaborative arrangement for Motesanib with Takeda [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payment obligation of partner under a collaborative arrangement as a percentage of future worldwide development costs (excluding Japan)	60.00%
Milestone payments deferred or capitalized [Member] \| Takeda Pharmaceutical Company Limited [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone payments received				$ 300
Milestone payments deferred or capitalized [Member] \| Takeda Pharmaceutical Company Limited [Member] \| Other revenues [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Amortization period of payments received and deferred under collaborative arrangements, in years				20 years

Collaborative arrangements (Details Textual 3) - Collaborative Arrangement with Daiichi Sankyo Company Limited [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Intangible assets, net [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone payments made		$ 60
Research and development [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Cost recoveries	$ 4	$ 3	$ 64
Cost of sales excludes amortization of certain acquired intangible assets [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Amortization period of milestone payments capitalized, in years	11 years

Related party transactions (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Related Party Transaction [Line Items]
Dividends received from related party	$ 0	$ 0	$ 110
Kirin-Amgen [Member]
Related Party Transaction [Line Items]
Ownership interest (in percent) in related party	50.00%	50.00%	50.00%
Dividends received from related party			$ 110
Payments that may be received upon the achievement of various substantive success-based development and regulatory approval milestones	$ 125
Kirin-Amgen [Member] \| Accrued liabilities[ Member]
Related Party Transaction [Line Items]
Amount owned to related party	75	$ 62
Kirin-Amgen [Member] \| Noncurrent other assets [Member]
Related Party Transaction [Line Items]
Approximate carrying value of the company's equity method investment net of dividends received	400	400
Kirin-Amgen [Member] \| Selling, General and Administrative [Member]
Related Party Transaction [Line Items]
Company's share of profits of related party	47	71	72
Kirin-Amgen [Member] \| Other revenues [Member]
Related Party Transaction [Line Items]
Revenues earned by Amgen from related party	130	96	102
Kirin-Amgen [Member] \| Research and development [Member]
Related Party Transaction [Line Items]
Cost recoveries by Amgen from related party	85	88	96
Kirin-Amgen [Member] \| Cost of sales excludes amortization of certain acquired intangible assets [Member]
Related Party Transaction [Line Items]
Royalties earned by related party from Amgen	$ 298	$ 322	$ 327

Cost savings initiatives and restructuring (Details Textual) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Cost savings initiatives and restructuring (Textual) [Abstract]
Impairment of fixed assets	$ 118	$ 6	$ 118	$ 21
Manufacturing operations optimization [Member]
Cost savings initiatives and restructuring (Textual) [Abstract]
Carrying value of remaining assets	$ 133		133
Manufacturing operations optimization [Member] \| Other operating expenses [Member]
Cost savings initiatives and restructuring (Textual) [Abstract]
Impairment of fixed assets			$ 118
Manufacturing operations optimization [Member] \| Cost of sales excludes amortization of certain acquired intangible assets [Member]
Cost savings initiatives and restructuring (Textual) [Abstract]
Incremental depreciation in excess of what otherwise would have been recorded		42
Charges related to lease period beyond supply period		23
Other cost savings initiatives [Member] \| Other operating expenses [Member]
Cost savings initiatives and restructuring (Textual) [Abstract]
Charges primarily related to severance		$ 109
Restructuring [Member]
Cost savings initiatives and restructuring (Textual) [Abstract]
Restructuring plan charges				70
Restructuring [Member] \| Other operating expenses [Member]
Cost savings initiatives and restructuring (Textual) [Abstract]
Charges primarily related to severance				25
Restructuring [Member] \| Selling, General and Administrative [Member]
Cost savings initiatives and restructuring (Textual) [Abstract]
Other restructuring costs				$ 32

Available-for-sale investments (Details) - USD ($) $ in Millions	Dec. 31, 2011	Dec. 31, 2010
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	$ 19,814	$ 17,107
Gross unrealized gains	224	256
Gross unrealized losses	(35)	(38)
Estimated fair value	20,003	17,325
US Treasury securities [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	3,878	5,044
Gross unrealized gains	68	50
Gross unrealized losses	0	(14)
Estimated fair value	3,946	5,080
Other government-related debt securities - Obligations of U.S. government agencies and FDIC-guaranteed bank debt [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	1,548	2,158
Gross unrealized gains	23	51
Gross unrealized losses	0	(1)
Estimated fair value	1,571	2,208
Other government-related debt securities - Foreign and other [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	441	837
Gross unrealized gains	9	16
Gross unrealized losses	0	(1)
Estimated fair value	450	852
Corporate debt securities - Financial [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	2,493	2,252
Gross unrealized gains	30	53
Gross unrealized losses	(15)	(9)
Estimated fair value	2,508	2,296
Corporate debt securities - Industrial [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	3,077	2,441
Gross unrealized gains	79	71
Gross unrealized losses	(10)	(5)
Estimated fair value	3,146	2,507
Corporate debt securities - Other [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	280	307
Gross unrealized gains	9	10
Gross unrealized losses	0	(1)
Estimated fair value	289	316
Mortgage- and asset-backed securities [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	1,789	841
Gross unrealized gains	6	5
Gross unrealized losses	(10)	(5)
Estimated fair value	1,785	841
Money market mutual funds [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	6,266	3,030
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Estimated fair value	6,266	3,030
Other short-term interest-bearing securities [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost		147
Gross unrealized gains		0
Gross unrealized losses		0
Estimated fair value		147
Total debt security investments [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	19,772	17,057
Gross unrealized gains	224	256
Gross unrealized losses	(35)	(36)
Estimated fair value	19,961	17,277
Equity securities [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	42	50
Gross unrealized gains	0	0
Gross unrealized losses	0	(2)
Estimated fair value	$ 42	$ 48

Available-for-sale investments (Details 1) - USD ($) $ in Millions	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets
Cash and cash equivalents	$ 6,946	$ 3,287	$ 2,884	$ 1,774
Other assets - noncurrent	1,524	1,271
Marketable securities	13,695	14,135
Total available-for-sale investments	20,003	17,325
Available-for-sale investments [Member]
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets
Cash and cash equivalents	6,266	3,142
Other assets - noncurrent	$ 42	$ 48

- Definition

Investments in debt and equity securities which are categorized neither as trading securities nor held-to-maturity securities and which are intended be sold or mature within one year from the balance sheet date or the normal operating cycle, whichever is longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 12
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 16
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 3
-Section A
-Paragraph 4, 5
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 13, 17
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 25
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6379932&loc=d3e22054-111558

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26626-111562

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 15C
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents Available-for-sale Securities which consist of all investments in certain debt and equity securities neither classified as trading or held-to-maturity securities. A debt security represents a creditor relationship with an enterprise. Debt securities include, among other items, US Treasury securities, US government securities, municipal securities, corporate bonds, convertible debt, commercial paper, and all securitized debt instruments. An equity security represents an ownership interest in an enterprise or the right to acquire or dispose of an ownership interest in an enterprise at fixed or determinable prices. Equity securities include, among other things, common stock, certain preferred stock, warrant rights, call options, and put options, but do not include convertible debt. An entity may opt to provide the reader with additional narrative text to better understand the nature of investments in debt and equity securities which are categorized as Available-for-sale.

+ References + Details

- Definition

Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 8, 9
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 1
-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7
-Footnote 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7, 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

+ Details

Available-for-sale investments (Details 2) - USD ($) $ in Millions	Dec. 31, 2011	Dec. 31, 2010
Fair values of available-for-sale debt security investments by contractual maturity
Maturing in one year or less	$ 6,811	$ 4,118
Maturing after one year through three years	6,346	6,736
Maturing after three years through five years	5,710	5,812
Maturing after five years	1,094	611
Estimated fair value	20,003	17,325
Total debt security investments [Member]
Fair values of available-for-sale debt security investments by contractual maturity
Estimated fair value	$ 19,961	$ 17,277

- Definition

+ References + Details

Available-for-sale investments (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Available-for-sale investments (Textual) [Abstract]
Cash	$ 680	$ 145
Total realized gains	191	115	$ 104
Total realized losses	$ 37	$ 25	$ 62

Inventories (Details) - USD ($) $ in Millions	Dec. 31, 2011	Dec. 31, 2010
Inventories
Raw materials	$ 158	$ 128
Work in process	1,802	1,382
Finished goods	524	512
Total inventories	$ 2,484	$ 2,022

Property, plant and equipment (Details) $ in Millions	12 Months Ended
Property, plant and equipment (Details) $ in Millions	Dec. 31, 2011 USD ($) yr	Dec. 31, 2010 USD ($)
Property, plant and equipment [Abstract]
Land	$ 366	$ 361
Buildings and improvements	3,463	3,392
Manufacturing equipment	1,897	1,802
Laboratory equipment	1,016	955
Other	3,745	3,547
Construction in progress	744	631
Property, plant and equipment, gross	11,231	10,688
Less accumulated depreciation and amortization	(5,811)	(5,166)
Property, plant and equipment, net	$ 5,420	$ 5,522
Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life (in years), Minimum \| yr	10
Property, Plant and Equipment, Useful Life (in years), Maximum \| yr	40
Manufacturing equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life (in years), Minimum \| yr	8
Property, Plant and Equipment, Useful Life (in years), Maximum \| yr	12
Laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life (in years), Minimum \| yr	8
Property, Plant and Equipment, Useful Life (in years), Maximum \| yr	12
Other [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life (in years), Minimum \| yr	3
Property, Plant and Equipment, Useful Life (in years), Maximum \| yr	15

Property, plant and equipment (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Property, plant and equipment [Abstract]
Depreciation and amortization charges associated with property, plant and equipment	$ 679	$ 594	$ 624

Intangible assets (Details) - USD ($) $ in Millions	Dec. 31, 2011	Dec. 31, 2010
Finite-Lived intangible assets
Gross carrying amount	$ 5,446	$ 5,387
Accumulated amortization	(3,537)	(3,157)
Intangible assets, net	1,909	2,230
Total identifiable intangible assets:
Identifiable intangible assets	6,121	5,387
Accumulated amortization	(3,537)	(3,157)
Identifiable intangible assets, net	2,584	2,230
In-process Research and Development [Member]
Total identifiable intangible assets:
Indefinite-lived intangible assets	675	0
Acquired product technology rights - Developed product technology [Member]
Finite-Lived intangible assets
Gross carrying amount	2,872	2,872
Accumulated amortization	(1,811)	(1,619)
Intangible assets, net	1,061	1,253
Acquired product technology rights - Core technology [Member]
Finite-Lived intangible assets
Gross carrying amount	1,348	1,348
Accumulated amortization	(850)	(760)
Intangible assets, net	498	588
Acquired product technology rights - Trade name [Member]
Finite-Lived intangible assets
Gross carrying amount	190	190
Accumulated amortization	(120)	(107)
Intangible assets, net	70	83
Acquired Research and Development technology rights [Member]
Finite-Lived intangible assets
Gross carrying amount	350	350
Accumulated amortization	(350)	(329)
Intangible assets, net	0	21
Other acquired intangible assets [Member]
Finite-Lived intangible assets
Gross carrying amount	686	627
Accumulated amortization	(406)	(342)
Intangible assets, net	$ 280	$ 285

Intangible assets (Details Textual) $ in Millions	12 Months Ended
Intangible assets (Details Textual) $ in Millions	Dec. 31, 2011 USD ($) yr	Dec. 31, 2010 USD ($)	Dec. 31, 2009 USD ($)
Intangible assets [Abstract]
Estimated useful lives of finite-lived intangible assets, minimum (in years) \| yr	5
Estimated useful lives of finite-lived intangible assets, maximum (in years) \| yr	15
Amortization charges associated with finite-lived intangible assets	$ 380	$ 423	$ 425
Total estimated amortization of finite- lived intangible assets for 2012	354
Total estimated amortization of finite- lived intangible assets for 2013	359
Total estimated amortization of finite- lived intangible assets for 2014	340
Total estimated amortization of finite-lived intangible assets for 2015	327
Total estimated amortization of finite-lived intangible assets for 2016	$ 317

Accrued liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2011	Dec. 31, 2010
Accrued liabilities
Sales deductions	$ 1,326	$ 1,144
Employee compensation and benefits	916	764
Sales returns reserve	339	339
Legal reserve	780	0
Other	1,667	1,119
Total accrued liabilities	$ 5,028	$ 3,366

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

Financing arrangements (Details) - USD ($) $ in Millions	Dec. 31, 2011	Dec. 31, 2010
Carrying values of long-term borrowings
Other notes, including our zero- coupon convertible notes	$ 184	$ 183
Total debt	21,428	13,362
Less current portion	(84)	(2,488)
Total noncurrent debt	21,344	10,874
0.125% convertible notes due 2011 (0.125% 2011 Convertible Notes) [Member]
Carrying values of long-term borrowings
Convertible notes	0	2,488
0.375% convertible notes due 2013 (0.375% 2013 Convertible Notes) [Member]
Carrying values of long-term borrowings
Convertible notes	2,346	2,213
1.875% notes due 2014 (1.875% 2014 Notes) [Member]
Carrying values of long-term borrowings
Total noncurrent debt	1,000	0
2.50% notes due 2016 (2.50% 2016 Notes) [Member]
Carrying values of long-term borrowings
Total noncurrent debt	999	0
4.85% notes due 2014 (4.85% 2014 Notes) [Member]
Carrying values of long-term borrowings
Total noncurrent debt	1,000	1,000
2.30% notes due 2016 (2.30% 2016 Notes) [Member]
Carrying values of long-term borrowings
Total noncurrent debt	748	0
5.85% notes due 2017 (5.85% 2017 Notes) [Member]
Carrying values of long-term borrowings
Total noncurrent debt	1,099	1,099
6.15% notes due 2018 (6.15% 2018 Notes) [Member]
Carrying values of long-term borrowings
Total noncurrent debt	499	499
4.375% euro denominated notes due 2018 (4.375% 2018 euro Notes) [Member]
Carrying values of long-term borrowings
Total noncurrent debt	714	0
5.70% notes due 2019 (5.70% 2019 Notes) [Member]
Carrying values of long-term borrowings
Total noncurrent debt	998	998
4.50% notes due 2020 (4.50% 2020 Notes) [Member]
Carrying values of long-term borrowings
Total noncurrent debt	300	300
3.45% notes due 2020 (3.45% 2020 Notes) [Member]
Carrying values of long-term borrowings
Total noncurrent debt	897	897
4.10% notes due 2021 (4.10% 2021 Notes) [Member]
Carrying values of long-term borrowings
Total noncurrent debt	998	0
3.875% notes due 2021 (3.875% 2021 Notes) [Member]
Carrying values of long-term borrowings
Total noncurrent debt	1,745	0
5.50% pound sterling denominated notes due 2026 (5.50% 2026 pound sterling Notes) [Member]
Carrying values of long-term borrowings
Total noncurrent debt	739	0
6.375% notes due 2037 (6.375% 2037 Notes) [Member]
Carrying values of long-term borrowings
Total noncurrent debt	899	899
6.90% notes due 2038 (6.90% 2038 Notes) [Member]
Carrying values of long-term borrowings
Total noncurrent debt	499	499
6.40% notes due 2039 (6.40% 2039 Notes) [Member]
Carrying values of long-term borrowings
Total noncurrent debt	996	996
5.75% notes due 2040 (5.75% 2040 Notes) [Member]
Carrying values of long-term borrowings
Total noncurrent debt	697	696
4.95% notes due 2041 (4.95% 2041 Notes)
Carrying values of long-term borrowings
Total noncurrent debt	595	595
5.15% notes due 2041 (5.15% 2041 Notes) [Member]
Carrying values of long-term borrowings
Total noncurrent debt	2,232	0
5.65% notes due 2042 (5.65% 2042 Notes) [Member]
Carrying values of long-term borrowings
Total noncurrent debt	$ 1,244	$ 0

Financing arrangements (Details 1) - USD ($) $ in Millions	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Schedule of 2013 convertible notes
Principal balance	$ 10,500	$ 2,500	$ 2,000
0.375% convertible notes due 2013 (0.375% 2013 Convertible Notes) [Member]
Schedule of 2013 convertible notes
Principal balance	2,500
Net carrying amount	2,346	2,213
0.375% convertible notes due 2013 (0.375% 2013 Convertible Notes) [Member] \| Liability component [Member]
Schedule of 2013 convertible notes
Principal balance	2,500	2,500
Unamortized discount	154	287
Net carrying amount	2,346	2,213
0.375% convertible notes due 2013 (0.375% 2013 Convertible Notes) [Member] \| Equity component [Member]
Schedule of 2013 convertible notes
Net carrying amount	$ 829	$ 829

Financing arrangements (Details 2) - USD ($) $ in Millions	12 Months Ended
Financing arrangements (Details 2) - USD ($) $ in Millions	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
The effective interest rates on notes after giving effect to the related interest rate swap agreements and the notional amounts of interest rate swap agreements
Notional amount	$ 3,600	$ 3,600	$ 1,500
Interest Rate Swap [Member]
The effective interest rates on notes after giving effect to the related interest rate swap agreements and the notional amounts of interest rate swap agreements
Notional amount	$ 3,600	3,600
Interest Rate Swap [Member] \| 5.85% notes due 2017 (5.85% 2017 Notes) [Member]
The effective interest rates on notes after giving effect to the related interest rate swap agreements and the notional amounts of interest rate swap agreements
Effective interest rate	LIBOR + 2.5%
Notional amount	$ 1,100	1,100
Interest Rate Swap [Member] \| 4.85% notes due 2014 (4.85% 2014 Notes) [Member]
The effective interest rates on notes after giving effect to the related interest rate swap agreements and the notional amounts of interest rate swap agreements
Effective interest rate	LIBOR + 0.3%
Notional amount	$ 1,000	1,000
Interest Rate Swap [Member] \| 5.70% notes due 2019 (5.70% 2019 Notes) [Member]
The effective interest rates on notes after giving effect to the related interest rate swap agreements and the notional amounts of interest rate swap agreements
Effective interest rate	LIBOR + 2.6%
Notional amount	$ 1,000	1,000
Interest Rate Swap [Member] \| 6.15% notes due 2018 (6.15% 2018 Notes) [Member]
The effective interest rates on notes after giving effect to the related interest rate swap agreements and the notional amounts of interest rate swap agreements
Effective interest rate	LIBOR + 1.8%
Notional amount	$ 500	$ 500

Financing arrangements (Details 3) $ in Millions	Dec. 31, 2011 USD ($)
Aggregate contractual maturities of long-term debt obligations
2012	$ 84
2013	2,500
2014	2,000
2015	0
2016	1,750
Thereafter	15,312
Total	$ 21,646

Financing arrangements (Details Textual) $ / shares in Units, € in Millions, £ in Millions, shares in Millions	12 Months Ended
	Dec. 31, 2011 USD ($) shares	Dec. 31, 2010 USD ($)	Dec. 31, 2009 USD ($)	Dec. 31, 2011 GBP (£)	Dec. 31, 2011 EUR (€)	Dec. 31, 2011 USD ($) $ / shares	Dec. 31, 2006 USD ($)
Financing arrangements (Textual) [Abstract]
Repayment of debt	$ 2,500,000,000	$ 0	$ 1,000,000,000
Aggregate principal amount of notes issued		2,500,000,000	2,000,000,000			$ 10,500,000,000
Total noncurrent debt		10,874,000,000				21,344,000,000
Interest expense, net	610,000,000	$ 604,000,000	578,000,000
0.125% convertible notes due 2011 (0.125% 2011 Convertible Notes) [Member]
Financing arrangements (Textual) [Abstract]
Stated contractual interest rate on note		0.125%
Repayment of debt	$ 2,500,000,000
Original debt discount						$ 643,000,000
Convertible notes conversion ratio into common stock	12.5247
Principal amount of notes to which the common stock conversion ratio is applied	$ 1,000
Conversion price per share of convertible notes \| $ / shares						$ 79.84
Effective interest rate on convertible notes	6.24%
Non-cash interest expense	$ 12,000,000	$ 146,000,000	136,000,000
Other convertible notes, current		2,488,000,000				$ 0
Interest expense, net	$ 13,000,000	$ 149,000,000	140,000,000
0.375% convertible notes due 2013 (0.375% 2013 Convertible Notes) [Member]
Financing arrangements (Textual) [Abstract]
Stated contractual interest rate on note		0.375%		0.375%	0.375%	0.375%
Aggregate principal amount of notes issued						$ 2,500,000,000
Convertible notes conversion ratio into common stock	12.7473
Principal amount of notes to which the common stock conversion ratio is applied	$ 1,000
Conversion price per share of convertible notes \| $ / shares						$ 78.45
Ratio of closing price of common stock to respective conversion price per share that needs to be exceeded in previous quarter to allow conversion	130.00%
Effective interest rate on convertible notes	6.35%
Non-cash interest expense	$ 133,000,000	$ 125,000,000	118,000,000
Convertible notes		2,213,000,000				$ 2,346,000,000
Interest expense, net	$ 143,000,000	$ 134,000,000	$ 127,000,000
Conversion of convertible notes before maturity period	within one month
5.85% notes due 2017 (5.85% 2017 Notes) [Member]
Financing arrangements (Textual) [Abstract]
Stated contractual interest rate on note		5.85%		5.85%	5.85%	5.85%
Redemption price as a percentage of the principal amount of notes that may be required to be paid in the event of a change in control triggering event	101.00%
Total noncurrent debt		$ 1,099,000,000				$ 1,099,000,000
6.15% notes due 2018 (6.15% 2018 Notes) [Member]
Financing arrangements (Textual) [Abstract]
Stated contractual interest rate on note		6.15%		6.15%	6.15%	6.15%
Redemption price as a percentage of the principal amount of notes that may be required to be paid in the event of a change in control triggering event	101.00%
Total noncurrent debt		$ 499,000,000				$ 499,000,000
5.70% notes due 2019 (5.70% 2019 Notes) [Member]
Financing arrangements (Textual) [Abstract]
Stated contractual interest rate on note		5.70%		5.70%	5.70%	5.70%
Redemption price as a percentage of the principal amount of notes that may be required to be paid in the event of a change in control triggering event	101.00%
Total noncurrent debt		$ 998,000,000				$ 998,000,000
3.45% notes due 2020 (3.45% 2020 Notes) [Member]
Financing arrangements (Textual) [Abstract]
Stated contractual interest rate on note		3.45%		3.45%	3.45%	3.45%
Redemption price as a percentage of the principal amount of notes that may be required to be paid in the event of a change in control triggering event	101.00%
Total noncurrent debt		$ 897,000,000				$ 897,000,000
6.375% notes due 2037 (6.375% 2037 Notes) [Member]
Financing arrangements (Textual) [Abstract]
Stated contractual interest rate on note		6.375%		6.375%	6.375%	6.375%
Redemption price as a percentage of the principal amount of notes that may be required to be paid in the event of a change in control triggering event	101.00%
Total noncurrent debt		$ 899,000,000				$ 899,000,000
6.90% notes due 2038 (6.90% 2038 Notes) [Member]
Financing arrangements (Textual) [Abstract]
Stated contractual interest rate on note		6.90%		6.90%	6.90%	6.90%
Redemption price as a percentage of the principal amount of notes that may be required to be paid in the event of a change in control triggering event	101.00%
Total noncurrent debt		$ 499,000,000				$ 499,000,000
6.40% notes due 2039 (6.40% 2039 Notes) [Member]
Financing arrangements (Textual) [Abstract]
Stated contractual interest rate on note		6.40%		6.40%	6.40%	6.40%
Redemption price as a percentage of the principal amount of notes that may be required to be paid in the event of a change in control triggering event	101.00%
Total noncurrent debt		$ 996,000,000				$ 996,000,000
5.75% notes due 2040 (5.75% 2040 Notes) [Member]
Financing arrangements (Textual) [Abstract]
Stated contractual interest rate on note		5.75%		5.75%	5.75%	5.75%
Redemption price as a percentage of the principal amount of notes that may be required to be paid in the event of a change in control triggering event	101.00%
Total noncurrent debt		$ 696,000,000				$ 697,000,000
4.95% notes due 2041 (4.95% 2041 Notes)
Financing arrangements (Textual) [Abstract]
Stated contractual interest rate on note		4.95%		4.95%	4.95%	4.95%
Redemption price as a percentage of the principal amount of notes that may be required to be paid in the event of a change in control triggering event	101.00%
Total noncurrent debt		$ 595,000,000				$ 595,000,000
4.50% notes due 2020 (4.50% 2020 Notes) [Member]
Financing arrangements (Textual) [Abstract]
Stated contractual interest rate on note		4.50%		4.50%	4.50%	4.50%
Redemption price as a percentage of the principal amount of notes that may be required to be paid in the event of a change in control triggering event	101.00%
Total noncurrent debt		$ 300,000,000				$ 300,000,000
4.85% notes due 2014 (4.85% 2014 Notes) [Member]
Financing arrangements (Textual) [Abstract]
Stated contractual interest rate on note		4.85%		4.85%	4.85%	4.85%
Total noncurrent debt		$ 1,000,000,000				$ 1,000,000,000
4.375% euro denominated notes due 2018 (4.375% 2018 euro Notes) [Member]
Financing arrangements (Textual) [Abstract]
Stated contractual interest rate on note				4.375%	4.375%	4.375%
Aggregate principal amount of notes issued \| €					€ 550
Redemption price as a percentage of the principal amount of notes that may be required to be paid in the event of a change in control triggering event	101.00%
Total noncurrent debt		0				$ 714,000,000
5.50% pound sterling denominated notes due 2026 (5.50% 2026 pound sterling Notes) [Member]
Financing arrangements (Textual) [Abstract]
Stated contractual interest rate on note				5.50%	5.50%	5.50%
Aggregate principal amount of notes issued \| £				£ 475
Redemption price as a percentage of the principal amount of notes that may be required to be paid in the event of a change in control triggering event	101.00%
Total noncurrent debt		0				$ 739,000,000
Zero coupon convertible notes due in 2032 [Member]
Financing arrangements (Textual) [Abstract]
Convertible notes		83,000,000
Other convertible notes, current						84,000,000
8.125% notes due 2097 (Other) [Member]
Financing arrangements (Textual) [Abstract]
Total noncurrent debt		100,000,000				$ 100,000,000
Warrants Issued Concurrent with Issuance of 2011 and 2013 Convertible Debt [Member]
Financing arrangements (Textual) [Abstract]
Potential settlements of warrants (In May 2011) \| shares	31.3
Potential settlements of warrants (In May 2013) \| shares	31.5
Exercise price of warrants \| $ / shares						107.90
2009 Notes [Member]
Financing arrangements (Textual) [Abstract]
Stated contractual interest rate on note			4.00%
Repayment of debt			$ 1,000,000,000
1.875% notes due 2014 (1.875% 2014 Notes) [Member]
Financing arrangements (Textual) [Abstract]
Stated contractual interest rate on note				1.875%	1.875%	1.875%
Redemption price as a percentage of the principal amount of notes that may be required to be paid in the event of a change in control triggering event	101.00%
Total noncurrent debt		0				$ 1,000,000,000
2.30% notes due 2016 (2.30% 2016 Notes) [Member]
Financing arrangements (Textual) [Abstract]
Stated contractual interest rate on note				2.30%	2.30%	2.30%
Redemption price as a percentage of the principal amount of notes that may be required to be paid in the event of a change in control triggering event	101.00%
Total noncurrent debt		0				$ 748,000,000
2.50% notes due 2016 (2.50% 2016 Notes) [Member]
Financing arrangements (Textual) [Abstract]
Stated contractual interest rate on note				2.50%	2.50%	2.50%
Redemption price as a percentage of the principal amount of notes that may be required to be paid in the event of a change in control triggering event	101.00%
Total noncurrent debt		0				$ 999,000,000
4.10% notes due 2021 (4.10% 2021 Notes) [Member]
Financing arrangements (Textual) [Abstract]
Stated contractual interest rate on note				4.10%	4.10%	4.10%
Redemption price as a percentage of the principal amount of notes that may be required to be paid in the event of a change in control triggering event	101.00%
Total noncurrent debt		0				$ 998,000,000
3.875% notes due 2021 (3.875% 2021 Notes) [Member]
Financing arrangements (Textual) [Abstract]
Stated contractual interest rate on note				3.875%	3.875%	3.875%
Redemption price as a percentage of the principal amount of notes that may be required to be paid in the event of a change in control triggering event	101.00%
Total noncurrent debt		0				$ 1,745,000,000
5.15% notes due 2041 (5.15% 2041 Notes) [Member]
Financing arrangements (Textual) [Abstract]
Stated contractual interest rate on note				5.15%	5.15%	5.15%
Redemption price as a percentage of the principal amount of notes that may be required to be paid in the event of a change in control triggering event	101.00%
Total noncurrent debt		0				$ 2,232,000,000
5.65% notes due 2042 (5.65% 2042 Notes) [Member]
Financing arrangements (Textual) [Abstract]
Stated contractual interest rate on note				5.65%	5.65%	5.65%
Redemption price as a percentage of the principal amount of notes that may be required to be paid in the event of a change in control triggering event	101.00%
Total noncurrent debt		$ 0				$ 1,244,000,000
Convertible notes [Member]
Financing arrangements (Textual) [Abstract]
Aggregate principal amount of notes issued							$ 5,000,000,000

Financing arrangements (Details Textual 1) £ in Millions, shares in Millions	12 Months Ended
	Dec. 31, 2011 USD ($) shares	Dec. 31, 2010 USD ($)	Dec. 31, 2009 USD ($)	Dec. 31, 2011 GBP (£)	Dec. 31, 2011 USD ($)
Financing arrangements additional (Textual) [Abstract]
Interest paid, net of interest rate swaps	$ 446,000,000	$ 323,000,000	$ 293,000,000
Interest costs capitalized	$ 22,000,000	33,000,000	32,000,000
Warrants to acquire shares of our common stock , expired \| shares	31.3
Total debt issuance costs	$ 55,000,000	17,000,000	$ 13,000,000
Cross Currency Swap [Member]
Financing arrangements additional (Textual) [Abstract]
Notional amount				£ 475	$ 748,000,000
Effective rate at which interest payments are received in Pounds Sterling under the cross currency swap contract	5.50%
Effective rate at which interest payments are made in US dollars under the cross currency swap contract	5.80%
Commercial Paper [Member]
Financing arrangements additional (Textual) [Abstract]
Amount outstanding under commercial paper program		0			0
Maximum borrowing capacity under commercial paper program					$ 2,500,000,000
Line of Credit [Member]
Financing arrangements additional (Textual) [Abstract]
Amount by which the borrowing capacity under a syndicated, unsecured, revolving credit agreement maybe increased upon our request at the discretion of the banks	$ 500,000,000
Interest rate charged over LIBOR on any amounts borrowed under the facility				0.90%	0.90%
Annual commitment fees for syndicated, unsecured, revolving credit agreement	0.10%
Previous revolving credit facilities, terminated in period	$ 2,300,000,000
Amount outstanding under syndicated, unsecured, revolving credit facility					$ 0
Maximum current borrowing capacity under a syndicated, unsecured, revolving credit agreement					2,500,000,000
Medium-term Notes [Member] \| Self Registration Statement [Member]
Financing arrangements additional (Textual) [Abstract]
Amount that may be issued under a medium term note program established under the shelf registration statement					400,000,000
Amount outstanding under medium term note program		$ 0			$ 0

Stockholders' equity (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended												12 Months Ended
	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2010	Sep. 30, 2010	Jun. 30, 2010	Mar. 31, 2010	Dec. 31, 2009	Sep. 30, 2009	Jun. 30, 2009	Mar. 31, 2009	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Stock repurchase program
Stock repurchases, in shares	86.0	45.4	12.9	0.0	20.5	6.6	10.3	29.1	21.7	0.0	0.0	37.5	144.3	66.5	59.2
Stock repurchases, in dollars													$ 8,307	$ 3,800
Stock repurchase program
Stock repurchase program
Stock repurchases, in dollars	$ 5,154	$ 2,421	$ 732	$ 0	$ 1,136	$ 364	$ 616	$ 1,684	$ 1,211	$ 0	$ 0	$ 1,997	$ 8,307	$ 3,800	$ 3,208

Stockholders' equity (Details 1) - USD ($) $ in Millions	12 Months Ended
Stockholders' equity (Details 1) - USD ($) $ in Millions	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Accumulated other comprehensive income
Beginning balance, Foreign currency translation	$ 22	$ 40	$ 25
Beginning balance, Cash flow hedges	3	(82)	50
Beginning balance, Available-for-sale securities	135	95	49
Beginning balance, Other	(7)	(8)	(7)
Beginning balance, Accumulated other comprehensive income	153	45	117
Other comprehensive income (loss):
Foreign currency translation adjustments	(6)	(29)	25
Unrealized gains (losses), Cash flow hedges	(51)	186	(213)
Unrealized gains (losses), Available-for-sale securities	125	155	116
Unrealized gains (losses), Other	2	1	(12)
Unrealized gains (losses), Accumulated other comprehensive income	76	342	(109)
Reclassification adjustments to income, Cash flow hedges	112	(46)	8
Reclassification adjustments to income, Available-for-sale securities	(154)	(90)	(42)
Reclassification adjustments to income, Accumulated other comprehensive income	(42)	(136)	(34)
Other	(8)		5
Other, Accumulated other comprehensive income	(8)		5
Income taxes, Foreign currency translation	5	11	(10)
Income taxes, Cash flow hedges	(21)	(55)	73
Income taxes, Available-for-sale securities	14	(25)	(28)
Income taxes, Other	0	0	6
Income taxes, Accumulated other comprehensive income (loss)	(2)	(69)	41
Ending balance, Foreign currency translation	21	22	40
Ending balance, Cash flow hedges	43	3	(82)
Ending balance, Available-for-sale securities	120	135	95
Ending balance, Other	(13)	(7)	(8)
Ending balance, Accumulated other comprehensive income	171	153	45
Foreign Currency Translation [Member]
Other comprehensive income (loss):
Foreign currency translation adjustments	$ (6)	$ (29)	$ 25

Stockholders' equity (Details Textual) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	1 Months Ended							3 Months Ended												12 Months Ended
	Mar. 07, 2012	Dec. 31, 2011	Dec. 15, 2011	Oct. 31, 2011	Sep. 30, 2011	Jul. 31, 2011	Apr. 30, 2011	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2010	Sep. 30, 2010	Jun. 30, 2010	Mar. 31, 2010	Dec. 31, 2009	Sep. 30, 2009	Jun. 30, 2009	Mar. 31, 2009	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Stock repurchases, in shares								86.0	45.4	12.9	0.0	20.5	6.6	10.3	29.1	21.7	0.0	0.0	37.5	144.3	66.5	59.2
Stock repurchases, in dollars																				$ 8,307	$ 3,800
Stockholders' equity (Textual) [Abstract]
Additional amount authorized by the Board of Directors under a stock repurchase plan				$ 6,100			$ 5,000
Amount available for stock repurchases under a board approved stock repurchase plan		$ 5,000		$ 10,000
Common stock, dividends declared per share			$ 0.36	$ 0.28		$ 0.28
Dividends paid per share	$ 0.36	$ 0.28			$ 0.28
Income taxes expense or (benefit) for unrealized gains and losses for cash flow hedges																				(20)	71	$ (76)
Income tax expense or (benefit) reclassification adjustments to income for cash flow hedges																				41	(16)	3
Income taxes expense or (benefit) for unrealized gains and losses for available-for-sale securities																				45	60	44
Income tax expense or (benefit) for reclassification adjustments to income for available-for-sale securities																				$ (59)	$ (35)	$ (16)
Preferred stock shares authorized		5.0						5.0				5.0								5.0	5.0
Preferred stock, par value		$ 0.0001						$ 0.0001				$ 0.0001								$ 0.0001	$ 0.0001
Preferred stock shares issued		0.0						0.0				0.0								0.0	0.0
Preferred stock shares outstanding		0.0						0.0				0.0								0.0	0.0
Modified Dutch auction tender offer [Member]
Stock repurchases, in shares																				83.3
Stock repurchased price per share																				$ 60.08
Stock repurchases, in dollars																				$ 5,000

Fair value measurement (Details) - USD ($) $ in Millions	Dec. 31, 2011	Dec. 31, 2010
Assets:
Total available-for-sale investments	$ 20,003	$ 17,325
Fair Value, Measurements, Recurring [Member]
Derivative Assets:
Interest rate swap contracts	377	195
Total assets	20,552	17,674
Derivative Liabilities:
Contingent consideration obligations in connection with a business combination	190
Total liabilities	264	103
Fair Value, Measurements, Recurring [Member] \| Foreign currency contracts [Member]
Derivative Assets:
Foreign currency contracts	172	154
Derivative Liabilities:
Foreign currency contracts	48	103
Fair Value, Measurements, Recurring [Member] \| Cross currency swap contracts [Member]
Derivative Liabilities:
Foreign currency contracts	26
Fair Value, Measurements, Recurring [Member] \| US Treasury securities [Member]
Assets:
Total available-for-sale investments	3,946	5,080
Fair Value, Measurements, Recurring [Member] \| Other government-related debt securities - Obligations of U.S. government agencies and FDIC-guaranteed bank debt [Member]
Assets:
Total available-for-sale investments	1,571	2,208
Fair Value, Measurements, Recurring [Member] \| Other government-related debt securities - Foreign and other [Member]
Assets:
Total available-for-sale investments	450	852
Fair Value, Measurements, Recurring [Member] \| Corporate debt securities - Financial [Member]
Assets:
Total available-for-sale investments	2,508	2,296
Fair Value, Measurements, Recurring [Member] \| Corporate debt securities - Industrial [Member]
Assets:
Total available-for-sale investments	3,146	2,507
Fair Value, Measurements, Recurring [Member] \| Corporate debt securities - Other [Member]
Assets:
Total available-for-sale investments	289	316
Fair Value, Measurements, Recurring [Member] \| Mortgage- and asset-backed securities [Member]
Assets:
Total available-for-sale investments	1,785	841
Fair Value, Measurements, Recurring [Member] \| Money market mutual funds [Member]
Assets:
Total available-for-sale investments	6,266	3,030
Fair Value, Measurements, Recurring [Member] \| Other short-term interest-bearing securities [Member]
Assets:
Total available-for-sale investments		147
Fair Value, Measurements, Recurring [Member] \| Equity securities [Member]
Assets:
Total available-for-sale investments	42	48
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member]
Derivative Assets:
Interest rate swap contracts	0	0
Total assets	10,254	8,158
Derivative Liabilities:
Contingent consideration obligations in connection with a business combination	0
Total liabilities	0	0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Foreign currency contracts [Member]
Derivative Assets:
Foreign currency contracts	0	0
Derivative Liabilities:
Foreign currency contracts	0	0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Cross currency swap contracts [Member]
Derivative Liabilities:
Foreign currency contracts	0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| US Treasury securities [Member]
Assets:
Total available-for-sale investments	3,946	5,080
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Other government-related debt securities - Obligations of U.S. government agencies and FDIC-guaranteed bank debt [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Other government-related debt securities - Foreign and other [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Corporate debt securities - Financial [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Corporate debt securities - Industrial [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Corporate debt securities - Other [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Mortgage- and asset-backed securities [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Money market mutual funds [Member]
Assets:
Total available-for-sale investments	6,266	3,030
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Other short-term interest-bearing securities [Member]
Assets:
Total available-for-sale investments		0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Equity securities [Member]
Assets:
Total available-for-sale investments	42	48
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member]
Derivative Assets:
Interest rate swap contracts	377	195
Total assets	10,298	9,516
Derivative Liabilities:
Contingent consideration obligations in connection with a business combination	0
Total liabilities	74	103
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Foreign currency contracts [Member]
Derivative Assets:
Foreign currency contracts	172	154
Derivative Liabilities:
Foreign currency contracts	48	103
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Cross currency swap contracts [Member]
Derivative Liabilities:
Foreign currency contracts	26
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| US Treasury securities [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Other government-related debt securities - Obligations of U.S. government agencies and FDIC-guaranteed bank debt [Member]
Assets:
Total available-for-sale investments	1,571	2,208
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Other government-related debt securities - Foreign and other [Member]
Assets:
Total available-for-sale investments	450	852
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Corporate debt securities - Financial [Member]
Assets:
Total available-for-sale investments	2,508	2,296
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Corporate debt securities - Industrial [Member]
Assets:
Total available-for-sale investments	3,146	2,507
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Corporate debt securities - Other [Member]
Assets:
Total available-for-sale investments	289	316
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Mortgage- and asset-backed securities [Member]
Assets:
Total available-for-sale investments	1,785	841
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Money market mutual funds [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Other short-term interest-bearing securities [Member]
Assets:
Total available-for-sale investments		147
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Equity securities [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member]
Derivative Assets:
Interest rate swap contracts	0	0
Total assets	0	0
Derivative Liabilities:
Contingent consideration obligations in connection with a business combination	190
Total liabilities	190	0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Foreign currency contracts [Member]
Derivative Assets:
Foreign currency contracts	0	0
Derivative Liabilities:
Foreign currency contracts	0	0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Cross currency swap contracts [Member]
Derivative Liabilities:
Foreign currency contracts	0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| US Treasury securities [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Other government-related debt securities - Obligations of U.S. government agencies and FDIC-guaranteed bank debt [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Other government-related debt securities - Foreign and other [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Corporate debt securities - Financial [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Corporate debt securities - Industrial [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Corporate debt securities - Other [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Mortgage- and asset-backed securities [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Money market mutual funds [Member]
Assets:
Total available-for-sale investments	0	0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Other short-term interest-bearing securities [Member]
Assets:
Total available-for-sale investments		0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Equity securities [Member]
Assets:
Total available-for-sale investments	$ 0	$ 0

Fair value measurements (Details Textual) £ in Millions, $ in Millions	Dec. 31, 2011 GBP (£)	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Dec. 31, 2009 USD ($)
Fair Value Measurement (Textual) [Abstract]
Interest rate swap contracts - fair value hedge - notional amounts		$ 3,600	$ 3,600	$ 1,500
Aggregate fair value of long-term debt, including current portion		23,000	14,500
Carrying value of long-term debt, including current portion		21,428	13,362
Cross currency swap contracts [Member]
Fair Value Measurement (Textual) [Abstract]
Foreign currency open contracts - cash flow hedges - notional amounts	£ 475	748
Foreign currency forward contracts [Member]
Fair Value Measurement (Textual) [Abstract]
Foreign currency open contracts - cash flow hedges - notional amounts		3,500	3,200
Foreign currency open contracts - not designated as hedges - notional amounts		389	670
Foreign currency option contracts [Member]
Fair Value Measurement (Textual) [Abstract]
Foreign currency open contracts - cash flow hedges - notional amounts		$ 292	$ 398

Derivative instruments (Details) - Derivatives in cash flow hedging relationships [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges contracts
Unrealized gain (loss) on derivative instruments recognized in Other Comprehensive Income, effective portion, net	$ (51)	$ 186	$ (213)
Foreign currency contracts [Member]
Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges contracts
Unrealized gain (loss) on derivative instruments recognized in Other Comprehensive Income, effective portion, net	(25)	191	(202)
Forward interest rate contracts [Member]
Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges contracts
Unrealized gain (loss) on derivative instruments recognized in Other Comprehensive Income, effective portion, net	0	(5)	(11)
Cross currency swap contracts [Member]
Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges contracts
Unrealized gain (loss) on derivative instruments recognized in Other Comprehensive Income, effective portion, net	$ (26)	$ 0	$ 0

Derivative instruments (Details 1) - Derivatives in cash flow hedging relationships [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Location in the Consolidated Statements of Income and the effective portion of gain/(loss) reclassified from Accumulated Other Comprehensive Income into earnings for our derivative instruments designated as cash flow hedges contracts
Total	$ (112)	$ 46	$ (8)
Foreign currency contracts [Member] \| Product sales [Member]
Location in the Consolidated Statements of Income and the effective portion of gain/(loss) reclassified from Accumulated Other Comprehensive Income into earnings for our derivative instruments designated as cash flow hedges contracts
The amount of gain (loss) recognized in product sales	(108)	47	(7)
Cross currency swap contracts [Member]
Location in the Consolidated Statements of Income and the effective portion of gain/(loss) reclassified from Accumulated Other Comprehensive Income into earnings for our derivative instruments designated as cash flow hedges contracts
The amount of gain (loss) recognized in interest and other income, net	(3)	0	0
Forward interest rate contracts [Member]
Location in the Consolidated Statements of Income and the effective portion of gain/(loss) reclassified from Accumulated Other Comprehensive Income into earnings for our derivative instruments designated as cash flow hedges contracts
The amount of gain (loss) recognized in interest expense, net	$ (1)	$ (1)	$ (1)

Derivative instruments (Details 2) - USD ($) $ in Millions	12 Months Ended
Derivative instruments (Details 2) - USD ($) $ in Millions	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Foreign currency contracts [Member] \| Interest and other income, net [Member]
Location in the Consolidated Statements of Income and the amount of gain/(loss) recognized in earnings for the derivative instruments not designated as hedging instruments
Derivatives not designated as hedging instruments	$ (1)	$ 32	$ (24)

Derivative instruments (Details 3) - USD ($) $ in Millions	Dec. 31, 2011	Dec. 31, 2010
Assets
Total derivative assets, fair value	$ 549	$ 349
Liabilities
Total derivative liabilities, fair value	74	103
Derivatives Designated as Hedging Instrument [Member]
Assets
Total derivative assets, fair value	549	349
Liabilities
Total derivative liabilities, fair value	74	103
Derivatives Not Designated as Hedging Instrument [Member]
Assets
Total derivative assets, fair value	0	0
Liabilities
Total derivative liabilities, fair value	0	0
Interest rate swap contracts [Member] \| Other current assets/Other noncurrent assets [Member] \| Derivatives Designated as Hedging Instrument [Member]
Assets
Total derivative assets, fair value	377	195
Interest rate swap contracts [Member] \| Accrued liabilities/Other noncurrent liabilities [Member] \| Derivatives Designated as Hedging Instrument [Member]
Liabilities
Total derivative liabilities, fair value	0	0
Foreign currency contracts [Member] \| Other current assets/Other noncurrent assets [Member] \| Derivatives Designated as Hedging Instrument [Member]
Assets
Total derivative assets, fair value	172	154
Foreign currency contracts [Member] \| Other current assets [Member] \| Derivatives Not Designated as Hedging Instrument [Member]
Assets
Total derivative assets, fair value	0	0
Foreign currency contracts [Member] \| Accrued liabilities/Other noncurrent liabilities [Member] \| Derivatives Designated as Hedging Instrument [Member]
Liabilities
Total derivative liabilities, fair value	48	103
Foreign currency contracts [Member] \| Accrued liabilities[ Member] \| Derivatives Not Designated as Hedging Instrument [Member]
Liabilities
Total derivative liabilities, fair value	0	$ 0
Cross currency swap contracts [Member] \| Other current assets/Other noncurrent assets [Member] \| Derivatives Designated as Hedging Instrument [Member]
Assets
Total derivative assets, fair value	0
Cross currency swap contracts [Member] \| Accrued liabilities/Other noncurrent liabilities[Member] \| Derivatives Designated as Hedging Instrument [Member]
Liabilities
Total derivative liabilities, fair value	$ 26

Derivative instruments (Details Textual) £ in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Dec. 31, 2009 USD ($)	Dec. 31, 2011 GBP (£)	Dec. 31, 2011 USD ($)
Derivative instruments (Textual) [Abstract]
Length of time hedged in foreign currency cash flow hedge	Approximately 3 years
Ineffective portions of cash flow hedging instruments (approximately), Gain (loss)	$ 1	$ (1)	$ (1)
Interest rate swap contracts - fair value hedge - notional amounts		3,600	1,500		$ 3,600
Interest expense, net [Member]
Derivative instruments (Textual) [Abstract]
Unrealized gain (loss) on the hedged debt	(182)	(105)	116
Offsetting unrealized gain (loss) on related interest rate swaps	$ 182	105	(116)
Foreign currency forward contracts [Member]
Derivative instruments (Textual) [Abstract]
Notional amount		3,200	3,400		3,500
Foreign currency open contracts - not designated as hedges - notional amounts		670	414		389
Foreign currency option contracts [Member]
Derivative instruments (Textual) [Abstract]
Notional amount		$ 398	$ 376		292
Foreign currency and cross currency swap contracts [Member]
Derivative instruments (Textual) [Abstract]
Amounts expected to be reclassified from accumulated other comprehensive income into earnings over the next 12 months - gains on foreign currency and cross currency swap					75
Forward interest rate contracts [Member]
Derivative instruments (Textual) [Abstract]
Amounts expected to be reclassified from accumulated other comprehensive income into earnings over the next 12 months - gain (loss)					$ (1)
Rate adjustment to LIBOR on Interest Rate Swap Agreements [Member]
Derivative instruments (Textual) [Abstract]
Derivative lower range variable interest rate				0.30%	0.30%
Derivative higher range variable interest rate				2.60%	2.60%
Cross currency swap contracts [Member]
Derivative instruments (Textual) [Abstract]
Notional amount				£ 475	$ 748
Fixed interest rate for interest received for counterparties on cross currency swap contract	5.50%
Fixed interest rate for interest paid to counterparties on cross currency swap contracts	5.80%

Contingencies and commitments (Details) $ in Millions	Dec. 31, 2011 USD ($)
Minimum future rental commitments under non-cancelable operating leases
2012	$ 116
2013	104
2014	85
2015	76
2016	65
Thereafter	328
Total minimum operating lease commitments	$ 774

Contingencies and commitments (Details Textual) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Sep. 30, 2011	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Contingencies and Commitments (Textual) [Abstract]
Future rental commitments for abandoned leases		$ 254
Rental expense on operating leases		131	$ 115	$ 114
Minimum contractual purchase commitments with third party manufacturers through 2014		157
Purchases under contractual purchase commitments		87	$ 68	$ 207
Legal settlement charge associated with proposed settlement of allegations	$ (780)	$ (780)

Segment information (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
Segment information (Details) - USD ($) $ in Millions	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2010	Sep. 30, 2010	Jun. 30, 2010	Mar. 31, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Revenues:
Product sales	$ 3,907	$ 3,877	$ 3,893	$ 3,618	$ 3,760	$ 3,759	$ 3,613	$ 3,528	$ 15,295	$ 14,660	$ 14,351
Other revenues									287	393	291
Total revenues									15,582	15,053	14,642
Neulasta [Member] \| United States [Member]
Revenues:
Product sales									3,006	2,654	2,527
Neulasta [Member] \| International [Member]
Revenues:
Product sales									946	904	828
NEUPOGEN [Member] \| United States [Member]
Revenues:
Product sales									959	932	901
NEUPOGEN [Member] \| International [Member]
Revenues:
Product sales									301	354	387
ENBREL [Member] \| United States [Member]
Revenues:
Product sales									3,458	3,304	3,283
ENBREL [Member] \| Canada [Member]
Revenues:
Product sales									243	230	210
Aranesp [Member] \| United States [Member]
Revenues:
Product sales									986	1,103	1,251
Aranesp [Member] \| International [Member]
Revenues:
Product sales									1,317	1,383	1,401
EPOGEN [Member] \| United States [Member]
Revenues:
Product sales									2,040	2,524	2,569
Sensipar [Member] \| United States [Member]
Revenues:
Product sales									518	459	429
Sensipar (Mimpara) [Member] \| International [Member]
Revenues:
Product sales									290	255	222
Vectibix [Member] \| United States [Member]
Revenues:
Product sales									122	115	97
Vectibix [Member] \| International [Member]
Revenues:
Product sales									200	173	136
Nplate [Member] \| United States [Member]
Revenues:
Product sales									163	129	78
Nplate [Member] \| International [Member]
Revenues:
Product sales									134	100	32
Prolia [Member] \| United States [Member]
Revenues:
Product sales									130	26	0
Prolia [Member] \| International [Member]
Revenues:
Product sales									73	7	0
XGEVA [Member] \| United States [Member]
Revenues:
Product sales									343	8	0
XGEVA [Member] \| International [Member]
Revenues:
Product sales									8	0	0
Other [Member] \| International [Member]
Revenues:
Product sales									$ 58	$ 0	$ 0

Segment information (Details 1) - USD ($) $ in Millions	12 Months Ended
Segment information (Details 1) - USD ($) $ in Millions	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Geographical information with respect to revenues [Abstract]
United States	$ 11,985	$ 11,636	$ 11,421
International countries	3,597	3,417	3,221
Total revenues	$ 15,582	$ 15,053	$ 14,642

Segment information (Details 2) - USD ($) $ in Millions	Dec. 31, 2011	Dec. 31, 2010
Geographical information with respect to long-lived assets
United States	$ 3,144	$ 3,248
Property, plant and equipment, net	5,420	5,522
Puerto Rico Excise Tax [Member]
Geographical information with respect to long-lived assets
International countries	1,993	2,079
International [Member]
Geographical information with respect to long-lived assets
International countries	$ 283	$ 195

Segment information (Details 3) - USD ($) $ in Millions	12 Months Ended
Segment information (Details 3) - USD ($) $ in Millions	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
AmerisourceBergen Corporation [Member]
Revenues earned from major customers
Gross product sales	$ 7,574	$ 7,678	$ 7,179
Gross product sales to major customer (as defined) as a percentage of total gross revenues	36.00%	38.00%	37.00%
Gross product sales to major customer (as defined) as a percentage of U.S. gross product sales	45.00%	47.00%	46.00%
McKesson Corporation [Member]
Revenues earned from major customers
Gross product sales	$ 4,591	$ 3,913	$ 3,694
Gross product sales to major customer (as defined) as a percentage of total gross revenues	22.00%	19.00%	19.00%
Gross product sales to major customer (as defined) as a percentage of U.S. gross product sales	27.00%	24.00%	24.00%
Cardinal Health, Inc. [Member]
Revenues earned from major customers
Gross product sales	$ 3,021	$ 2,813	$ 2,841
Gross product sales to major customer (as defined) as a percentage of total gross revenues	14.00%	14.00%	15.00%
Gross product sales to major customer (as defined) as a percentage of U.S. gross product sales	18.00%	17.00%	18.00%

Segment information (Details Textual) - Customer	12 Months Ended
Segment information (Details Textual) - Customer	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Segment information (Textual) [Abstract]
Number of major customers (as defined) accounting for more than 10% of total revenue	3	3	3
Threshold as a percentage of total revenues for determining a major customer for additional disclosures	10.00%	10.00%	10.00%
Percentage of worldwide gross revenues derived from major customers (as defined) on a combined basis	72.00%
Percentage of United States gross product sales derived from major customers (as defined) on a combined basis	90.00%
Major customers (as defined) accounting for more than 10% of gross trade receivables	3	3
Combined trade receivables for all major customers (as defined) as a percentage of net trade receivables	60.00%	54.00%
Percentage of net trade receivables due from customers located outside the United States, primarily in Europe	39.00%	44.00%
AmerisourceBergen Corporation [Member]
Revenue, Major Customer [Line Items]
Amount due from major customer (as defined) as a percentage of gross trade receivables	exceeded 10%	exceeded 10%
McKesson Corporation [Member]
Revenue, Major Customer [Line Items]
Amount due from major customer (as defined) as a percentage of gross trade receivables	exceeded 10%	exceeded 10%
Cardinal Health, Inc. [Member]
Revenue, Major Customer [Line Items]
Amount due from major customer (as defined) as a percentage of gross trade receivables	exceeded 10%	exceeded 10%

Subsequent event (Details) - Business Combination [Member] $ / shares in Units, $ in Millions	1 Months Ended
	Jan. 26, 2012 USD ($) $ / shares
Subsequent Event (Textual) [Abstract]
Common stock, price per share \| $ / shares	$ 11
Aggregate amount \| $	$ 1,160

Quarterly financial data (unaudited) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2010	Sep. 30, 2010	Jun. 30, 2010	Mar. 31, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Quarterly financial data (unaudited)
Product sales	$ 3,907	$ 3,877	$ 3,893	$ 3,618	$ 3,760	$ 3,759	$ 3,613	$ 3,528	$ 15,295	$ 14,660	$ 14,351
Gross profit from product sales	3,251	3,272	3,291	3,054	3,188	3,172	3,060	3,020
Net income	$ 934	$ 454	$ 1,170	$ 1,125	$ 1,022	$ 1,236	$ 1,202	$ 1,167	$ 3,683	$ 4,627	$ 4,605
Earnings per share:
Basic	$ 1.09	$ 0.50	$ 1.26	$ 1.21	$ 1.09	$ 1.29	$ 1.25	$ 1.19	$ 4.07	$ 4.82	$ 4.53
Diluted	$ 1.08	$ 0.50	$ 1.25	$ 1.20	$ 1.08	$ 1.28	$ 1.25	$ 1.18	$ 4.04	$ 4.79	$ 4.51

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

+ Details

- Definition

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Quarterly financial data (unaudited) (Details Textual) - USD ($) $ in Millions	3 Months Ended			12 Months Ended
	Sep. 30, 2011	Dec. 31, 2010	Sep. 30, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Quarterly financial data (unaudited) [Abstract]
Legal settlement charge associated with proposed settlement of allegations	$ (780)			$ (780)
Legal settlement charge associated with proposed settlement of allegations (net of tax)	$ (705)
Income tax benefit for resolving certain transfer pricing issues with tax authorities		$ 113
Impairment of fixed assets (net of tax)		74
Impairment of fixed assets		$ 118		$ 6	$ 118	$ 21
Income tax benefit as the result of resolving certain transfer pricing issues with tax authorities for prior periods			$ 38

- Definition

The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 144
-Paragraph 26
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 144
-Paragraph 7, 25
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6390789&loc=d3e2420-110228

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2921-110230

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 225
-Section 45
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6743430&loc=d3e92212-112881

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Impairment
-URI http://asc.fasb.org/extlink&oid=6515133

+ Details

Valuation Accounts (Details) - USD ($) $ in Millions	12 Months Ended
Valuation Accounts (Details) - USD ($) $ in Millions	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Allowance for doubtful accounts
Balance at beginning of period	$ 42	$ 32	$ 38
Additions charged to costs and expenses	17	10	(6)
Other additions	0	0	0
Deductions	5	0	0
Balance at end of period	$ 54	$ 42	$ 32